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ABSTRACT

Melanoma is an aggressive disease with few effective treatment options. Nontoxic, anti-tumor therapies and prophylactic approaches are currently being investigated
to identify treatment options that will control and remove late-stage melanoma.
The overall goal of this project was to establish an effective delivery method for a
plasmid encoding human interleukin (phIL-15) into mouse melanoma cells (B16.F10)
1

using the gene transfer technique electroporation (EP) . The EP delivery phIL-15 was
optimized using an in vitro 3D tumor model. The purpose was to translate these IL-15
delivery conditions into an in vivo mouse melanoma model to study IL-15 signal
transduction and stimulate immune cells to destroy tumor antigens as well as promote
an anti-tumor immune memory response.
The in vitro 3D tumor model and the mouse model demonstrated similar
expression patterns when delivering phIL-15 with different EP conditions. Intra-tumoral
delivery using 500V/cm 20ms enhanced gene delivery and increased IL-15 protein
expression compared to 1300V/cm 100µs. There was also a visible increase in
transfection efficacy between tumor cells compared to skin cells when delivering pmIL12 and phIL-15 plasmid constructs in vivo. The plasmid+EP groups 1300V/cm and
500V/cm stimulated increased expression of cytokines IL-1β, IL-6, INFγ, MIP-1β and
TNFα. These EP groups also promoted tumor regression by up-regulating CD8+ T cells
and CD4+ T cells which targeted melanoma. Regression and survival studies
demonstrated that 73.3% of mice cleared B16.F10 cells when treated with phILx

15+1300V/cm and pVax+500V/cm. In addition, 53% of the mice responded to the phIL15+500V/cm treatment group. Furthermore, 75% of the mice from group phIL15+500V/cm survived secondary inoculation and tumor challenge. In conclusion,
plasmid with encoding gene insert phIL-15 delivered by EP has the potential to act as an
anti-tumor therapy because it promotes melanoma regression and enhances mouse
survival through innate and adaptive cell-mediated immune responses.

xi

INTRODUCTION

Melanoma Disease Target
Melanoma is a poorly immunogenic and aggressive cancer localized in the
epidermis, it is very dangerous when left untreated, but the survival rate increases if
1

detected early and removed completely . Currently, melanoma’s 5 year survival rate is
≤10% for stage IV metastatic cells that have spread to other organs, ≤30% for stage IIIC
metastatic cells that have spread to nearby tissue and lymph nodes, ≤45% for stage IIC
ulcerated tumors, at least 1mm thick and cells have not migrated to the lymph nodes and
≤95% for stage IA tumors that are not ulcerated, nor undergoing mitosis and are less
than or equal to 1mm thick

2-3

. Melanoma is sometimes difficult to identify and lesions are

located in places that can easily be ignored. Melanoma cells are melanocytes that have
undergone genetic mutations and exhibit enhanced oncogenic properties. Melanoma
transformation can develop from UV irradiation activating p53 gene mutations causing
melanocytes to lose their cell cycle control. Many pathways are affected by excessive
UV exposure (Figure 1) such as continuous autocrine stimulation by growth factors

4-5

which causes prolonged MEK/ERK activation resulting in cell proliferation and
differentiation

6

and constitutive oncogenic g-protein N-RAS activity

7

that binds to

receptor tyrosine kinase (RTK). Additional oncogenic mutations are found in kinase
activating domain V599E of B-RAF

7-9

which enhances DNA proliferation and cell

survival. Mutations cause loss of receptor function and enhanced melanogenesis, for
example mutations in melanincortin-1-receptor constitutively bind α-Melanocyte
1

Stimulating Hormone (αMSH) causing increase in tumor survival

4,10-14

. Additionally,

melanoma mutations cause down regulation of tumor suppressor genes PTEN/AKT and
inhibitory pathways P53/APAF-1 in non-metastatic melanoma

7

which increases cell

survival. Also, melanoma evades the immune response by using immune suppressor
14

factors to decrease cytokine production stimulated by the JAK/STAT pathway .

Figure 1: Melanoma Development and Oncogenic Mutations
4-18
(Figure Referenced in Literature
).

Melanoma formation also occurs when there is a continuous stimulation by
mitogenic growth factors promoting excessive melanocyte formation into a population of
pigmented cells called nevi or moles

15-16

. Nevi formation is dependent on distinct growth

factors like bFGF different from the growth factors stimulating other melanocytes found
ubiquitously in the epidermis. When CDKN2A/P16
2

INK4

cell cycle inhibitor is up-regulated

it controls nevi proliferation

4,14-17

. Nevi that do not undergo senescence and replicate

uncontrollably form many nevi or moles that may give rise to melanoma due to a defect
in CDKN2A/P16

INK4 14,18

,

(Figure 1).

Melanocytes are highly migratory cells that move towards keratinocytes when the
epidermis is exposed to UV radiation. The melanocytes function by transferring their
19

melanin to keratinocytes to shield against UV exposure . Melanocytes also elevate antiapoptotic properties like BCL-2 and αMSH which contribute to cell immortalization

10, 20

.

These properties associated with up-regulating melanocyte protection from UV exposure
are the same properties that protect melanoma cells from cell death and immune attack.
Once melanoma invasively migrates to deeper layers of the skin and invades the blood
2,14

stream it causes secondary disease and spreads to the liver, lung, and brain

.

Treatment options for late stage melanoma are limited and the aggressive disease
rapidly floods the body causing irreversible damage. The current treatment options are
surgery, chemotherapy, cytotoxic drugs and radiotherapy

2,7

. Melanoma is highly

resistant to chemotherapy and alkylating agents that cause cytotoxic DNA cross-linking.
Melanoma is resistant because cells can undergo increased DNA repair and detoxify
chemotherapeutic drugs by up-regulating alkyl transferases like glutathione S2

transferase to chemically reduce cytotoxic cross-linking . Melanoma can also impair
drug transport and drive out the chemical via P-glycoprotein efflux pumps. Melanoma is
known to be resilient to cytotoxic drugs at doses which cause toxicity in patients.
Scientists are investigating other alternative therapies to target melanoma such as
cytokine immune therapy

2,7

.

3

Current Melanoma Gene Therapy
Some of the cytokines that have been studied for their potential use in immune
2

therapies are INFα, IFNγ, IL-2, IL4, IL6, IL-12, IL-18, IL-21, GMCSF, IL-12, and TNFα .
In 2007, a study using FDA approved high dose recombinant protein INFα and IL-2 was
administered to patients with advanced stage melanoma (II, III and IV). The results
showed limited tumor response 10-15% and resulted in high platelet toxicity

2,21

.

Currently, investigators are developing adjuvant therapies that will promote anti-tumor
efficacy dependent on the stage of tumor growth. One idea is to target early stage (I/II)
melanoma in patients not at risk of relapse and increased survivability with resection, is
to use low dose recombinant proteins to target early stage existing disease. The
22

approach is to induce a protective immune response against new primary melanoma .
Another strategy is to mount a protective immune response against tumor cells by
employing an adjuvant delivery system that will transfect genes encoding cytokines into
specific cells and signal surrounding immune effector cells to enhance their own
23

cytotoxic effect against intermediate and late stage melanoma .

Gene Delivery Techniques
There are many gene delivery techniques that are used to promote the
introduction of nuclei acid into cells, these include viral vectors, gene gun, charged
polymers,

liposomes,

calcium

phosphate

precipitation,

microinjections, pressure perfusion, and electroporation (EP)

ultrasound,

23-25

intracellular

. The purpose is to use

a safe and minimally toxic system that can effectively target specific cells and deliver
specific genes which would direct downstream events leading to an enhanced immune
response

23-24

.The injection of naked DNA into tissues or cells is not an efficient

4

transfection approach. This efficiency can be significantly improved using physical
approaches such as gene gun or EP. Both devices facilitate transport of DNA through
the cell membrane and cytosol allowing them to reach the nucleus at high proficiency
24

23-

. The pressure perfusion method (hydrodynamic) forces large volumes of plasmid DNA

into a vein. A typical target using this technique is the liver and the high injected volume
inflates the organ and leads to efficient gene delivery and high expression. While
successful, this approach is not easily translated to the clinic

23-25

. Although recombinant

viral vectors can deliver DNA efficiently and achieve high levels of protein expression,
they are accompanied by some safety concerns. These include immune response to the
virus, possible insertional mutagenesis and over expression of a gene resulting in high
toxicity

23-25

. An alternative is to use a non-viral vector that will deliver therapeutic genes

into the cell’s nucleus without damage as well as limiting systemic toxicity. Delivery of
plasmids using mechanical devices such as EP, is safe, promotes efficient, transient
delivery and allows short-term gene production for downstream stimulus

24, 26-27

. The

goal is to deliver a gene encoding a cytokine to stimulate pathways of the immune
response and promote antigen recognition by effector cells that can up-regulate multiple
28

arms of the immune response as well as a protective response by memory cells .
Many laboratories such as the Heller Lab utilize gene delivery systems to employ
anti-tumor therapies into existing disease. Based on previous studies with interleukin 12
(IL-12), intra-tumoral delivery of the gene using EP enhanced DNA delivery into mouse
melanoma (B16.F10) improved protein production by tumor cells compared to injection
of IL-12 plasmid only

28-30

. These studies showed that local delivery of the plasmid to the

tumor reduced tumor burden, prevented tumor metastasis and increased mouse
survival. The study also showed up-regulation of innate and adaptive immune

5

responders such as IFNγ by ELISA and CD8+/CD4+ T cells by immunohistochemistry.
The delivery of IL-12 was able to reduce tumor size using EP intra-tumoral delivery and
prevent melanoma lung colonization when delivering IL-12 into the gastrocnemius
muscle. The mice responded well to treatment, had no deleterious side effects and did
not succumb to melanoma metastasis

28-30

. The purpose of the subsequent study was to

expand upon the knowledge gathered from the IL-12 studies and characterize EP
delivery conditions for human interleukin-15 (IL-15). The goal was to test the delivery of
IL-15 primarily in vitro and then translate the information in vivo. Activation of immune
responses against B16.F10 antigens and evaluation of memory response could be
studied following delivery of plasmid encoding IL-15 (pIL-15). Evaluation of those results
would contribute to understanding what effector cells caused reduction in tumor burden
31

and increased mouse survival .

Electroporation
Electroporation is a technique that provides temporary permeabilization of cells
allowing the entry of molecules and desired genes

32-36

. “Poration” occurs when electric

fields are applied across charged electrode plates and creates potential energy at the
poles to help feed molecules or DNA into cells

32,37

. It is suggested that DNA is

introduced into the cells by different mechanisms, such as electrophoretic forces
37

26,32,35-

38

, endosomes envagination , and binding of DNA to the membrane with lateral
34

diffusion . To promote DNA entry into the cells, it has been suggested that the electric
fields cause deformation of the DNA to compensate for the bulky supercoiled size. The
pulses orient the DNA parallel to the electric field and facilitate movement of the DNA
33

into the cytosol within milliseconds . The “pore” radius depends on the size of the DNA

6

providing passage of excess DNA found in the extracellular matrix

33-34

. The plasma

membrane regulates resealing of the “pores” a few minutes after the pulses to reduce
33

cellular damage by reverting to normal transmembrane potential . Once inside the cell,
it is suggested that the DNA uses the cells’ transcription and translation factors to
produce protein

31,35,38

. The process of DNA introduction into the cell is still being

investigated; studies are attempting to unravel the process of uptake and translocation of
the DNA into the nucleus for protein expression

33,35-36

.

Electroporation has been utilized to enhance DNA delivery of many types of
genes into different cells and promote specific up-regulation of protein signaling

28,31,36,39

.

This technique uses the protein stimuli in cells to up-regulate different down-stream
29

pathways that are beneficial to target disease or restore signaling in cells . To promote
specific immune responses the delivery system must ensure efficient transfection of
DNA into target cells. Delivery of the plasmid and resulting expression can be controlled
by regulating EP parameters. EP is controlled by adjusting pulse parameters such as
pulse duration, length and frequency as well as plasmid concentration

29,39

. The applied

electric field must exceed a minimal threshold to destabilize the membrane and ensure
DNA transfer

36,39-40

.

The delivery of luciferase using low electric fields with long pulse durations
(600V/cm 5ms 1Hz 8 pulses) demonstrated increased expression of luciferase
compared to the combination of high electric fields with short pulse durations and very
low electric field with longer pulse durations (1200V/cm 100µs 2Hz 1 pulse and 140V/cm
30

50ms 2Hz 8 pulses, respectively) . Researchers found that long, low voltage electric
pulses enhance DNA movement into cells compared to combination pulses

30,36,41

.

Additionally, the route of plasmid administration, orientation of the electric fields and
7

direction of pulses influence the magnitude of transfection when delivering to a particular
tissue type. It has been suggested that delivery to the liver, spleen, and kidney show
41

more luciferase and β galactosidase expression than muscle and skin . While this one
study demonstrated higher expression with the specific EP parameters tested in liver,
spleen and kidney, it is quite possible that utilizing different pulse parameters could lead
to higher levels in muscle and skin. Many factors influence EP delivery such as cell size,
cellular characteristics, relative conductivity since EP is limited to the area the field is
applied, the amount of plasmid available and direction of pulses applied. The application
of electric fields in multiple directions enhances delivery of the gene to many cells at one
time reducing cell damage

39,41-42

. The electrode applicators utilized to deliver pulses to

the cells are also tissue specific. Penetrating needle electrodes are used for muscle and
tumor, while multi-electrode arrays and plate electrodes are used for skin and muscle

39

.

It is important to determine EP parameters for specific cells and tissues to select
appropriate delivery conditions that would result in the appropriate protein expression
and down-stream signaling.

3D Modeling and Tissue Engineering
There is a concerted effort to develop an in vitro model that mimics cellular
properties similar to cells in vivo. It is important to develop models that will help elucidate
the cellular physiology, pathology, drug interactions, cellular behavior, and protein
43

signaling . Two dimensional (2D), monolayer cell cultures have provided extensive
information on cellular behavior, cell signaling and function. However, cells seeded in a
2D monolayer culture differ from cells cultured in vivo, because they are morphologically
different than structures observed in vivo which may lead to physiological differences
45

.
8

44-

It is suggested that cells cultured in a monolayer may differ from cells in vivo because
of the way they are cultured, specifically altering cell interaction, communications,
differentiation, growth, migratory properties, metabolism, adhesive properties, protein
expression, protein secretion, cytoskeleton organization, intracellular and extracellular
signaling characteristics, receptor stimuli, agonist and antagonistic properties

45-49

. It has

been demonstrated that tumor cells grown in a 2D culture are less likely to be drug
resistant than cells grown in a 3D model

45,50

. One method used to test the differences in

cellular properties is to develop a 3D model sitting in a synthetic micro-environment that
51

will allow cells to mimic their natural state . Generation of a 3D tissue-like construct has
become a useful tool in cell culture providing the ability to study cell-cell interactions from
homogeneous or heterogenous cell populations. This model gives researchers the
opportunity to study cellular functions independently from other factors found in vivo that
enhance or inhibit cellular processes

43-44,52-53

.

The key is to generate a 3D model that can sustain cells in suspension, provide
passive diffusion of oxygen, nutrients and allows cells to behave similar to their cell cycle
in vivo. A microgravity bioreactor was engineered to promote cellular aggregation in a
free-floating synthetic environment constantly rotating at less than 1 gravitational force
(1g)

51,52

. The bioreactor allows cells to be submerged in media and is equipped with a

silicon membrane to ensure oxygen and carbon dioxide exchange for the cells. This
device known as the high aspect ratio vessels (HARVs) was engineered by NASA
in1986 and Synthecon in 1990, to promote 3D growth of cells in a microgravity
environment. The cells residing in the vessel experience minimal interference and
shearing, while growing in a state of free fall or solid body rotation

52,54-58

. The rotation of

the vessels concentrate cells in one location allowing aggregation and cell-cell contact

9

59

54

59

amongst epithelial adherent cells , immune cells, stem cells , melanoma , sertoli cells
60

, and pancreatic islets

51,54

.

Cells grown in suspension forming 3D cellular aggregates are a good model to
study tumor development and cell interactions. Tumor cells residing in a 3D construct,
mimic cells in vivo they can organize themselves, polarize and support tumor cell
51

behavior . Tumor cells can organize into small masses mimicking the properties of
tumor lesions in nature, proliferating in an oxygenated or hypoxic environment containing
viable cells residing on the surface while dying, necrotic cells reside in the center

51-52

.

Tumor cells grown in a 3D model instead of in a 2D culture will provide advantages to
understanding the pathology of tumors and answer questions about drug targeting, gene
therapy, angiogenesis, migration, tumorigenesis, cells cycle pathways, evasion of
apoptosis and invasive properties

51,56,61

. Although this is not a completely organized

natural system it is a good template for understanding the biology of tumor cells growing
51

in a synthetic 3D microenvironment that can be translated and further tested in vivo .
The construction of a 3D tumor model must contain cell types that will properly
interact and appropriately signal. These signals include growth factors, protein
regulators, and adherent proteins that enhance synthesis of extracelluar matrix and
scaffolding. These proteins will also help promote growth, differentiation, and survival of
cells involved in the 3D model

62-64

. For instance, melanoma is a common skin cancer

that is studied in vivo to identify early and late stage treatment protocols. This is an
interesting model to study because it is poorly immunogenic and resistant to
2

chemotherapy . The tumor cells cultured in the 3D model will possibly mimic cellular
behavior and help isolate cellular mechanisms that attribute to the disease pathology.
The information gathered from the model may reveal signaling pathways that can be

10

targeted using chemotherapeutics or optimize expression levels of genes using EP
45

delivery methods to regulate down-stream signaling . A good tumor model is one that
contains complementing cells that normally interact such as keratinocytes from the
epithelium with melanoma that reside in the skin. Melanoma are melanocytes that act to
protect the skin, but that have undergone genetic alterations, mutations and upregulation of oncogenic properties

45,51

.

In vivo, the basal layer is the germinal layer of the epidermis and contains
14

proliferative, non keratinized keratinocytes that house melanocytes . The keratinocytes
communicate with melanocytes and melanoma through their dendrite-like processes.
Keratinocytes provide survival signals to melanocytes in the epidermis and prevent
14

apoptosis, promote melanocyte differentiation, and migration . As mentioned
previously, keratinocytes are constantly controlling and communicating with melanocytes
as well as melanoma. Melanocytes need keratinocytes because if they migrate to the
dermis they can undergo apoptosis in the absence of keratinocyte survival signals

14,65

.

The interesting feature of melanoma is that they have the ability to escape keratinocyte
control. The keratinocytes control melanoma by preventing escape from deregulation
and invasion. At early stages, keratinocytes express adhesive proteins E-cadherin to
66

limit melanoma migration . One evasion tactic used by melanoma is the downregulation of E-cadherin and up-regulation of N-cadherin through PI3K pathway

67

as well

as reducing the integrins in keratinocyte for melanoma migration. E-cadherin is
expressed by epidermal cells Langerhans, keratinocytes and melanocytes while N
cadherin is expressed by vascular endothelial cells and fibroblasts

66,68

. Some studies

show an up-regulation of N-cadherin by melanoma cells themselves to escape
66

keratinocyte control . Melanoma migrates into deeper layers of the epidermis reaching

11

the blood stream and metastasizing to distant sites from the primary tumor site

17,69

. Up-

regulation of integrins is a result of UV irradiation in order to promote migration of
melanocytes to the area of UV exposure

70-72

.

Investigators interested in 3D models want to analyze specific processes to
clearly understand mechanisms such as receptor up-regulation, protein synthesis,
protein phosphorylation, mutation of genes, uncontrolled cancer cell proliferation, and
tumor evasion

56,61

. A 3D tumor model provides an alternative method for analyzing

treatment regimens using gene delivery methods and will assist in unraveling additional
45

therapeutic options for melanoma . Evaluating the effectiveness of cytokine therapy
against cancer cells in vivo could be first optimized for EP delivery conditions in vitro
using a 3D model and then translated to in vivo testing thus, reducing the use of animals
for EP optimization.

Interleukin-15
One of the cytokines that is being studied for delivery to tumors using EP is
interleukin-15 (IL-15). IL-15 is a 14-15kDa pleiotropic cytokine

73-74

that was discovered

in 1994 by JD Burton and KH Grabstein. IL-15 protein forms a 4-α helix structure that
specifically binds with high affinity to IL-15Rα, but can also bind to IL-2Rβ and IL-2Rγ
77

73-

. The IL-15 gene consists of 9 exons and 8 introns. When translated, the IL-15 protein

is 114 amino acids (aa) long encoded from 4 exons and 3 introns containing structural
77

similarities to IL-2 . IL-15 binds IL-15Rα with high affinity; the IL-15Rα contains a
positively charged sushi domain that binds negatively charge IL-15

77-78

. Mouse IL-15

shares 73% aa homology with human IL-15 and human IL-15Rα shares 54% aa
sequence homology with mouse. While the human IL-15Rα sushi domain which actively
12

binds ligand IL-15 shares an 85% aa sequence homology with mouse IL-15 sushi
domain

77,79-80

.

IL-15 and IL-2 share many activities, but differ in functional properties of the
immune system

74,76-77

. IL-2 is mainly a modulator of T cells

potent producer of NK cells

77,82

77,81

, while IL-15 protein is a

, IFNγ, CTL effector cells and most importantly

maintaining the survival of memory CD8+ T cells. IL-15 messenger RNA is expressed by
dendritic cells (DC)

77,83

, monocytes
77,87

skin cells, keratinocytes
cells
77,87

77,89

77,84

77,86

77,85

, fibroblasts

77,86

, epidermal

and epithelial cells such as lung, heart, kidney

, skeletal muscle, and placenta

, fibroblasts

, macrophages

74,77

77,88

, nerve

IL-15 protein is expressed by epithelial cells

84

, monocytes , and DC

77,83

. Although, IL-15 is ubiquitously

expressed it is difficult to detect because IL-15 is tightly regulated at the level of
translocation, transcription, translation, protein expression, intracellular trafficking, and
secretion from the golgi apparatus

77,90-97

. There are two alternatively spliced isoforms of

human IL-15 expression that exist, there is long signal peptide (LSP) that measures 48aa and short signal peptide (SSP) measuring 21-aa

77,90,94,98-100

. Human IL-15 isoforms

differ from mouse IL-15 isoform measuring 26-aa in length even though they share a
73% aa sequence homology

77,79,98

. The IL-15 SSP is sequestered and stored

intracelluarly in the cytoplasm while IL-15 LSP is found in the golgi, leading to secretion.
The role of IL-15 SSP has been elucidated as a type of autocrine regulatory signal that
binds to IL-15Rα in the nucleus and regulates IL-15 gene transcription. Messenger RNA
for IL-15Rα is also expressed by many cell types including B cells, NK cells, T cells,
macrophage, bone marrow and thymic cells, kidney, lung, heart, skeletal muscle, brain,
intestine, and liver

77,79,101-105

. When IL-15 binds to IL-15Rα, cells show low levels of

signal transduction by the receptor

77,106-108

, in turn when IL-15 binds to IL-2Rβγ there is

13

an increase in signaling transduction. IL-2Rβγ recruits JAK kinases and activates STAT
transcription. The phosphorylated STAT proteins translocate to the nucleus and
activates gene expression of inflammatory responses, which signals differentiation and
expansion of T cells

77,109-111

(Figure 2).

IL-15Rα exists in two forms, membrane bound and soluble. The cleaved soluble
form was detected in the mouse serum and cell supernatant from cultured human
glioblastoma and mouse fibrosarcoma

77,80,112-113

. IL-15 has a short half life due to down77

regulation by monoctye or dendritic cell’s negative feedback inhibition pathway .
Soluble IL-15Rα acts as an agonistic binding IL-15 to prolong its half-life and regulates
IL-15 concentration within a tissue over a period of time

77,114-115

. On the other hand,

constitutively expressed membrane-bound IL-15Rα can act as an antagonist by binding
soluble IL-15 through an autocrine pathway regulating excessive stimulation of IL-15
signaling and limits activation

77,112-113,115

(Figure 2).

Figure 2: IL-15 Signaling and Stimulation of the Immune Response
74-86,109-131
(Figure Referenced in Literature
).
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IL-15 shares some of the same signaling pathways with melanoma, aiming to
sustain tumor growth and reduce apoptosis. These pathways including Src family
kinases PI3K and AKT, anti-apoptotic BCL-2, AP-1, and Ras/Raf/Mek/MAPK

106

. More

importantly, IL-15 stimulates pro-inflammatory pathways NF-κB, to target tumor cells
such as melanoma

77,106,110

. This information could help elucidate why IL-15 is so tightly

regulated when stimulated by immune effector cells. Membrane associated IL-15/IL15Rα complex expressed on monocytes allows for trans endosomal recycling to
enhance memory CD8+ T cell stimuli

77,116-117

adjacent CD8+ T cells and NK cells

or trans-presentation of IL-15 to stimulate

77,105,118-119

. It is suggested that this is the main

signaling function of IL-15Rα during trans-presentation and up-regulation of the adaptive
immune response and memory response

77,105,119

(Figure 2).

IL-15 Stimulates the Immune Response
IL-15 induces a strong innate immune response recruiting DC, macrophage, NK
cells, augments INFγ production, and in turn up-regulates the adaptive response by
enhancing costimulatory molecules CD40, CD86, MHC class I, CD8 T cells CTL, MHC
class II CD4+T cells, Th1 cytokines, and ultimately promoting the production of long
lasting CD8+ T cell memory immune response against the antigens of interest
122

77,83,120-

. IL-15 expands, stimulates functional activities and maintains balance of NK and

survival of memory CD8+ T cells

77,81-82,93,123-124

. IL-15 also regulates B-cell survival and

proliferation. B cell follicular DCs produce IL-15 which promotes the production and
secretion of IgA, IgG and IgM by CD40L activated B- cells

77,125-126

. IL-15 produced by

monocytes up-regulate proinflammatory cytokines IL-6, IL-8, TNFα
increases phagocytosis, inhibit neutrophil and eosinophil apoptosis
15

77,112,127

77,128

which

. IL-15 also

enhances mast cell development and proliferation
monocyte production of cytokines IL-12

77,130

77,129

and up-regulates adjacent

, IL-8, and chemokines MCP-1

77,131

promote neutrophil phagocytosis of pathogen infection for the body’s protection

to

77,108

(Figure 2).
IL-15 is also expressed by non-immune cells like fibroblasts, epithelial,
77

endothelial, muscle cells, adipocytes, osteoclasts, neuronal and glial cells . IL-15
functions to protect these cell types from apoptosis, stimulates proliferation pathways,
supports microglial growth, T cell migration in endothelium, reduce proteolysis in skeletal
muscle, weakens nitric oxide production from microglial cells, stimulate angiogenesis
and inhibits lipid deposition

77,132-137

.

IL-15 has many useful qualities for clinical therapies to promote or inhibit
signaling in many diseases and disorders. It is important to regulate IL-15 expression
because over production of IL-15 can lead to hypersensitivity, tissue damage and
77

autoimmunity . Currently, IL-15 is being used as a target to ameliorate difficulties
patients face with rheumatoid arthritis, Lupus, inflammatory bowel disease, diabetes type
1, hypertension, muscle degeneration, and B-cell lymphoma

77,135,138-145

. IL-15 protein is

ubiquitously expressed and it can bind more than one receptor IL-15R and IL-2R. IL-15
signaling can be presented in many forms such as a free soluble protein, soluble
receptor bound, or membrane receptor bound. This suggests that regulatory
mechanisms of IL-15 can serve as a good mediator to control therapeutic mechanisms
77

against aggressive form of melanoma .

Significance
Melanoma and other cancers have the ability to increase immunosuppressive
genes expression, decrease their adhesive properties, lose MHC expression and lose
16

expression of T cell co-stimulatory molecules, enhance tumor progression, and build
Tcell tolerance against an immune response that could up-regulate effector cells to
target tumorogenic epitopes22. It is predicted that a gene therapy approach can promote
sufficient levels of a particular cytokine from the transfected cells to stimulate and restore
the body’s own natural defenses to destroy cancer cells. By controlling levels of the
cytokine it is possible to induce an immune response that recognizes tumor burden,
promotes apoptosis, CTL response, and memory response while reducing the potential
toxicity often associated with cytokine therapies performed with recombinant protein. It
has been previously demonstrated in both preclinical and clinical IL-12 studies that an
effective cytokine therapy against melanoma could be established utilizing EP to induce
an appropriate immune response with minimal toxicity

17

28,146,147

.

OBJECTIVES

The long-term goal of this study is to establish an immunotherapy using a nonviral gene delivery approach to specifically target advanced-stage cancer cells like
28

melanoma . Although gene therapy is a relatively young field, it is a promising system
to treat existing disease

24-25

. The purpose of the project is to establish a gene therapy

technique entailing the delivery of a gene encoding cytokine human IL-15 using EP into
an established mouse melanoma B16.F10 tumors. It is anticipated that the delivery of
pIL-15 will stimulate an innate and adaptive immune response removing existing disease
31

and adapting a protective response against continuous tumor antigens . The short-term
goal is to characterize EP delivery methods using mouse melanoma B16.F10 and
human keratinocytes HaCaT cells in vitro prior to translating the delivery parameters in
vivo. Melanocytes, melanoma and keratinocytes contain functional properties shared by
both human and mouse providing a useful alternative for testing delivery conditions in
vivo. There are no known macroscopic free-floating tumor models that can adapt EP
59

electrodes for delivery experiments . The in vitro 3D model will be used to examine
delivery conditions and compare results to an in vivo C57BL/6 mouse model for the
delineation of further treatment options in vivo. The objective of using a mouse model is
to determine the type of immune response attained during EP delivery of IL-15 directly
into tumor cells.

18

Hypothesis
The hypothesis of the following project is the 3D tumor model does mimic natural
cellular properties that will provide a platform to establish EP delivery conditions in vitro
and translate delivery conditions in vivo. Delivery of IL-15 by EP in vivo will recruit
effector cells to the tumor site causing tumor regression and promote a long-term
immune response during secondary tumor challenge.

Specific Aims
Specific Aim 1:
To develop a three-dimensional tumor model that could be used to evaluate gene
transfer procedures and to examine cell to cell interactions.
The work in Aim 1, included generating an in vitro 3D tumor model to study
delivery of different genes using EP to identify the best transfection efficiencies attained
when delivering into tumor cells and skin cells. The EP conditions were tested amongst
different cell types HaCaT, B16.F10 and human melanoma SKMEL-5 to examine the
differences in gene expression. To ensure positive delivery of genes into the cells of the
in vitro 3D model and to measure transfection efficiency, green fluorescent protein (GFP)
and IL-15 were separately delivered at different EP conditions by varying electric field
(EF) strengths, pulse duration and pulse number. The highest protein production
obtained in vitro was then compared to patterns of transfection efficiency and protein
production in mouse subjects. The 3D tumor model is a useful template to identify
practical EP conditions and applicators that provide optimal transfection efficiency of
genes into different cell types residing in a synthetic microenvironment. The 3D model
helps predict how cells behave when subjected to gene delivery techniques and
19

translates observations of delivery in vivo to target melanoma. The model was used to
not only translate delivery parameters in vivo, but more importantly reduce the animal
subjects for gene delivery trials. Essentially, the purpose of designing a delivery system
is to develop an immune adjuvant system that stimulates inflammatory responses
against disease targets and prime surveillance cells for continuous recognition of
specific epitopes.

Specific Aim 2:
To evaluate the intra-tumor delivery phIL-15 and the resulting protein expression to
determine if expression of IL-15 would promote tumor regression and enhance mouse
survival in an aggressive mouse melanoma model.
The work in Aim 2, used the information gathered from preclinical studies

28

and

the 3D tumor model to further test delivery conditions in vivo. The purpose was to deliver
a plasmid encoding human IL-15 (phIL-15) using EP into established melanoma tumors
and determine by ELISA, the expression levels obtained at different time points. Also,
test differences in transfection efficacy between tumor cells and skin cells when
delivering pmIL-12 and phIL-15 both in vivo. It is inferred that EP conditions producing
the highest expression level would promote the strongest immune response that would
cause tumor regression and increase mouse survival. Three different treatment (Tx)
protocols (1Tx, 2Tx and 3Tx) were used to deliver on different days to understand the
type of expression levels produced from the tumor cells and implement the protocol that
would potentially enhance effector activity that would lead to

tumor regression.

Established tumors were treated with the 3Tx protocol and tumor volumes were
monitored for 50 days. The surviving mice were challenged and monitored for an

20

additional 50 days to understand whether phIL-15+EP+ could potentially enhance a
long-term memory response against secondary tumor inoculation.

Specific Aim 3:
To identify key immune effector cells and cytokines that were directly or indirectly
stimulated following intra-tumoral delivery of pIL-15 using EP.
The work in Aim 3, characterized the signals involved in up-regulating the innate
and adaptive immune response against treated tumor cells. In this section, melanoma
was established in mice and treated with either the empty backbone pVax or phIL-15 in
the presence or absence of EP. The primary response to the treatment protocol was
analyzed at different time points to discern the type of immune cells and cytokines
present

during

stimulation.

The

following

assays

were

performed

ELISpot,

immunohistochemistry (IHC) and Luminex bead array to determine the types of immune
modulators present at the time of tumor regression and contribute to mouse survival.
Late stage cancer therapies are scarce and new types of treatment regimens are
needed to work quickly against aggressive cancers and prolong patient survival. EP
delivery system is a promising technique to control immune response stimuli, mount
one’s own immune response against existing disease and improve survival outcome of
patients

26, 31

.
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MATERIALS AND METHODS

Cell Lines
B16.F10 mouse melanoma cell line (ATCC, Manassas, VA) was used in the in
vitro 3D tumor model and inoculated into the mouse model to form solid tumors in vivo.
The human melanoma cell line SKMEL-5 (ATCC, Manassas, VA) was also used in the
3D tumor model. Both cell lines were primarily grown in a T275 flask as a 2D monolayer
of cells diluted 1:10, B16.F10 were supplemented with McCoy’s media and SKMEL were
supplemented with DMEM containing 10% FBS (Atlanta Biologicals Lawrenceville, GA)
and 0.2% Gentamycin (Mediatech, Cellgro, Manassas, VA, Mid Sci St. Louis, MO)
HaCaT human keratinocytes used in the 3D model to form the scaffolding, were a
generous gift from Dr. Mark Jaroszeski (University of South Florida, College of
Engineering). The HaCaT cells were supplemented with DMEM media containing 10%
FBS and 0.2% Gentamycin. HaCaT cells originated from an immortalized, transformed
cell line that had the ability to adhere tightly to the flask and to grow without feeder cells
148

. All cells were grown in an incubator at 37°C and 5% CO2 in humidified air. Cells were

removed from flasks using trypsin 1x without EDTA (Atlanta Biologicals Lawrenceville,
GA). Following removal from the flasks, trypsinized cells were neutralized with media,
washed in DPBS (Mediatech, Cellgro, Manassas, VA) and kept on ice until utilized for
the 3D model or inoculation in to the mouse model.

22

Plasmids
The IL-15 plasmid,

a generous gift from Dr. David B. Weiner University of

Pennsylvania College of Medicine, was cloned using human IL-15 construct (Sequence
from Gene Bank, Accessory number NM00585) into pVAX1 cloning vector (Invitrogen,
Carlsbad, CA) and was carried out by PCR amplification. The plasmid was engineered
to enhance IL-15 protein expression

149

. The long signal peptide was replaced with an

optimized leader sequence 18aa human IgE region to increase secretion levels of IL-15.
IL-15 mRNA was also optimized by removing inhibitory up-stream AUGs start codons
which normally contains 8-10 AUGs contributing to the tight translational regulation.
Also, the replacement of a weak kozak sequence with a stronger kozak sequence
designed to enhance protein IL-15 production was introduced into the plasmid

149-151

.

The optimized human IgE IL-15 insert was ligated into a pVax plasmid containing
kanamycin resistant gene, a constitutively active human CMV promoter, high copy
number pUC Origin of replication and bovine growth hormone polyadenylation site to
enhance bacterial growth

151

. IL-15 plasmid was used in the 3D model studies and in

mouse studies. Green Fluorescent Protein pEGFP-N1 (GFP) was purchased from
Clonetech (Palo Alto, CA) to study transfection efficiencies in the 3D model. The IL-15
plasmid, the empty backbone p-Vax1 plasmids (control vector) and GFP were
commercially prepared by Aldevron (Fargo, ND) to be endotoxin free. Commercially
produced plasmids provide lot consistency between experiments. Prior to use, the
plasmids were diluted to the appropriate concentration using sterile saline for each
experiment.

23

3D Model System
The High Aspect Ratio Vessels (HARVs) promote 3D cellular aggregation while
suspended in a microgravity environment (Synthecon, Houston TX)

54-55

. These vessels

rotate on their base at 1 gravitational force (1g) providing an optimal environment for
cells to grow without restraint, experiencing minimal shear and interference by the vessel
walls or disruption from the media. The bubble less system allows cellular expansion to
occur in a state of free fall or solid body rotation while floating in media

52,55-58

. The

vessels are equipped with two luer locks ports and an easy access sampling port. The
vessels contain a silicon membrane for passive diffusion of oxygen and carbon dioxide
enhancing growth of cells

44, 57,153-154

.

HARV Bioreactor Utilization
For long-term use the bioreactor motor systems RCCS-1 or RCCS-4SCQ were
disinfected with 70% ethanol and sporicide to prevent rust and contamination by
microorganism into cultured cells. In the incubator, the vessels were fastened to the
base and rotate in a clockwise motion. To promote aggregate formation, the HARV
apparatus was set to 15-17 rotations per minutes (rpm) depending on the density of the
cells placed into the HARV. The cells remained suspended in media during the rotation
and experienced minimal interference. The pH and oxygen levels between the cells and
media remained balanced because the silicon membrane allowed passive diffusion of
oxygen and carbon dioxide. This even exchange of gases ensured viability of cells
providing the necessary nutrients for cellular replication.

24

3D Tissue Culture
3-5X106 cells of HaCaT were seeded into four T275 flasks (Falcon BD
Biosciences Franklin Lakes NJ) grown in DMEM (MediaTech Manassas, VA) containing
0.2% 50mg/ml Gentamycin (MidSci St. Louis, MO), and 10% Fetal Bovine Serum (FBS)
(Atlanta Biologicals Lawrenceville, GA). After 2-3 days, confluent cells were Trypsinized
1x with EDTA (Atlanta Biologicals Lawrenceville, GA), collected and viability was
determined using trypan blue. On Day 0, 35-50X106 live cells were seeded into a HARV
in a final volume, dependent on vessel of choice 10ml or 50ml. After 1-2 days HaCaT
cells aggregated into a spheroid measuring approximately 1 cm diameter. The HARVs
were initially set for 15 revolutions per minute (rpm) for 12h and then increased to 16.518.0 rpm depending on size and shape of spheroid and stability of rotation. After 20-24h
fresh media was replaced into the HARVs containing the aggregated cells. In parallel, 12X106 B16.F10 or SKMEL-5 cells were seeded separately into two T275 flasks and
harvested for injection on Day 2.

Loading Cells into the HARV
To load the cells into the HARV or to change media, both knobs of the luer locks
were turned to the open position and a 14 gauge cannula was attached to a syringe
containing HaCaT cells suspended in media. The syringe was fastened to one open port
and then cells were slowly injected into the HARV. It was necessary to remove all
bubbles from the vessel to prevent disruption to spheroid formation. This was achieved
by injecting the media containing cells into one port of the HARV and then slowly tilting
the vessel gently forcing the bubbles with a piston-like motion into an empty syringe

25

attached to the opposite port. An important factor when handling the vessels is to avoid
57

increased pressure on the membrane .

Injection of B16.F10 into Spheroids
A monolayer of B16.F10 or SKMEL cells were harvested from T275 flask,
washed, counted using a hemocytometer and resuspended in a small volume to
concentrate cells in about 2-10x106 B16.F10 cells per 25-50µl. A 28 gauge ½ inch
needle was used to inject B16.F10 into HaCaT spheroids. Once HaCaT spheroid
aggregates formed a 1cm diameter construct, the vessel was removed from the base
and the spheroid was manipulated towards the sample port for injection of tumor cells.
The adherent properties of the HaCaT cells allowed for the spheroid to accommodate
the volume of the introduced melanoma cells. This displacement of volume was easily
observed by a slight ballooning of the spheroid during the injection. The spheroid was
durable enough to withstand one to three different injection sites, although one injection
site was sufficient. The sample port was sealed again and additional media was added
to the HARV removing excess bubbles. A mixture of two different media were used to
promote the growth of melanoma and Keratinocytes, this included 70% McCoy’s and
30% DMEM for B16.F10 or 70% MEM and 30% DMEM for SKMEL-5. 50% of the media
was changed daily in the HARV. To avoid two media changes in one day the CO 2 levels
were decreased to 1.5-1.9%. The reusable HARVs were cleaned and sterilized after
every use, per manufactures’ instructions (Synthecon, Houston TX). Briefly, the HARVs
were soaked in autoclaved deionized water or nanopure water overnight, then the
HARVs were soaked in 70% ethanol for 8-16 hours (hr), air dried, wrapped in foil and
autoclaved at 105-110°C for 30 minutes (min).
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Plasmid Delivery to 3D Spheroid
As mentioned previously, the HaCaT scaffolding forms after two days, the stable
spheroids were removed from the HARV and placed into a chamber slide (Fisher
Pittsburg, PA). 500µl of fresh DMEM was used to coat the spheroid, concentrating the
media around the delivery area. The EP electrodes were submerged in the media
around the spheroid during delivery. A 25-gauge-5/8 inch needle 1ml-syringe (BD
Biosciences Franklin Lakes, NJ) was used to inject spheroids with 50µl of a mixture
containing 3-5X106 B16.F10 or SKMEL-5 and 1.0mg/ml of GFP or IL-15 plasmid. The
EP electrodes were placed around the spheroid and pulsed at different EP parameters,
6-plate electrode (6-PE) 1300V/cm 100µs 6 pulses (P), 500V/cm 20ms 6P, 4-needle
100V/cm 20ms 12P, 4-plate electrode (4-PE) 100V/cm 150ms 8P or 200V/cm 20ms 8P.
After EP, 1-2ml of media was added to the chamber slide, covered and placed into a
1.5% CO2 37˚C humidified incubator. The spheroids were monitored and harvested 24h48h after transfection.

Stability of 3D Model Construct
HaCaT cells aggregate to form spheroids containing 50X106 cells forming about 1
cm in diameter “tissue-like” construct after 24 hours (h). The peak stability for HaCaT
spheroids occurs by 48h. The stability time points were determined by collecting
observations for HaCaT spheroid formation up to 15 days (d).The peak stability for
HaCaT spheroids injected with B16.F10 or SKMEL-5 cells was 4d after inoculation,
totaling 6d for the heterogeneous spheroid. By Day 6, melanoma had grown within and
amongst the HaCaT cells. Additionally, we observed that HaCaT spheroid aggregates
residing alone in the HARV reached terminal differentiation after 5-7d; viability was
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determined using trypan blue. HaCaT spheroids injected with melanoma remained
stable in the HARV for up to15d.

Double Staining Immunohistochemistry
(IHC) Paraffin-embedded samples were stained to identify different cell types
within the spheroid B16.F10, HaCaT and SKMEL-2. Spheroids containing proliferating
B16.F10 or SKMEL-5 cells were fixed in 4% paraformaldehyde or 10% formalin (Fisher
Pittsburg, PA) for at least 6-24h, processed and embedded in paraffin wax for
preservation. Before staining, the samples were depariffinized using Xylene (SigmaAldrich St. Louis, MO). The recipe for deparaffinization included dipping sections in
coplin jars separately containing Xylene, 100%, 95%, and 80% ethanol washes then
placed in a humidified chamber. The samples were enzymatically pre-treated for antigen
retrieval using 0.4% Pepsin in 0.01M HCL (Sigma-Aldrich, St Louis, MO). After the
incubation period, samples were rinsed with 1x phosphate buffered saline (PBS, Sigma
St. Louis MO). It was necessary to include an endogenous peroxide quenching step
containing 10% hydrogen peroxide in 30% methanol (Fisher, Pittsburg, PA) to avoid
non-specific binding of secondary conjugated Strepavidin-HRP antibodies that react with
diaminobenzidine (DAB). The sections were blocked with 2.5% normal goat serum
diluted (Thermo Scientific, Waltham MA) in 1x tris buffered saline (TBS, Boston
Bioproducts, Worcester MA) containing 0.1% BSA (Fisher Pittsburg, PA). For samples
labeled with primary antibody of mouse anti-human AE1/AE3 (MAB3412 Milipore,
Billerica MA) goat anti-mouse IgG bound to alkaline phosphatase AP (80200 QED
Bioscience Inc. San Diego CA) was used as the secondary antibody. For rabbit antimouse S100 (AB941 Millipore, Billerica MA) 2.5% bovine serum was used to block for
the secondary antibody bovine anti-rabbit IgG HRP (sc-2370 Santa Cruz Biotech, Santa
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Cruz CA). In this experiment, AE1/AE3 (1-10mg/ml) was diluted 1:100 in TBS +
0.1%BSA and then the secondary antibody goat anti-mouse IgG AP was diluted 1:20 in
TBS + 0.1%BSA. The samples were developed using Fast Red substrate chromogen
developer solution, per manufacturer’s instructions (Thermo Scientific, Waltham MA).
Briefly, 3ml of Napthol Phosphate Substrate was mixed with 1 drop 40ul of Liquid Fast
Red Chromogen. All staining procedures were repeated incubating S100 (1:800) in 2.5%
normal bovine serum. Then the samples were incubated with secondary antibody bovine
anti-rabbit IgG HRP (1:20) in 2.5% normal bovine serum. A DAB substrate was used per
manufacturer’s instructions one tablet 10mg was mixed in distilled water (Acros
EASYtablets, Geel Belgium) to develop the stain. The sample slides were
counterstained using Hemotoxylin (Sigma, St Louis MO), rinsed, mounted and slides
were observed under a light microscope (Leica Wetzlar Germany). Negative controls
were included to show specificity of the primary antibodies and the lack of nonspecific
binding of the secondary antibodies. For example, the primary antibody was added to
the slide but a secondary antibody that did not match was also added and showed no
reactivity.

TdT-FragEL DNA Fragmentation Detection and Immunohistochemistry (IHC)
Assay
The TdT-FragEL DNA Fragmentation Detection assay (Calbiochem San Diego,
CA) was performed on paraffin embedded samples to identify cells undergoing cell
death followed by a double IHC assay to specifically identify the cells that were
undergoing apoptosis. The assay was performed per manufacturer’s instructions. Briefly,
a positive and negative control was performed simultaneously with the assay. The
positive control, DNAse I (Promega, Madison WI) intentionally nicked the DNA ends and
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the negative control was absent of the TdT reaction mix. The samples on the slide were
deparaffinized and rehydrated by immersing slides in Xylene and then in different
concentrations of ethanol (Sigma-Aldrich St. Louis, MO). The sections were
permeabilized using 2mg/ml of Proteinase K (Thermo Sci Waltham, MA) 1:100 in 10mM
Tris pH 8, then blocked for endogenous peroxidases 30% hydrogen peroxide (Thermo
Sci Waltham, MA ) in methanol (Sigma-Aldrich). The sections were equilibrated, labeled
with TdT labeling reaction mix and conjugated with Strep-HRP and developed with DAB
solution. Double IHC staining, the primary mouse anti-human AE1/AE3 antibody was
diluted 1:200 in 2.5% normal goat serum (All chicken, goat and rabbit serum Molecular
Probes, Carlsbad CA) and the secondary goat anti-mouse IgG AP was diluted 1:50 in
2.5% goat serum. All slides were developed using Fast Red. Then, sections were
incubated with primary antibody S100 goat anti-mouse (sc-7849 Santa Cruz Biotech,
Santa Cruz CA) diluted 1:100 in rabbit serum. The sections were incubated with the
secondary rabbit anti-goat IgG HRP (HAF017 R&D Systems, Minneapolis MN) diluted
1:20 in rabbit serum and developed using DAB. Finally, the sections were
counterstained with methyl green, mounted using permount (Fisher, Pittsburgh PA) and
then observed under a light microscope. A methyl green counter-stain distinguished
normal cells from apoptotic cells by producing a tan or blue-green stain for viable cells
and a dark brown stain for dead cells. Viable cells were counted using an ocular lens
micrometer at 200x Magnification (Mag).

Double Immunofluorescence (IF)
This assay was performed based on protocol described on the Cell Signal
website (www.cellsignal.com/support/protocols/IF.html). Briefly, the sections were
deparaffinized and rehydrated using xylene and ethanols. The antigen retrieval step
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involved using 10mM of sodium citrate pH 6 in deionized water. The slides were placed
in a coplin jar and heated in a water bath up to 87°C for 20min. The sections were
blocked using cocktail blocking buffer mixed separately from different host serum. Total
volume 25ml: mixed 2.5ml 10x PBS, 1.25ml normal chicken or rabbit serum, 21.25ml of
deionized water were mixed, and 75μl of TritonX-100 (100%, Sigma St. Louis MO). A
primary antibody cocktail was prepared separately and then combined on the slide; a
10ml antibody dilution buffer was prepared using 400μl of 10x PBS, 3.6ml of deionized
water mixed, 0.040g of Bovine Serum Albumin (BSA Fisher, Pittsburgh PA) and 12μl
TritonX-100. Mouse anti-human AE1/AE3 was diluted 1:100 and goat anti-mouse S100
(sc7849 Santa Cruz Biotech, Santa Cruz CA) was diluted 1:50 in dilution buffer. The
cocktail of antibodies were incubated at 4°C overnight. The following day the slides were
washed in 1x PBS, an additional wash was added 0.4M high salt 1x PBS solution to
reduce background staining. The sections were blocked again to avoid non-specific
binding by the secondary antibodies. The rabbit anti-goat IgG FITC was diluted 1:100
and chicken anti-mouse IgG Rhodamine was diluted 1:100 (sc-2777 and sc-2861 Santa
Cruz Biotech, Santa Cruz CA). The sections were washed with PBS and high salt PBS.
The sections were also re-incubated with rabbit anti-goat IgG FITC diluted to 1:50 to
ensure binding of this secondary antibody. The samples were mounted using
vectashield medium (Vectashield, Burlingame CA) and excited at two different wave
lengths
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simultaneously with this assay. The primary antibodies were added but mis-matched
secondary antibodies were used to check for cross reactivity.
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Proliferation Assay and Extracellular Matrix Staining
A double IHC was performed to stain for proliferating cells and cells synthesizing
their own extracellular matrix. An Abcam (http://www.abcam.com) protocol was used to
perform staining procedures. Briefly, slides were deparaffinized, rehydrated, antigens
were unmasked using 20μg/ml of Proteinase K 30min 37°C and samples were blocked
using straight goat serum plus 0.025% triton X. The slides were labeled with primary
antibody Ki-67 1:200 (ab15580 Abcam Cambridge MA) or Fibronectin 1:200 (ab2413
Abcam Cambridge MA) and then incubated with secondary antibody goat anti-rabbit
IgG-HRP 1:20 (ab6721 Abcam Cambridge MA). The labeled samples were developed
using DAB and then visualized under a light microscope. The slides were counterstained
using AE1/AE3 1:200 and secondary antibody goat anti-mouse IgG AP 1:200 as
mentioned above. A negative control was tested along with the sample slides where the
secondary antibody was tested for non-specific binding in the absence of the primary
antibody.

Odyssey Western Blots
The western blot was performed using 4%-15% separating ready-gels and
transfer blot apparatus (Biorad Hercules, CA) to detect the following protein markers Ecad (MAB3199Z Chemicon Millipore Billerica, MA), Cyto-8 (sc-8020 Santa Cruz Biotech
Inc Santa Cruz, CA) and Beta Actin (#4967 Cell Signaling Danvers, MA). Total protein
concentrations was determined by BCA protein assay kit (Pierce, Rockford, IL).The 32µg
of total protein was loaded into each well of the SDS gel and the odyssey’s two color
protein molecular weight marker ranging 10-250kDa. Proteins were separated using
120V for 5mins then 110V for 55mins. The bands were transferred onto a Millipore
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Immobilon PVDF Membrane (Licor Lincoln, NE) for 1hr at 110V. The membrane was
blocked using Odysseys’ Blocking Buffer (Licor) for 1hr, and then incubated with primary
antibody 1:2,000 E-cad or 1:500 Cyto-8 at room temperature (RT) on a shaker overnight.
After 16-18h the membrane was incubated with 1:15,000 secondary antibody 0.5mg
goat anti-mouse IRDye 800CW NHS Ester for 1hr (Licor). An Odyssey Infrared
scanner/reader was used to detect fluorescently labeled bands. A New-Blot PVDF
stripping reagent (All reagents and products purchased from Li-cor Biosci Lincoln, NE)
was used to analyze the two different primary antibodies. Protein bands were normalized
against 1:5,000 Beta Actin (Cell Signaling Danvers, MA).

GFP Delivery
To ensure delivery of GFP in the spheroid, spheroids were formed by day 2,
injected with a mixture of (1.0mg/ml) GFP+ (2-3X106) B16.F10 and immediately
electroporated. After 24h, spheroids were collected, snap frozen and sectioned. Sections
were labeled with nuclear (1:1,000) DAPI to visualize all cells and then sections were
analyzed for GFP expression using an Olympus microscope at 200x Mag. The images
show that spheroids that received EP at 500V/cm and 1300V/cm.

Immunofluorescence Frozen Sections
Spheroids were collected at 24-48h, snap frozen and cryo-sectioned. Samples
were labeled with 1:1,000 DAPI (Sigma-Aldrich St. Louis, MO) for 10mins, blocked with
2.5% chicken serum (Thermo Sci Waltham, MA) for 1hr, incubated with primary antibody
1:100 AE1/AE3 (MAB3412 Chemicon Millipore Billerica, MA) for 2hrs and then incubated
with 1:100 secondary antibody chicken anti-mouse IgG Rhodamine (sc-2861 Santa Cruz
Biotech. Inc. Santa Cruz, CA) for 1h on shaker at RT. An Olympus microscope with
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camera was used to analyze GFP transfection. Leica Stereoscope with digital camera
was used to analyze GFP transfected into spheroids macroscopically.

Flow Cytometry Analysis of GFP
Spheroid aggregates were pressed through a 40µm Nylon cell strainer (BD
Biosciences Franklin Lakes, NJ) and viability was determined by trypan blue (Fisher Sci.
Pittsburg, PA). For live/dead gating, 1-3X106 cells were incubated with 10µl of Propidium
Iodide 250ug/ml (Immunochemistry Bloomington, MN) for 30mins and then sampled
using the FACS Aria I to quantitate GFP expression between controls and transfected
groups.

Tumor Production
Cultured B16.F10 cells were harvested, counted for >90% viability by trypan blue
exclusion dye method and resuspended in sterile 1XDPBS and diluted to 20 X10 6
cells/ml prior to mouse inoculation. Female 6-8week-old C57BL/6 mice from Jackson
Laboratories (Bar Harbor, ME) were injected subcutaneously into the shaved left flank
with 0.05 ml containing 1x106 murine melanoma B16.F10. Tumors cells were incubated
in mouse for 6-10 days or until the tumor measured approximately 30-60mm3 in size.
Mouse studies were performed to study IL-15 transfection efficiency, establishing
plasmid concentrations, tumor treatment schedules, immune response stimulatory
assays, regression studies and challenge studies.

Tumor Treatment
Mice were anesthetized during all treatments. Anesthesia was administered by
placing animals into an induction chamber infused with a mixture of 3% isoflurane and
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97% oxygen for several minutes. After animals were anesthetized, the mice were fitted
with a standard rodent mask and continuously anesthetized with 2-3% isoflurane in
oxygen. Each mouse was closely followed after EP treatment until fully recovered from
anesthesia.
Intra-tumoral treatments were performed as described; anesthetized mice were
injected with 50µl of 1.0mg/ml-2.0mg/ml of phIL-15 or mouse pmIL-12 plasmid DNA in
sterile saline. An applicator containing 6 penetrating electrodes was placed around the
tumor slightly penetrating the skin for full contact. Tumor was immediately electroporated
with the following conditions: 1300 V/cm of 100 µs 6 pulses (P) or 500V/cm 20ms 6P
using a six needle array. The six needle array was selected based on previous studies
demonstrating that this electrode design was able to pulse in six different directions
encompassing the entire area of the tumor (39).
C57BL/6 mice were intra-dermally injected with phIL-15 or pmIL-12 and
immediately electroporated using a 4-PE with 100V/cm 150ms 8p and 200V/cm 20ms
8P conditions. All samples were collected after 12h, 18h, 24h and 48h; snap frozen and
stored at -80˚C until processed for ELISA analysis. The mouse IL-12 plasmid was used
to confirm EP parameters and compare transfection efficiency and protein production
levels between cytokine plasmids. Tumor and skin samples were tested, to understand
cytokine delivery outcomes between different tissue types using multiple EP conditions.

Tumor Measurements
To determine initial tumor volume and monitor tumor regression, tumors were
measured prior to treatments and at periodic intervals following treatment using a digital
caliper. Volume was calculated using the following equation V=ab2 /6: where (a) is the
longest diameter and (b) is the shortest diameter perpendicular to (a). The tumor volume
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+/- standard deviation (S.D.) was calculated for each group at each selected time point.
The mice were followed up to 50 days or until the tumor volume reached 1000 mm 3.The
mice were humanely euthanized with CO2 under vivarium staff supervision.

ELISA
Levels of IL-15 were obtained using a monoclonal human IL-15 Quantikine kit
(D1500 R&D Systems Minneapolis, MN) and ELISA performed following the
manufacturer’s instructions. Spheroids and media were collected from the 3D model and
snap frozen. Retro-orbital bleeding was performed on mice under anesthesia for serum
collection and the mice were humanely euthanized for the collection of tumor samples.
Tumors were snap frozen and stored at -80˚C until analyzed. The sample were thawed
on ice, weighed, diluted in 500µl-800µl of phosphate buffered saline (Omnipur
EMD4Biosci Darmstadt, Germany) plus Protease Inhibitor Cocktail (Roche Brandford,
CT) dependent on sample size and homogenized using a PowerGen 700 (Fisher
Scientific Pittsburg, PA ). The homogenate was centrifuged at 1000rpm for 5 minutes at
4˚C and the supernatant was assayed the same day by colorimetric analysis to measure
differences in protein levels. Serum levels were calculated as pg of cytokine per ml of
serum (Average pg/mL). Cytokine levels were calculated as pg of cytokine per weight of
tumor (Average Total pg/0.1g).

Western Blot
Tumor and serum samples were collected to test production of human IL-15.
Hong Yang M.D. performed western blot analysis for phIL-15 expression following intratumoral delivery using EP. BCA assay was used to test total protein levels of
homogenized supernatant. To a 15% separating gel, 40µg of each sample was added to
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the wells. The samples were initially separated at 80V for 30 mins then 160V until
molecular weight marker separated on the gel. The gel was wet transferred to
nitrocellulose membrane (Bio-rad) by electrophoresis at 130V for 1 h. The membrane
was blocked for 1hr at RT shaking in 3%BSA then incubated 1:5,000 rabbit anti-human
IL-15 polyclonal antibody (PA0672 Cell Sciences Canton, MA) overnight in 3% BSA. The
following day the membrane was washed and incubated with 1:1,000 secondary bovine
anti-rabbit IgG HRP (sc2370 Santa Cruz Biotech Santa Cruz, CA) in 5% milk for 1h.
Protein levels were normalized against internal control rabbit anti mouse β-actin (4967
Cell Signaling Canton, MA) 1:1,000 in 5% milk 1hr and 1:5000 goat anti-rabbit IgG HRP
(ab6721-1 Abcam Cambridge, MA)for 1hr. Developed the membrane using Super Signal
West Pico chemilluminescent substrate solution (Thermo Sci Pittsburg, PA) for 5 mins,
blot then expose to film 30s-1min.

Frozen Immunohistochemistry
Tumor samples were collected from mice and fixed in zinc fixative (BD
Pharmingen BD Biosci Franklin Lakes, NJ) at room temperature for 2hrs up to 24hrs.
Then samples were embedded in OCT (Tissue Tek Dublin, OH), snap frozen on dry ice
and stored at -80°C until cryo-sectioning. The blocks were kept at -16 to-23°C during
sectioning, the blocks were sectioned 7-10µm, fixed in cold acetone, then stored at 20°C until staining. The samples were removed from -20°C, air dried for15-30mins and
then marked with a pap pen (Biogenex optiplus Hyderabad, India).Sections were rinsed
fixed tissue with TBS 2x for 10 mins in humidity chamber with gentle agitation at room
temperature on a shaker at 50 rpm. Sections were blocked with 5% normal rabbit
serum/TBS for CD4/8+T cells, or goat serum/TBS for NK at room temperature for 1hr.
Samples were also blocked with Avidin/Biotin kit for 15mins each (SP 2001 Vector Labs
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Burlingame, CA). Primary antibody was added 1:20 purified rat-anti-mouse CD8a
IgG2aκ (550281 Clone 53-6.7 BD Pharmingen), 1:20 rat anti-mouse CD4 IgG2aκ
(220280 Clone RM4-5 BD Pharmingen) or 1:10 anti-mouse CD49IgM κ pan-NK-ells
NK1.1 (108902 Clone DX5 Biolegend San Diego, CA) for 1hr. Washed then incubated
with 1:250 secondary antibody IgG rabbit biotinylated antibody (BA-4001 Vector Labs)
for CD4+ and CD8+ or 1:1,000 mouse absorbed affinity purified secondary antibody
biotinylated Goat Anti-rat IgG, IgM, IgA (612106130 Rockland Gilbertsville PA) for 1hr.
Washed then incubated in enzyme 1:300 Alkaline phosphatase streptavadin (SA-5100
Vector Labs) or 1:100 Enzyme Horseradish peroxidase streptavadin 1:100 for 15mins
(SA-5004 Vector Labs). Washed and then incubated in Alkaline phosphatase substrate
kit red or blue for 7-8mins (SK5100 or SK5300 Vector Lab Burlingame, CA) or DAB kit
Easy Tablets. Rinsed with DiH2O and counterstained using methyl green for 1-2 mins
(H-3402 Vector Labs). Washed with tap water and dehydrated with ethanols, dried and
mounted using a permanent mounting media (H5000.Vector labs).

Luminex Bead Assay
Milliplex (Millipore #MPXMCYTO-70k Billerica, MA) bead assay was used to test
multiple cytokine stimulation from tumor and serum samples. These beads were
purchased as a 10-plex kitassay measuring expression levels of specific antibody beads
including INF-, TNF-, GM-CSF, IL-1β, IL-2, IL-4, IL-6, IL-10, IL-12, and MIP1β. The
color coded polystyrene beads bind to an unknown amounts of cytokines and quantified
by Luminex xMap software analysis. Briefly, as per manufacturer’s instructions, 96-well
plate is prepared by pre-wetting the filter plate using 200μl with wash buffer then vacuum
filtered. Normalized samples were diluted for the assay and kept on ice. 25μl of
standards, controls were added to 25μl of assay buffer. Matrix buffer PBS+PI was added
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to the sample wells, then 25μl of samples were added to the wells, and finally 25μl of
premixed beads were added to all wells. The plate was incubated on a shaker at 500800 rpm overnight, The next day, plates were washed and vacuumed, 25μl of detection
antibodies were prepared and added for 1hr with shaking and then 25μl Streptavidin-PE
was added directly to detection antibody for 30mins with shaking. The plate was then
vacuum filtered. The beads were resuspended in 150μl of sheath fluid and then the plate
was read on the Luminex.

ELISPOT Assays:
Spleen and PBMCs were collected at different time points to determine specific
anti-tumor responses following treatment with various protocols. Response was based
on IFNγ production ex vivo following stimulation with tumor antigens. ELISpot assay was
performed as per manufacturer’s instructions (R&D Systems Minneapolis, MN). Briefly,
the day after the last therapeutic injection of IL-15 plasmid, samples were collected,
prepped for cell culture, red blood cells were lysed with ACK (Quality Biologicals
Gaithersburg, MD) and washed. The cells were counted using typan blue, a total of
2X106 PBMCs isolated from blood and 30X106 splenocytes isolated from spleens. The
cells were placed in 24-well plates and incubated overnight to stabilize cells. The next
day 300,000 PBMCs and splenocytes were transferred to 96-well V-bottom plates with
media and stimulated with target 30,000 B16.F10 cells for 4-6 days. The 96-well plates
were coated with antibody IFN-γ on day 3 or 5 (SEL485 R&D Systems) then blocked at
RT for 2h. After appropriate incubation and washing, the effector and target cells were
added to membrane plates containing IFNγ and incubated for overnight in the incubator
at 37˚C 5% CO2. The plates were washed the following day and then incubated with
appropriate detection antibody overnight at 4˚C. The plate was washed on the following
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day and then developed using a strepavidin-alkaline phosphatase/substrate system
(SEL002 R&D Systems). Positive control concanavalin A (Sigma Aldrich) and
recombinant protein IFNγ (Peprotech Rockhill, NJ) were tested and media served as a
negative control.

Statistical Analysis
The results were analyzed using SPSS (IBM Chicago, IL) software to examine
significance between treatment groups and controls samples using a two different tests.
In the in vitro 3D tumor model experiments a one-way ANOVA post-hoc LSD test was
utilized for statistical analysis. In the in vivo mouse model measuring phIL-15 and mIL-12
expression a two- tailed Student’s t-test was utilized for statistical analysis. The data was
graphed based on the groups mean and standard deviation. 4-6 independent
experiments were performed depending on the assay. Results were considered
significance at p≤0.05. The experimental variation was analyzed using standard
deviation and fold change was compared between the mean of each group tested.
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RESULTS
Specific Aim 1
To develop a three-dimensional tumor model that could be used to evaluate gene
transfer procedures and to examine cell to cell interactions.

The purpose for developing and utilizing an in vitro 3D tumor model was to
evaluate EP conditions that efficiently deliver plasmids into specific cell types and in turn,
promote gene expression by the cells’ own transcription/translation factors. The work
performed in Aim 1 was focused on creating the 3D tumor model, testing the model’s
stability, cellular functionality and over all applicability. The goal was to use the 3D tumor
model to develop gene delivery techniques in vitro and translate those methods in vivo
to develop a treatment regimen that would induce an immune response against
melanoma. The objective was to grow a large synthetic tumor model (spheroid) to test
plasmid delivery in vitro and compare results to preliminary studies in vivo and evaluate
transfection efficiency and efficacy of delivery parameters. The advantage is that this
model would reduce the number of animal subjects otherwise needed to test several
preliminary plasmid delivery conditions.
Many different methods have been used to generate 3D tumor models in
particular to study melanogenesis. Several different methods have been attempted to
generate a large-scale 3D tumor model. A few techniques that were assessed include
the liquid overlay method
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, matrigel/algi matrix (Gibco), cytodex/plastic beads scaffold

(Sigma/Solohill) and extracel sponges (Glycosan).
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The liquid overlay method consists of an agar/collagen platform that surrounds
cells to help stimulate 3D growth and enhance proliferation of cells in a non-adherent
matrix (Figure 3). Solidified agar coats the bottom of a plate keeping adherent cells such
as B16.F10 cells from attaching. The cells are then coated with a collagen matrix that

Figure 3: Liquid Overlay Method
containing B16.F10 sampled after 26
days in culture. Size: 500µm.

Figure 5: Cytodex Beads Scaffold
B16.F10 sampled from HARV after
adhering to beads and expanding for 10
days. Size 619µm.

Figure 4: Algi Matrix containing B16.F10
sampled after 17days in culture. Size:
375µm.

Figure 6: Plastic Beads Scaffold
B16.F10 sampled from HARV
aggregating after 10 Days. Size 407µm.
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Figure 7: Sponge Matrix Scaffold B16.F10 sampled from the HARV aggregating
after 49 days. Size 750µm.

polymerizes around the cells to act as an extracellular matrix that supports cellular
aggregation and migration. The system promotes collective “tissue-like” growth of cells
in an artificial environment without the need of biological stimulus. It was observed that
B16.F10 cells tend to adhere to one another stimulating continuous proliferation and
expansion until they form a melanoma mass. In nature, aggressive growth of melanoma
needs the presence of a germinal layer for mass formation and cellular expansion. The
liquid over lay method thus provides this matrix and substitutes as a scaffolding,
extracellular matrix, or basement membrane to promote proliferation and differentiation.
The matrix facilitates adherent cells communication for cellular development. In this 3D
method, cells aggregate and form several small tumor mass populations on top of the
agar, but were limited to µm in size even after a month in culture. The separate
populations formed small mass about 250-500µm in diameter over a 3-4 week period.
The cells behaved similar to melanoma in nature because the aggregated cells formed
masses that contained viable cells towards the outside and necrotic cells towards the
center. Although, the isolated populations did not aggregate towards each other to form
one large mass, they formed several small populations. The cells did form a 3D tumor
system similar to in vivo tumors, but expansion rates were slow. This approach was
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deemed unsuitable as the goal was to generate a tumor system that was about 1 cm in
diameter to enable testing of delivery conditions using electrode applicators containing a
1 cm gap. The objective was to administer electric pulses to enhance delivery to target
cells or tissue in a manner that would simulate the in vivo procedure.
Other methods were used to help promote cellular expansion and large-scale
tumor mass formation in vitro. To enhance mass formation more cells were required to
be present in the same location. Two methods were tested: the agar/collagen matrix and
algi matrix. In both synthetic materials, the cells were pierced into the matrix. This
allowed for more cells to grow together and expand more quickly in size. The idea was
to increase the number of B16.F10 cells in a location to allow cells the opportunity to
communicate, adhere to one another and expand into a tumor mass at a faster rate
(Figure 4). The cells did aggregate and formed a 3D tumor model as suggested prior
studies
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, but the size of the model remained too small to accomplish the goal of this

study and for macroscopic manipulation. A few more matrixes were used to help
promote larger cellular expansion such as an extracel sponge made of a polymer
material that ensures expansion of cells, but was limited to µm in size. Experiments
using the matrices described above were successful in promoting cellular aggregation of
melanoma to a size of 50μm to 500μm. The techniques supplied useful information of
3D modeling on a microscale. The matrices provided structure and scaffolding for
cellular accumulation, but the aggregates were not solid and did not maintain mass
formation, they were easily disturbed when manipulated or transferred. The other
limitation was that cells needed to be in the same location and constantly bathed in fresh
nutrients. Additional experiments were conducted to attempt to obtain tumor sizes closer
to 1cm in diameter.
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The necessity to keep cells close to each other was an important feature for
cellular expansion and mass formation. The factors that possibly limited cellular
expansion using the matrices was reduction in nutrient/oxygen availability to cells and
possibly the act of embedding the cells into the matrix limited expansion. The key
concepts for mass formation included continuous oxygen exchange, surplus supply of
nutrients and cellular contact. A group of NASA scientists developed a bioreactor system
(high aspect ratio vessel, HARV) that promoted large-scale cellular aggregation bathing
cells in a large volume of fresh nutrients, while growing suspended in an oxygen-rich
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synthetic environment . The HARV’s horizontal rotation exerts forces onto these dense
particles and drives cells towards co-localization

56-57

.These researchers tested many cell

types and found that cells aggregated into 3D constructs using homogeneous or
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heterogeneous cells populations . The bioreactor provides a microenvironment suitable
for cellular growth and development to facilitate natural cellular behavior. The next
experiments utilized the bioreactor system to seed B16.F10 cells alone and use their
own adherent properties to bind each other and promote mass aggregation. The
bioreactors were also seeded with B16.F10 injected into sponge matrix, or grown onto
plastic beads or cytodex beads to serve as a scaffold for cellular proliferation and mass
formation
B16.F10 cells were harvested and seeded onto cytodex dextrose coated beads
(Figure 5), plastic beads (Figure 6) or extracel sponge(Figure 7) over night for
adherence and then injected into the HARV. The use of cytodex beads, plastic beads or
extracell sponge was to stabilize melanoma spheroid development (Figure 5-7). The
cells were monitored for 10 days and up to 49 days. The beads facilitated mass
formation and slightly increased aggregate stability during handling. The cytodex beads
strongly adhered cells to the dextrose coating, but limited expansion by concentrating
45

cells to the beads themselves. The plastic beads and sponge matrix allowed slightly
more cells to adhere to one another concentrating them into dense cellular populations,
but again limited expansion because the construct was weak and cells would slough off
into small sheets. The cells behaved as suggested by NASA/Synthecon bioreactor
researchers forming a mass ranging from 600-700µm, but the magnitude and stability of
the construct remained unresolved.
B16.F10 cells were injected into the HARV without a scaffold or matrix and
instantly these cells aggregated forming a tissue-like construct (Figure 8). The drawback
of this method was that the cells were weakly attached to one another and were easily
disrupted by stopping the HARV’s rotation or while changing media, leading to
detachment of large cellular sheets from the mass. These observations led to the idea
that cells must need a scaffold that would keep the cells in a stable mass formation.
Based on the mechanics instilled on cells by the HARV, description in the literature on

Figure 8: B16.F10 Cells Placed into
HARV with No Scaffold. Loose cells
were observed after 24h.
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Figure 9: HaCaT Aggregate.
HaCaT cells placed into HARV forms
a spheroid after 24h. Size 1cm.

the effects of the HARV has on adherent cells

56-57

and the observations suggested that

a biological scaffold would possibly provide the structure needed to maintain a stable
aggregates containing melanoma cells that would enhance cell interaction and
communication.

Figure 10: Injecting B16.F10 and
HaCaT into the HARV Simultaneously,
formed two separate cellular aggregates
after Day 2.

Figure 11: HaCaT Layering Effect.
Injecting B16.F10 and HaCaT into the HARV
simultaneously and adding additional HaCaT
cells every day for 6 days.

The concept that melanocytes grow in the epidermis and that they are stabilized
by keratinocytes gave the idea that adherent keratinocytes would act as the necessary
scaffolding needed to promote adherent growth of melanoma cells. The human
keratinocytes (HaCaT) were seeded in the HARV at many different concentrations 3060X106 cells/10ml. The HaCaT immediately aggregated into small and large sacs of
cells or spheroids after 24hours (h) (Figure 9). The sacs of aggregated cells were tightly
adherent to one another and the construct consisted of a smooth external layer, while
the cells in the center were mostly loose and dense. Observing the cells under the
microscope, the outer cells were sheets of tightly adherent cells and the cells in the
center were smaller aggregates of HaCaT populations. These spheroids were so stable
after 48h to 72h that interrupting the HARV’s rotation, changing the media or handling
did not cause the spheroid to fall apart. These stable aggregates contained adherent
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properties that formed the 3D construct measuring about 1cm in diameter (Figure 9).
The spheroid was easily handled and had the potential to be used for plasmid delivery
experiments. The large constructs remained intact when transferred from the HARV to a
petri dish.
To introduce the B16.F10 cells into the system and promote tumor mass
formation, the HaCaT and B16.F10 were seeded into the HARV simultaneously (Figure
10). The B16.F10 cells formed loose secondary aggregates that were unincorporated
into the spheroids and were slightly adherent to the outside of the spheroid. Another way
to incorporate B16.F10 cells into the HaCaT was to layer the B16.F10 cells with HaCaT
by initially seeding a small amount of HaCaT, allowing spheroid formation and then
B16.F10 incorporation. This process was repeated after 24h and thereafter, every 48h72h for 6 days (Figure 11). Unfortunately, the layering-effect also did not incorporate
B16.F10 as well as expected. Both attempts at tumor mass formation were unsuccessful
because B16.F10 did not incorporate into the system and enhance stability of the
construct. The HaCaT spheroid did not form properly when B16.F10 were introduced. It
seemed that when two populations of cells with different densities attempted to
aggregate in the same space spheroid formation was less likely to occur.

Figure 12: B16.F10 Injection into
HaCaT. 3-5X106 B16.F10 injected into
HaCaT spheroid by Day 2.
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Since HaCaT alone spheroids were so stable, the thought was that the HaCaT
may be able to withstand an injection of B16.F10 cells into the center of the spheroid
(Figure 12). A total of 3-5X106 B16.F10 cells were injected into the HaCaT spheroid
construct without losing its shape’s integrity. The spheroid stability after 24-72h was
impressive; the spheroid was malleable, accommodated volume displacement during
injections and was resilient to multiple needle punctures. The spheroid provided the right
conditions for B16.F10 cells to expand within the HaCaT spheroid after 5 to 7 days
(Figure 13-14). The tan colored cells were the HaCaT and the dark brown pigmented
cells were the B16.F10. Figure 13 shows tumor spheroid in suspension and Figure 14
shows a stable tumor spheroid transferred to a petri dish measuring about 0.9 cm. The
construction of a 3D tumor model containing a heterogeneous population of
HaCaT+B16.F10 cells was successfully developed. This is the first report of a large,
free-floating 3D tumor model measuring about 1cm in diameter. The utilization of
bioreactors provided the necessary qualities to promote heterogeneous cellular
integration.

Figure 13: B16.F10 and HaCaT
Spheroid Residing in HARV
remained bouyant and stable after a
total of 6 days.
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Figure 14: Stability of HaCaT and
B16.F10 Spheroid Measuring
About 1cm, remained stable during
transfer after a total of 6 days in the
HARV. Size 0.9cm.

Figure 15: Immunohistochemistry Viability Assay B16.F10 and HaCaT
paraffin embedded and sectioned for pathologist analysis. Morphology and
cell viability were analyzed after 6 days. Bar=20µm. 100x Magnification.

With the construction of an appropriate 3D tumor model, it was critical to test the
3D model’s cell viability, proliferative properties, differentiation state, stability,
communication, cellular interactions, functionality, and applicability. Cells viability was
confirmed by paraffin embedded IHC. In Figure 15, an immunohistochemisty (IHC)
analysis was performed on multiple paraffin embedded spheroid HaCaT+B16.F10
samples. It was confirmed through histological evaluation by Jane Messina M.D.(H. Lee
Moffitt Cancer Center Tampa, FL) that 80% of B16.F10 stained brown and HaCaT
stained red, cells remained viable in this construct. Samples were injected with B16.F10
on Day 2 after the spheroid was formed and 4-6 days later the HaCaT+B16.F10 were
collected for staining. Dr. Messina confirmed that the cells’ nuclei were intact, cytoplasm
was free of granules and model contained a 3:1 ratio of HaCaT cells to B16.F10. This
indicated that the amount of B16.F10 cells grew rapidly over time making up one third of
the construct, even though, initially, the spheroid contained 10 times more HaCaT cells
than B16.F10 cells (Figure 15).
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To provide further evidence of the viability of cells residing in the construct, TdTFragEL DNA Fragmentation Detection assay (TdT) and double IHC assays were
preformed. TdT assay was performed to identify live from dead cells and IHC was

Figure 16: TdT and IHC analysis. B16.F10 and HaCaT sectioned for viability assay and stained
with double immunohistochemistry. a. positive control DNAseI B16.F10 stained brown, apoptotic
nuclei stained dark brown b. B16.F10 brown, HaCaT red viable cells stained tan, or blue-green,
samples were collected 4-5 days after B16.F10 inoculation. Bar=100µm Magnification 400x.

Figure 17: Double Immunoflourescence Orientation. B16.F10 and HaCaT cells were labeled
with specific fluorescently labeled fluorophores. a. B16.F10 stained green in FITC channel, b.
HaCaT staining red in TRITC channel. c. Merged image of B16.F10 and HaCaT, with enlarged
magnification of a population of cells. Bar=200µm. 200x + 16x Magnification.
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performed to show the specific cell types present such as HaCaT and B16.F10 (Figure
16). Cells that were reactive to the TdT assay had stained dark brown nuclei and those
that were non-reactive had tan or blue-green stained nuclei. To confirm the staining
protocol a positive control slide was subjected to DNAseI enzyme, which nicked the DNA
and allowed TdT labeling to bind free 3’OH groups and produce a dark brown stain. The
nuclei that stained dark brown indicated that these cells were dead undergoing a pseudo
apoptotic process (Figure 16a). The negative control showed that the nuclei of cells did
not stain. In Figure 16b, the viable cells were stained tan or blue, were counted at 100x
magnification, from 10 different quadrants, a total of 3 times from 3-4 different samples.
It was observed that 80-90% of the B16.F10 cells and HaCaT cells remained viable after
residing within the spheroid for 6-7 days (Figure 16b). These stained sections
demonstrated that B16.F10 cells were proliferating and grouping together amongst the
HaCaT cells forming isolated aggregates as though these cells populations were
grouping to form tumor masses.
Observations of the spheroid suggested that cells were interacting and
communicating with one another.

A double immunofluorescence (IF) assay was

performed to evaluate the spatial orientation of HaCaT cells relative to B16.F10
tumorgenic cells (Figure 17). This particular spheroid construct was harvested 5 days
after B16.F10 inoculation. Figure 17a, shows the fluorescent excitation of B16.F10 cells
attached to S100 and conjugated Fluorescein Iso-thiocyanate (FITC) antibody bound
fluorophore and Figure 17b shows excitation of HaCaT cells AE1/AE3 and conjugated
Tetramethyl Rhodamine Isothiocyanate (TRITC) antibody bound fluorophore, each cell
type fluoresced independently of one another. The final panel in Figure 17c shows the
two images merged to analyze the amount of overlap that occurred between the two cell
types growing in the HARV. The green fluorescently labeled B16.F10 cells were
52

surrounded by HaCaT and also integrated with HaCaT cells stained in red (single
arrows). The B16.F10 cells appeared as though they were grouped in isolated
populations as well as growing on top of the HaCaT cells (single arrows). The HaCaT
cells appeared as though they were organized; flattening and stacking making up the
walls of the spheroid, while B16.F10 grew on top of the HaCaT (triple arrows). A growth
pattern and cellular arrangement amongst these cells were clearly identified in the
pictures. B16.F10 cells appeared as though they were growing processes and beginning
to display elongated morphological changes (Figure 18a). The development of cellular
processes was also observed in a monolayer of cultured cell which indicated cellular
growth and differentiation into mature cells types. Figure 18b represents a negative
control of FITC in the TRITC channel to show specific fluorescent staining B16.F10 and
Figure 18c shows both images merged.

Figure 18: Immunofluorescence B16.F10 Morphology. B16.F10 and HaCaT sectioned for
3D cellular morphology analysis using specific fluorescently labeled fluorophores. a B16.F10
demonstrating development of cellular processes b. negative control for FITC staining. c.
Merged image of B16.F10 in the FITC and TRITC channel Bar=200µm. Magnification 200x.
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Figures 16-18, provides initial evidence of active cellular proliferation, grouping of
B16.F10 cells and possible maturation. To further confirm this type of cellular behavior,
an IHC assay was performed on spheroid samples 3 to7 days after B16.F10 inoculation.
The cells were stained using Ki-67 to identify whether B16.F10 cells were undergoing
proliferation and to determine if cells are progressing through different phases of the cell
cycle (Figure 19).

Figure 19: Proliferation Assay. B16.F10 and HaCaT sectioned to identify cell cycle
proliferation. a. negative control staining Bar=50µm 100X. b. Ki-67 staining and magnified picture
of stained nuclei. Bar=100µm 200x + 16x Magnification.

The cells were stained and then analyzed at 200x for differential nuclei staining.
Analysis of nuclei staining demonstrated different shades of brown (Figure 19b),
indicating that B16.F10 cells were present at different phases of the cell cycle. The
difference in staining ranged from dark to lighter nuclear staining (Figure 19b magnified).
Although, the presence of differential nuclear staining was noted, additional nuclear
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staining assays are necessary to identify the specific cell cycle stage, this analysis was
not performed

157

. A negative control was included to show that non-specific binding of

Ki-67 was not observed (Figure 19a).
The spheroids were also stained to identify whether B16.F10 cells proliferating in
the spheroids had the ability to produce their own extracellular matrix. Another set of
sections were stained with fibronectin antibody, a component of the extracellular matrix.
fibronectin stains at the surface of cells as depicted in Figure 20. The AE1/AE3 specific
staining displayed identifiable round cellular shape of HaCaT and the fibronectin
antibody bound to the B16.F10 and HaCaT surfaces displayed an uncharacteristically
matrix-like, fibrous shape surrounding the cells. A negative control slide showed that
fibronectin antibody was specific to cell surface antigens.
The

3D

spheroid

was

used

to

promote

growth,

differentiation,

and

communication, between B16.F10 and the HaCaT scaffold. The next set of experiments
performed were used to determine the model’s stability, potential to stimulate
proliferation of a different cell line such as human melanoma SKMEL-5, understand the
functional properties between melanoma and the HaCaT scaffold and to determine
overall applicability of the model. It has been established that HaCaT cells aggregate to
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form spheroids after 24h . These aggregates contain 50X106 cells forming a 1cm in
diameter “tissue-like” construct and observations suggest that peak stability for
replicating HaCaT spheroids occurs by 48h. The stability time points were determined by
observing HaCaT spheroid formation over 15 days (d).The peak stability for HaCaT
spheroids injected with B16.F10 cells is 4d after inoculation, totaling 6d for the
heterogeneous spheroid. By Day 6, melanoma had grown within and amongst the
HaCaT (Figures 13-15, Figure 17). To identify the 3D model’s ability to promote
proliferation and aggregation of different cell lines, a human melanoma cell line, SKMEL55

5, was injected into the HaCaT scaffold and monitored for 4-6d. The HaCaT and
SKMEL-5 demonstrated the same stability and aggregation patterns as HaCaT and
B16.F10. The viability of SKMEL-5 injected into spheroids was determined using the
TdT-FragEL DNA Fragmentation Detection assay on paraffin sections (Figure 21). The
SKMEL-5 cells were stained brown with melanoma specific antibody S100 and HRP
conjugated secondary antibody. The HaCaT cells were stained red with keratinocyte
specific antibody AE1/AE3 and AP conjugated secondary antibody to identify between
the cells types. Nuclei that stained tan signified that cells were viable and the nuclei that
stained dark brown indicated that cells had undergone apoptosis (Figure 21). The level
of viability for the SKMEL-5 was >80%, similar to the TdT assay performed on B16.F10
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(Figure16) proliferating in spheroids . During stability experiments, it was observed that
HaCaT spheroid aggregates residing alone in the HARV reached terminal differentiation
after 5-7d, viability was determined using trypan blue. However, the HaCaT spheroids
injected with melanoma extended HaCaT cell proliferation and stability up to15d in the
HARV. These observations suggest that terminal differentiation was delayed due to
melanoma injection, evidence of these observations is provided in Figure 22.

Figure 20: Extracellular Matrix Analysis.
B16.F10 and HaCaT sectioned to identify
extracellular matrix production. Bar=100µm
200x Magnification.

Figure 21: Viability Assay. SKMEL-5
and HaCaT sectioned to analyze viability
of human melanoma collected on Day 6.
Bar=100µm 400x Magnification.
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Figure 22: 3D Model Functionality Test. Testing the communication between HaCaT and
B16.F10 by the up-regulation of adherent protein E cadherin and differentiation marker
Cytokeratin 8. Samples were collected on Day 2 and 4. HaCaT alone was compared to
HaCaT+B16.F10 or HaCaT+SKMEL-5.

The 3D model demonstrated that two heterogeneous populations of cells could
co-exist and form a viable and stable tumor model, but the functional properties were
unknown. These IF sections illustrated also demonstrated dendrite-like processes
radiating from melanoma cells when interacting with keratinocytes in the 3D model. This
suggests a type of communication occurring between B16.F10 and HaCaT. To test the
functional communicative properties of the B16.F10 or SKMEL-5 separately injected into
the HaCaT spheroid construct, a western blot analysis was performed to identify upregulation of adherent proteins E-Cadherin (E-cad) and differentiating protein
Cytokeratin 8 (Cyto 8) (Figure 22). The adherent proteins E-cad are known to be upregulated when keratinocytes and melanocytes or melanoma cells interaction.
Keratinocytes promote melanocyte survival and controls melanoma proliferation and
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invasion

14, 66

. The B16.F10 or SKMEL-5 were separately injected into HaCaT and then

monitored 2-4d after inoculation, totaling 4-6d. Samples were collected on day 2 or Day
4 after injection into the spheroid, homogenized and the supernatant was tested by the
western blot to identify the up-regulation of cyto-8 and E-cad (Figure 22). Positive control
MCF-7 breast cancer cells and negative control B16.F10 cells were collected from a
monolayer of cultured cells to test primary antibody specificity and to detect protein
expression. Each band was normalized against beta actin and fold-change (fold) was
determined by comparing each melanoma inoculated spheroid group to control group
HaCaT at Day 2 or Day 4. Cyto-8 differentiation marker presents consistently low band
densities, <1-fold in groups HaCaT+B16.F10 and HaCaT+SKMEL-5 compared to
HaCaT alone on Day 2 and 4. As predicted, there was a 2.3-fold up-regulation of
adhesive protein E-cad in HaCaT+B16.F10 group at Day 2 and 1.9-fold increase at Day
4. However there was slightly lower levels of E-cad expression <1-fold in
HaCaT+SKMEL-5 group, as suggested in the literature there is a notable reduction in Ecad expression in this cell line

158

. SK-MEL-5 does not up-regulate expression of E-cad

even in the presence of keratinocytes, it is not clear in the literature, if this is due to an
inhibitory mechanism. It was observed that the spheroid stability was reinforced while in
the presence of HaCaT+melanoma compared to HaCaT alone. These observations
were linked to the increased expression of adherent protein E-cad in HaCaT+B16.F10
detected at Day 2 and reduction by Day 4. The increase in E-cad was also linked to the
decrease in differentiation marker Cyto 8 at Day 2 and Day 4 in HaCaT+B16.F10. It
appears that melanoma had slowed HaCaT terminal differentiation to keep HaCaT cells
receptive to melanoma signaling proteins and promote melanoma proliferation

59, 159

.

Overall, comparing Cyto-8 to E-Cad there was a decrease in differentiation, but an
increase in adherent protein when injecting B16.F10 into HaCaT. There were brighter
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bands of E-cad and Cyto 8 proteins on Day 2 compared to Day 4, suggesting that
protein production was controlled by keratinocytes at early stages.
To evaluate the usefulness of the in vitro 3D model the delivery of plasmid DNA
with electroporation (EP) into HaCaT and B16.F10 cells was tested. The transfection
efficiency of plasmids into the spheroids using different EP parameters was also tested.
To determine if there was difference in delivery and protein expression between the cell
types, plasmid encoding green fluorescent protein (GFP) was delivered using EP to the
3D spheroid containing only HaCaT cells. GFP expression was analyzed at 24h using a
fluorescent stereomicroscope. The results indicated low GFP transfection levels in the
HaCaT spheroids when delivered with a 4-needle penetrating electrode (4N) (Figure
23a,b) and with a non-invasive 4-plate electrode (4-PE) (Figure 23c). The EP electrodes
and conditions established for the skin were utilized because the HaCaT mimics
epidermal cells sitting on the basement membrane in vivo
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. Testing the skin EP

conditions 4N 100V/cm 150ms 12 pulses (P) or 4PE 200V/cm 20ms 8P, on the spheroid
did not result in the distribution or intensity level of GFP expression that was predicted.
The GFP expression was produced near the surface of the spheroid and specifically
those cells in close contact with electrodes (Figure 23b,c).
In the next set of experiments, a mixture of (1.0mg/ml) GFP and 3-5X106
melanoma in a 50µl volume was injected into a HaCaT spheroid to monitor differences in
transfection efficacy with different EP parameters. Here, GFP was delivered using a non28

invasive 6-PE with EP conditions established for tumor . Increased levels of GFP
expression by melanoma cells were observed (Figure 23d-g) compared to the HaCaT
alone spheroid in Figure 23b and Figure 23c. A good representation of GFP distribution
and transfection efficacy was observed between the HaCaT and B16.F10 cells in vitro.
Additionally,

there

was

a

difference

in
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transfection

levels

when

delivering

GFP+melanoma into the spheroid using different electrode applicators and EP
conditions. For Example, 6-PE EP conditions including field strength of 1300V/cm, pulse
width of 100µs and 6P demonstrated lower transfection efficacy than 500V/cm, 20ms
and 6P.

Figure 23: GFP Transfection into HaCaT and HaCaT plus B16.F10. a. HaCaT cells
alone, injection of reporter gene GFP and EP with 4-needle electrode. b. HaCaT GFP
expression at 4-needle electrode puncture EP 100V/cm 150ms 12P. c. HaCaT GFP
expression using 4-PE 200V/cm 20ms 8P. d. GFP expression in B16.F10+HaCaT 6PE
1300V/cm 100µs 6P. e-g. GFP expression HaCaT+B16.F10 500V/cm 20ms 6P.

At GFP+1300V/cm (Figure 23d), expression was concentrated in two small locations and
at GFP+500V/cm many more cells were found to express GFP mainly near the point of
injection and some cells opposite the site of injection/EP (Figure 23e-g).
The stereoscopic pictures indicate a difference in delivery and expression
between HaCaT and B16.F10. Delivery of GFP+melanoma was further analyzed for
GFP expression and distribution by cryosectioning frozen spheroid samples and staining
with DAPI (Figure 24).
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Sections were analyzed with an inverted fluorescent microscope and the sections
demonstrated that there was an increase in GFP expression. There was an increase in
GFP expression near the surface and towards the center of the spheroid and an
increase in GFP distribution with the GFP+500V/cm group (Figure 24 a,b,c) than with the
GFP+1300V/cm group (Figure 24 d,e,f)

Figure 24: GFP Distribution Analysis. HaCaT+B16.F10 sections analyzed
for distribution: Injection of reporter gene GFP and EP a. Spheroid 500V/cm
20ms b. Section 500V/cm 20ms 6P Bar=200µm c. Section 500V/cm 20ms 6P
Bar=200µm d. Spheroid 1300V/cm 100us 6P e. Section 1300V/cm 100us 6P
Bar=200µm f. Section 1300V/cm 100us 6P Bar=200µm 200x Magnification.

. Although there was visual evidence that there was an increase of GFP expression and
distribution in the highest expressing groups GFP+500V/cm, it was not clear which of the
cell types HaCaT, B16.F10 or both were actually expressing GFP. To differentiate GFP
expression

between

HaCaT

and

B16.F10,

HaCaT+B16.F10

spheroids

were

electroporated at GFP+500V/cm and collected after 24h, snap-frozen and cryosectioned for immunofluorescent staining (Figure 25a). Sections were labeled with DAPI
for all nuclear staining and HaCaT were stained with AE1/AE3 and conjugated red
fluorescent antibody TRITC for contrast. The negative slides showed no autofluorescence of the cells in the FITC (Figure 25b) or TRITC (Figure 25c) channels. The
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positive slides showed specific GFP expression in the FITC channel (Figure 25d) and
HaCaT cells showed specific Rhodamine staining in the TRITC channel (Figure25e) The
DAPI and FITC channels were merged to show location of GFP transfection amongst all
cells (Figure 25f).

Figure 25: Specific GFP Expression by HaCaT and B16.F10. HaCaT+B16.F10 sections
analyzed for cell type transfection: Injection of reporter gene GFP and EP with a-j
500V/cm 20ms. b-c. negative FITC and TRITC controls Bar=200 µm and 100µm. d.
positive FITC control Bar=100 µm. e. positive TRITC control Bar=100 µm. f. merging DAPI
and FITC channels Bar=200 µm. g-h. merging FITC and TRITC channel Bar=100 µm. i-j.
merging of DAPI, FITC, TRITC channels Bar=100 µm 200x Magnification.
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Merging of FITC and TRITC channels showed the fluorescent labeled HaCaT
specifically stained red colocalized with green fluorescent GFP producing an orange hue
meaning that HaCaT were transfected. The cells expressing green GFP protein
indicated that solely melanoma cells were transfected with GFP (Figure 25 g-h). Merging
the FITC, TRITC and DAPI channels showed localization of all cells transfected with
GFP (Figure 25 i-j). Based on these images we visually examined the relative ratios of
cells expressing GFP. There were many more solid green melanoma cells that were
transfected with GFP compared to combined orange HaCaT cells.
Flow analysis was utilized to quantitate GFP expression levels amongst four
groups HaCaT, B16.F10, GFP+1300V/cm and GFP+500V/cm. Spheroids were injected
with the GFP+B16.F10 mixture, immediately electroporated, and after 24h, spheroids
were collected and processed for same day analysis. The transfected cells were
analyzed using FACS ARIA I; P1 gates drawn around the HaCaT+B16.F10 cells, the
ARIA I measured 100,000 events (Figure 26a,c,e,g), an H-gate was drawn around live
cells and from those live cells a quadratic-gate was used to delineate between GFP
positive and negative populations (Figure26b,d,f,h). The total percentages of GFP
detected from the total population were as follows; HaCaT 0.29%, B16.F10 0.063%,
HaCaT+B16.F10 1300V/cm 0.32% and HaCaT+B16.F10 500V/cm 1.88%. Mean
Fluorescent Intensities (MFI) was statistically analyzed using a histogram curve derived
from FlowJo software. HaCaT+B16.F10 GFP MFI levels in GFP+1300V/cm and
GFP+500V/cm were 4.2-fold and 6.8-fold higher than HaCaT, respectively (Figure 27ab). Figure 27c demonstrated GFP background levels in both no treatment HaCaT and
B16.F10 groups. The GFP+500V/cm group provided 1.6-fold higher level of GFP
expression than GFP+1300V/cm group (Figure 27d). The MFI data obtained from the
four histograms were plotted onto a graph.
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Figure 26: Flow Analysis of GFP Expression. HaCaT +B16.F10 Flow analysis to
quantitate GFP expression percentage from total population of cells from FITC
channels Area/Height. a-b. HaCaT cells only control GFP 0.29%. c-d. B16.F10 cells
only control GFP 0.063%. e-f. HaCaT+B16.F10+GFP expression 1300V/cm 100µs
GFP 0.32%. g-h. HaCaT+B16.F10+GFP expression 500V/cm 20ms GFP 1.88%.
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Figure 27a: Flow Analysis GFP Quantitation Histograms. HaCaT+B16.F10 Flow
analysis used to quantitate GFP expression from 3D model. a-d histograms of MFI. a. Solid
line unfilled curve HaCaT MFI 7,811, Filled Curve HaCaT+B16.F10 1300V/cm MFI 32,882.
b. Solid line unfilled curve HaCaT MFI 7,811, Filled Curve HaCaT+B16.F10 500V/cm MFI
52,963. c. Solid line unfilled curve B16.F10 MFI 3,311, Filled Curve HaCaT MFI 7,811. d.
Solid line unfilled curve HaCaT only 1300V/cm MFI 32,882, Filled Curve HaCaT only
500V/cm MFI 52,963.

The MFIs indicated that both EP conditions expressed higher levels of GFP production
than MFI background levels from HaCaT and B16.F10 (Figure 27). HaCaT+B16.F10
transfected with GFP+1300V/cm expressed 3.2-fold higher GFP than HaCaT. The
highest expressing group was HaCaT+B16.F10 GFP+500V/cm expressed a significant
7.3-fold more GFP than HaCaT (*p=0.001) (Figure 27).
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Figure 27b: Flow Analysis MFI GFP Quantitation. MFI graphed n=4 (*p=<0.001)
compared to no treatment HaCaT cells alone. Error bars were calculated as standard
deviation. Statistical analysis was performed using One Way ANOVA LSD Test.

The next set of experiments tested the transfection efficacy of plasmid encoding
human interleukin IL-15 (phIL-15) delivered to the 3D tumor model. The purpose was to
demonstrate that the 3D model could be used to predict IL-15 expression patterns
compared to delivery results in vivo. The spheroids were injected with mixture of
(1.0mg/ml) phIL-15 and 3-5X106 B16.F10, electroporated, and collected after 24-48h.
Both the spheroid (Average Total pg) and the media (Average pg/ml) were tested for IL15 protein production using ELISA analysis. The expression of IL-15 was compared
between HaCaT only spheroids and HaCaT+B16.F10 spheroids amongst the following
groups: no treatment, injection alone, phIL-15+1300V/cm and phIL-15+500V/cm. Low
levels of IL-15 expression were detected in HaCaT only spheroid lysate (Figure 28a
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dotted line), from groups phIL-15 injection alone, phIL-15+1300V/cm and phIL15+500V/cm groups compared to the HaCaT+B16.F10 groups (solid line Figure 28a). In
the spheroid lysated there was a <1.2-<2.2-fold increase for phIL-15 injection,
phIL15+1300V/cm and phIL-15+500V/cm at 24h and 48h in HaCaT alone. Transfection
of phIL-15 into HaCaT+B16.F10, spheroid lysate mixture showed significant 3.1-fold 24h
and 2.6-fold 48h increase in expression with the phIL-15+500V/cm group. Fold-change
was compared to the no treatment group HaCaT+B16.F10 (solid line Figure 28a). In the
media, there was a <1.6 fold increase for phIL-15 injection, phIL15+1300V/cm and phIL15+500V/cm at 24h and 48h in HaCaT alone (Figure 28b dotted line). Delivery to
HaCaT+B16.F10 showed increased levels of IL-15 production in the media at 3.1-fold
and 2.3-fold in phIL-15+1300V/cm group and a significant 13.7-fold and 19.5-fold
increase with phIL-15+500V/cm at 24h and 48h, respectively, compared to no treatment
group HaCaT+B16.F10 (solid line Figure 28b). Slight decrease in expression levels after
48h in both the HaCaT and HaCaT+B16.F10, was possibly due to decrease in live cells
after EP, or that HaCaT reached terminal differentiation decreasing overall transfection
efficiency (Figure 28b solid and dotted line).
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Figure 28: Expression of phIL-15 in the 3D Model. HaCaT +B16.F10 Delivery of human
plasmid IL15 to quantitate expression of IL15 protein from the 3D tumor model. a.
spheroid lysate HaCaT alone dotted line and HaCaT+B16.F10 solid line n=4-10
(*p=<0.001). b. media supernatant from HaCaT alone dotted line and HaCaT+B16.F10
solid line n=4-6 (*p=<0.05) all groups compared to no treatment HaCaT or
HaCaT+B16.F10. Error bars were calculated as standard deviation. Statistical analysis
was performed using One Way ANOVA LSD Test.
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In vitro delivery of plasmids to a monolayer of cells is not always representative
of what happens in vivo. It is expected that the 3D model will serve as a good indicator
of expression levels when delivering phIL-15 to skin and tumor by utilizing HaCaT alone
or HaCaT+B16.F10. To test whether the IL-15 results from the 3D model were indicative
of expression patterns in vivo, the EP delivery conditions were performed in a C57BL/6
mouse model to compare transfection efficacies between HaCaT+B16.F10 in vitro to
skin and tumor in vivo. Four mice per group were injected intra-dermally with phIL-15
(dotted line Figure 29). At 12h the phIL-15+100V/cm group showed a 1.9-fold increase in
IL-15 expression and the phIL-15+200V/cm group demonstrated a 2.6-fold increase in
expression compared to phIL-15 injection alone. The skin showed a slight increase of IL15 expression in groups phIL-15+100V/cm and phIL-15+200V/cm electroporated with
skin EP conditions, but were insignificant at 12h. Many individual skin samples in these
groups at 12h resulted in zero expression levels compared to ELISA standards. The skin
samples at the 18h time point, expressed significantly higher levels of IL-15 than 12h,
demonstrating a 17.9-fold increase in phIL-15+100V/cm group and a 38.2-fold increase
in phIL-15+200V/cm group of IL-15 expression compared to phIL-15 injection alone. The
24h and 48h time points were much lower and many individual samples expressed zero
level of IL-15 plasmid (dotted line Figure 29). Another set of experiments containing four
mice per group were inoculated with B16.F10 cells subcutaneously and after 6-10 days,
tumors formed. The tumors were injected with phIL-15 and then electroporated using
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penetrating 6-needle electrode (similar to 6-PE in vitro)

with EP conditions phIL-

15+1300V/cm or phIL-15+500V/cm. In the tumor, the phIL-15+500V/cm group had
significant 8.9-fold increase in IL-15 expression at 12h compared to injection of pIL-15.
The 1300V/cm group was not significant, the highest expression occurred at 12h with
4.7-fold increase compared to injection of phIL-15 (solid line Figure29).
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Figure 29: Comparison of phIL-15 Expression to Skin and Tumor In Vivo.
Comparing IL15 expression to in vivo skin dotted line n=12 100V/cm18h *p=<0.02,
200V/cm 18h *p=<0.001, 24h, *p=<0.03, and 48h *p=<0.02 and tumor samples
solid line n=4; 12h 500V/cm *p=<0.02, 18h *p=<0.01, 24h *p=<0.02 compared to
injection phIL-15 alone. Error bars were calculated as standard deviation. Statistical
analysis was performed using the Student’s t-test.

There was a difference in transfection efficacy between skin and tumor mostly at 12h
and a slight difference at 18h and 24h. Expression in both tumor and skin dropped at
48h.
As predicted by the 3D tumor model there was a significant difference in IL-15
expression between the cells types HaCaT only, HaCaT+B16.F10, skin and tumor.
There were also differences in expression levels of IL-15 between EP parameters at
100V/cm, 200V/cm, 1300V/cm and 500V/cm as well as the time points tested 12h, 18h,
24h, and 48h. Transfection of phIL-15+EP+ (100V/cm and 200V/cm) into HaCaT and in
the skin, revealed that there were similar IL-15 expression patterns at 24h and 48h from
the HaCaT only group in the supernatant and in the media in vitro compared to the skin
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homogenate in vivo. The in vitro 3D model demonstrated higher levels of IL-15
expression at 24h in the HaCaT+B16.F10 samples, using EP conditions phIL15+500V/cm, transfected into mostly B16.F10 cells. This was compared to the in vivo
model, the IL-15 expression levels were detected primarily in the established melanoma
cells at 12h using the EP condition phIL-15+500V/cm. Although, IL-15 expression levels
were detected at different time points between the in vitro model and the in vivo model,
the expression patterns were very similar between the cell types and EP conditions used
to deliver phIL-15. The highest expression of IL-15 was detected in B16.F10
electroprated at 500V/cm groups in vitro and in vivo. The results demonstrate that the
3D tumor model serves as a tool to predict EP conditions and plasmid expression levels
prior to moving delivery techniques in vivo.
Many studies show that IL-15 protein is highly regulated in nature and not easily
detected in vivo
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. The results showed that the 3D tumor model produced higher levels

of IL-15 expression from cells secreted into the supernatant at 24h compared to the IL15 production measured from the tumor lysate at 12h in vivo. Compared to Kutzler et. al,
the optimized plasmid human IL-15 showed greater IL-15 expression from human
rhabdomyosarcoma cells
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, compared to mouse B16.F10 cells. This is indicative that

IL-15 protein was highly regulated in vitro and in vivo possibly due to cellular and
extracellular regulatory mechanisms. The in vitro studies also showed that the plasmid
does have the ability to express the gene of interest, but some IL-15 protein remains
sequestered in the cytoplasm of the B16.F10 cells. The mechanism behind plasmid
delivery using EP and IL-15 regulation at the cellular level remains to be further analyzed
in vivo.
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Summary
The HARV vessel was used to promote tumor formation of B16.F10 cells in a
free-floating environment that did not require a matrix. The 3D tumor model was a stable
and functional system that could be used to evaluate plasmid delivery utilizing EP and
subsequent protein expression. The delivery of GFP and phIL-15 using EP into the 3D
model provided useful information about cellular reaction to different electric fields, pulse
lengths and pulse number. The 3D model was used to test plasmid delivery between
different cell types and the expression levels attained at different time points. The same
expression trend was observed when plasmids were delivered using the in vitro 3D
model containing HaCaT+B16.F10 and tumors in vivo. Delivery of phIL-15 with
1300V/cm EP conditions promoted less IL-15 production at 1.0mg/ml than phIL15+500V/cm at 12h in vivo tumor samples and in vitro HaCaT+B16.F10 at 24h. There
were also differences in transfection patterns between skin and tumor in vivo that were
also detected in the in vitro 3D tumor model. Transfection of phIL-15+EP+ into the skin
showed less IL-15 expression levels compared to tumor in vivo, and the highest
expression levels was observed using EP 200V/cm 20ms at 12-18h compared to EP
condition 100V/cm. In the 3D tumor model the HaCaT only group showed low levels of
expression compared to HaCaT+B16.F10, comparable to results in vivo.

Specific Aim 2
To evaluate the intra-tumor delivery of phIL-15 and the resulting protein expression to
determine if expression of IL-15 would promote tumor regression and enhance mouse
survival in an aggressive mouse melanoma model.
The work in Aim 1 evaluated the delivery of phIL-15 using a few EP parameters
in the in vitro 3D tumor model and determined whether those in vitro results correlated
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with in vivo experiments. This gave us a better understanding of the delivery conditions
needed to obtain appropriate protein expression of the plasmid. In Aim 2, the work was
designed to further explore EP conditions used to deliver phIL-15 into tumor and skin,
and based on protein expression levels of IL-15 select the best route of plasmid
administration and EP parameters to help target established melanoma.
Several EP conditions at different time points were tested. The phIL-15 results
were compared to delivery of plasmid encoding mouse IL-12 to show differences
between transfection efficacy and expression levels using different plasmids delivered to
the tumor. The goal was to evaluate the delivery of phIL-15 intra-tumoral to elicit
expression of the protein, promote tumor regression and enhance mouse survival
against the aggressively fast growing melanoma.

Figure 30: Gel Electrophoresis 1% agarose gel testing plasmid aliquots for
back bone with and without gene insert.
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IL15 protein 24h
Β-Actin

IL15 protein 48h
Β-Actin

Figure 31: Testing Functionality of phIL-15 for IL-15 gene expression from 2007 at 24h and
48h. Western Blot performed by Hong Yang M.D.University of South Florida, Tampa, FL.

The first few experiments tested plasmid purification using gel electrophoresis
and plasmid functionality using western blot analysis. The purpose was to identify that
the plasmids used in all experiments were identical and did not have contaminants that
would interfere with results. All plasmid cDNA tested in vitro and in vivo were primarily
separated by size exclusion on an agarose gel to verify aliquot content containing empty
backbone pVax or plasmid including the gene insert phIL-15. Figure 30 shows backbone
pVax and IL-15 plasmid cDNA separated on a standard agarose gel after each plasmid
was double digested. Three backbone plasmids and three plasmids with inserts were
purified by aldevron between 2005 to 2009, each plasmid was double digested with
ECOR1 and XHO1 enzymes. The 2005 plasmids were stock aliquots, the 2007 plasmids
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were used in the majority of the experiments from Aim 1-3 and the 2009 plasmids were
also used for experiments from Aim 3. Each plasmid was a product of the stock 2005
plasmid purified by Aldevron and guaranteed endotoxin free. The first three bands on the
gel are ladders lambda Hind III, 100 base pair (bp) and 400 bp. The next three bands
are cut pVax plasmid ranging about 3kb in size and the last three bands are human IL15 plasmid cut and separated into backbone and gene insert. The top band is the
backbone pVax ranged 2.6kb in size and the bottom band is IL-15 gene insert ranged
around 400 bp. The information gathered from the gel indicates that the IL-15 plasmid
utilized is the optimized plasmid containing IL-15 insert 396 bp. All plasmids used in
experiments were of the correct size and free of contaminants, as guaranteed by
Aldeveron.
The functionality of the plasmid was tested by western blot analysis for
expression of IL-15 delivered into tumor cells. The plasmid that was constructed to
express the IL-15 gene was delivered using EP into mouse melanoma and the presence
of IL-15 expression from tumor cells was analyzed (Figure 31). B16.F10 cells were
injected subcutaneously into the left flank of C57Bl/6 mice, 6-10 days post B16.F10
inoculations, tumors were monitored and volumes were measured. Mice containing
tumor volumes ranging in size from 30-60mm3 were separated into 4 groups including no
treatment (Tx), pVax injection (inj) plus EP, phIL-15 inj only or phIL-15 inj plus EP. Each
group contained four mice. Tumor bearing mice were administered 1.0mg/ml of phIL-15
or pVax plasmid and then immediately electroporated at 1300V/cm 100µs 6P for those
mice in the EP groups. The tumors were collected at 24h and 48h after one treatment
(1TX), and then the samples were prepped for western blot analysis. Total protein of
each group was determined using the BCA assay and then 100µg of total protein was
loaded into the polyacrylamide gel. IL-15 protein expression tested from the four groups
75

is shown in Figure 31. The total protein loaded into the wells was verified by internal
control β-actin. The no treatment group, pVax+EP+ and phIL-15 injection groups showed
low background levels of IL-15 production, while the phIL-15+EP+ group showed upregulation of plasmid IL-15 expression at 24h. At 48h the tumors were tested, the no
treatment, pVax+EP+, and phIL-15 injection groups showed low background levels of IL15 expression and surprisingly the phIL-15+EP+ group also demonstrated low levels of
IL-15 production as well. The time period between 24h to 48h demonstrated that IL-15
expression levels were decreased in the tumors. The observations attained from the WB
reaffirm the results obtained in Aim 1. Aim 1 tested the EP conditions in the 3D tumor
model and in vivo at 12, 18, 24, and 48h, and the ELISA results demonstrated reduced
IL-15 protein expression over time. The reduction of IL-15 in the tumor was indicative
that IL-15 production is short lived.
The next step was to test a delivery approach using different EP parameters in
tissues such as the tumor and skin and at the different time points 12h, 18h, 24h, 48h to
understand expression kinetics of phIL-15. The goal is to establish a potential treatment
regimen against mouse melanoma (B16.F10), to determine the best route of
administration and expression levels of IL-15 when delivered into tumor or skin. Figure
32 demonstrates expression levels of phIL-15 at different time points following delivery
into existing B16.F10 tumors using a 6-needle electrode with different EP conditions and
different concentrations of the phIL-15. Figure 33 demonstrates the expression levels of
IL-15 detected in the serum after EP delivery to the tumor. The EP conditions were
chosen based on previous studies
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and the results from the 3D tumor model. A high

electric field 1300V/cm with short pulses 100µs and two low electric fields 500V/cm and
200V/cm with long pulses 20ms were utilized in mouse studies. The plasmid
concentrations selected for the studies were 1.0mg/ml and increased to 2.0mg/ml based
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on low protein concentration observed in the western blot. Previous studies
demonstrated low expression levels and suggested that small detectable IL-15
production occurs because it is known to be highly regulated and short lived (163). The
groups

tested

in

the

mouse

studies

were

phIL-15

injection

only,

phIL-

15+EP+1300V/cm,100µs, 6P, phIL-15+ EP+ 500V/cm and phIL-15+EP+ 200V/cm 20ms
6P at 12h, 18h, 24h and 48h n=8-17 for each group (Table 1). Expression levels of hIL15 were determined from tumor lysate using a sensitive hIL-15 ELISA assay.
Table 1: Number of Animals Used to Evaluate of IL-15 Protein Production.
N
Values
Time

IL-15
Inj
1.0mg/
ml

IL-15
Inj
2.0mg/
ml

+1300V/
cm
1.0mg/
ml

+1300V/
cm
2.0mg/
ml

+500V/
cm
1.0mg/
ml

+500V/
cm
2.0mg/
ml

+200V/
cm
1.0mg/
ml

+200V/
cm
2.0mg/
ml

12h
18h
24h
48h

8
8
16
16

8
8
8
8

16
13
16
17

12
8
8
8

16
12
8
8

11
8
8
8

8
8
8
8

8
8
NA
NA

Fold change (fold) of all expression levels were compared to IL-15 injection at
either 1.0 mg/ml or 2.0mg/ml. In Figure 32, the highest expression of IL-15 obtained from
tumor lysate was collected at 12h in the hIL-15+EP+ 500V/cm 2.0mg/ml group after 1Tx
and was found to be 23.6-fold higher than hIL-15 injection at 2.0mg/ml, but was not
significant. The phIL-15+EP+ 500V/cm group was not significant because there was one
sample that had expression of 602pg compared to the average 92pg. It is not real clear
whether this one outlier was increased due to the damaging effects of this specific EP
condition or error in the ELISA assay. Although it remains unclear, there was only one
mouse from an n of 11 that showed this result.
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Figure 32: IL-15 Expression in the Tumor In Vivo. Comparing IL-15 expressions
from in vivo tumor lysate. Delivery of phIL-15 1300V/cm, 500V/cm and 200V/cm at
1.0-2.0mg/ml compared to injection of phIL-15.*p=<0.04. Error bars were calculated
as standard deviation. Statistical analysis was performed using the Student’s t-test.

The following groups were found to have the next highest IL-15 expression levels
in tumor lysate, 1.0mg/ml phIL-15+EP+ 500V/cm producing significant 17.6–fold
(p=0.001) increase at 12h, 11.1-fold (p=<0.001) increase at 18h 1.0mg/ml and a
significant 27.9-fold (p=0.0001) at 18h 2.0mg/ml in IL-15 expression compared to phIL15 injection. With respect to protein levels for phIL-15+EP+1300V/cm there was a
significant increase in expression from 12-24h, containing expression levels with a 10.9fold (p=<0.0001) at 1.0mg/ml and 19.9-fold (p=0.001) at 2.0mg/ml.
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Figure 33: IL-15 Expression in the Serum Post Tumor Treatment.
Comparing IL-15 expression from in vivo mouse serum to injection alone
group *p=0.03. Error bars were calculated as standard deviation. Statistical
analysis was performed using the Student’s t-test.

The phIL-15+500V/cm significantly dropped by 24h, and EP conditions phIL15+500V/cm and phIL-15+1300V/cm significantly dropped further by 48h. These IL-15
expression levels were similar to expression levels obtained in the WB analysis when
delivered with 1300V/cm. In the western blot, protein expression was visible at 24h and
no longer detectable at 48h (Figure 31). Expression of IL-15 in the phIL15+EP+200V/cm group was very low and not significant. For this EP condition, the phIL15 1.0mg/ml injected and electroporated at 12h, 18h, 24h, and 48h produced very low
levels of expression. There was a slight peak at 18h for the 2.0mg/ml 200V/cm group,
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since expression levels were so low, delivery of phIL-15 using these EP conditions were
no longer tested at 24h or 48h. Figure 33, shows IL-15 expression levels in the serum,
there was small difference in expression between the time points. There was a slight
significant peak for the phIL-15+EP+500V/cm groups 1.0mg/ml and 2.0 mg/ml in the
serum, but overall expression levels were as low as tumor lysate phIL-15+200V/cm
group from Figure 33.
In Aim 1, using the 3D model experiments demonstrated a difference in
transfection efficacy between the HaCaT and B16.F10 as well as delivery between the
skin and tumor (Figure 29). Work in Aim 2, demonstrated that by increasing plasmid
concentration for phIL-15 there was an increase in protein expression levels when
delivering to tumors in vivo (Figure 32).

Figure 34: IL-15 Expression in the Skin In Vivo. Comparing IL-15 expression from in
vivo mouse skin. Delivery of phIL-15 at 100V/cm and 200V/cm compared to injection of
phIL-15 at 2.0mg/ml.*p=<0.01. Error bars were calculated as standard deviation.
Statistical analysis was performed using the Student’s t-test.
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Figure 35: IL-15 Expression in the Serum Post Skin Treatment. Delivering phIL15 2.0mg/ml and comparing IL-15 expression from in vivo mouse skin serum to
injection phIL-15 alone. Error bars were calculated as standard deviation. Statistical
analysis was performed using the Student’s t-test.

The next experiments tested delivery of phIL-15 to the skin and then compared
expression levels to the tumor with increased plasmid concentrations 2.0mg/ml, as
suggested by the 3D model. Three mice per group were injected intra-dermal with
2.0mg/ml phIL-15 at 4 points on their dorsal side, each site received 100µg of phIL-15
for a total of n=12 per group for evaluating expression levels in skin. Delivery to the skin
used a 4 PE applicator injecting phIL-15 with 2.0mg/ml and immediately electrporating,
phIL-15+EP+200V/cm group showed a significant (p=<0.001) increase in expression at
12h compared to 1.0mg/ml plasmid dosage (Figure 29), but expression quickly
decreased over time (Figure 34). The phIL-15+EP+ 100V/cm maintained significant
expression levels 12-24h and then significantly dropped at 48h. The expression levels in
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the skin were lower than expression in tumor lysate at 12-48h. Serum levels also
showed very low and insignificant expression levels with an n=3 (Figure 35).
Surprisingly, many samples did not demonstrate higher IL-15 expression in the serum
especially since the three mice per group received 4 doses of the plasmid injected intradermal and electroporated. Based on these observations the skin delivery was no longer
pursued as a treatment route for tumor regression studies. The IL-15 expression
experiments showed that delivery of phIL-15 to the tumor with EP had a direct
correlation of increased expression with a higher concentration of plasmid as observed
in the 3D tumor model. Also, there was a difference in expression levels between skin
and the tumor. The differences in expression of IL-15 seem to be dependent on plasmid
dose, different EP conditions and the different EP electrode applicators used.
Delivery of a plasmid encoding a different cytokine was able to demonstrate a
difference in expression levels using varied EP conditions when delivered into tumor and
skin. The use of a different cytokine that may not be as highly regulated as phIL-15, was
used to demonstrate that the low expression may not have been due to the EP delivery
parameters but the gene being delivered. There was a significant increase in expression
when delivering mouse plasmid interleukin-12 (pmIL-12) into the tumor using a variety of
EP parameters after 1Tx (Figure 36). The 1.0mg/ml of pmIL-12 delivery was able to
promote increased IL-12 expression levels in the tumor lysate and serum. There was a
significant increase in mIL-12 protein expression at 24h compared to mIL-12 injection
(Figure 36) and to the hIL-15 expression levels at 24h (Figure 32). EP was able to
ensure delivery of both plasmids and while hIL-15 expression decreased over time, all
EP conditions that delivered pmIL-12 maintained expression levels 24h-96h.
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Figure 36: IL-12 Expression in the Tumor In Vivo. Delivery of pmIL-12 1300V/cm,
500V/cm, 200V/cm, 804V/cm, 667V/cm compared to injection pmIL-12 1.0mg/ml.
**p=<0.05. Error bars were calculated as standard deviation. Statistical analysis was
performed using the Student’s t-test.

The best EP conditions that demonstrated increased mIL-12 expression at 24h
utilized a caliper electrode to deliver pmIL-12 with EP condition 667V/cm 100ms 1 pulse
(24h p=0.001, 48h p=0.03, and 96h p=0.02) into the tumor, n=12. The level of
expression was significantly higher amongst all EP conditions and expression levels did
not diminish quickly between 24-96h. EP conditions 1300V/cm and 500V/cm using the 6needle electrode, showed significant expression of mIL-12 (p=<0.01, p=<0.04) over time
compared to injection only. After 24h there was a significant decrease of expression in
the 1300V/cm group (p=0.01 24h, p=<0.01 48h and p=0.01 96h), although 500V/cm
maintained expression past 48h (p=0.01 24h, p=0.004 48h and p=0.04 96h).

83

Figure 37 IL-12 Expression in the Serum Post Tumor Treatment. Delivery of
pmIL-12 1.0mg/ml and measuring IL-12 expression from in vivo mouse. Serum
compared to pmIL-12 injection alone.*p=<0.03, **p=<0.02, ***0=<0.007. Error
bars were calculated as standard deviation. Statistical analysis was performed
using the Student’s t-test.

Overall, both groups delivering pmIL-12 with 1300V/cm and 500V/cm showed a
dramatic increase of mIL-12 expression compared to hIL-15 expression using the same
EP conditions. As demonstrated in the 3D tumor model with GFP and phIL-15 delivery,
there were differences in expression between tumor and skin also observed with the
delivery of pmIL-12.
As described in Aim1, the lower electric field and longer pulses provided the best
genetransfer and protein expression levels 500V/cm and 667V/cm, but caused the most
damage. Comparing EP conditions, the least damaging EP parameters used higher
electric fields and shorter pulses, 1300V/cm seem to produce high expression early at
24h in tumor lysate and leveled out with the other EP groups at 48h. The 804V/cm
conditions expressed slightly lower levels of mIL-12 at 24h n=8 than 1300V/cm n=12,
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while 1300V/cm dropped in expression, 804V/cm maintained expression levels possibly
because they have slightly longer pulses than 1300V/cm. In addition to evaluating
expression in tumor lysate (Figure 36), serum from these mice was also evaluated for IL12 expression levels (Figure 37).

There was significant expression (p=<0.007 24h,

p=<0.03 48h and p=<0.02 96h) of mIL-12 in the serum n=7-12. The serum levels were
slightly lower than tumor lysate in mIL-12 experiments and decreased over time, but
expression patterns correlated with mIL-12 tumor expression. Tumor and serum
increased at 24h, and slowly decreased 48h-96h. The information gathered from mIL-12
tumor delivery supports the observations from the in vitro 3D model and in vivo mouse
models in Aim 1, suggesting that IL-15 must be highly regulated at the cellular level
causing a decrease in expression. Also there was a correlation between lower
transfection in the skin and higher transfection in the tumor compared to 3D tumor model
cell types. The highest expression levels were observed in the tumor using EP
conditions 500V/cm and 667V/cm, low electric field strengths with longer pulses. EP
conditions enhanced higher transfection and promoted more expression of mIL-12 in the
tumor cells than hIL-15 delivery. Both phIL-15 and pmIL-12 peaked at early time points
after 1Tx, slightly decreased and maintained expression levels 48h and 96h,
respectively.
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Delivery of pmIL-12 into the skin resulted in at least 30x less IL-12 expression
compared to tumor levels (Figure 38). The mice were injected at one site on the dorsal
side with pmIL-12 1.0mg/ml in a 50µl bubble. The 4PE was used to EP the plasmid
bubble injected intra-dermal and then the skin was marked with permanent marker to
identify location during tissue collection after 24h-48h. There was a significant increase
in expression using the 4PE to deliver pmIL-12+EP+ 200V/cm after 24h (p=<0.01),the
skin samples maintained expression up to 48h (p=<0.005) n=8-16.

Figure 38: IL-12 Expression in the Skin In Vivo. Delivery of pmIL-12 at 100V/cm
and 200V/cm compared to injection pmIL-12 1.0mg/ml and measureing IL-12
expression from in vivo mouse skin compared to pmIL-12 injection alone *p=<0.05,
**p=<0.01, ***p=0.005. Error bars were calculated as standard deviation. Statistical
analysis was performed using the Student’s t-test.

The pmIL-12+EP+ 100V/cm group showed significant expression of IL-12 after 48h
(p=<0.05), maintaining the same expression for 2 days after 1TX. The levels of IL-12 in
the serum at 24-48h following delivery of pIL-12 to the skin resulted in even less
expression of IL-12 at 24h compared to serum levels following delivery to tumor (Figure
39). mIL-12 increased at 24h pmIL-12+EP+200V/cm n=2-3 then dropped quickly by 48h.
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The values were analyzed using the student t-test, but results did not present statistically
significant expression levels in the skin serum.

Figure 39: IL-12 Expression in the Serum Post Skin Treatment. Delivery of pmIL12 1.0mg/ml to skin and measureing expression of IL-12 measured in mouse serum
compared to pmIL-12 injection alone. Error bars were calculated as standard
deviation. Statistical analysis was performed using the Student’s t-test.
.

Overall, delivery to the skin resulted in much more defined mIL-12 expression
than hIL-15 expression. The mIL-12 data is comparable to the levels of mIL-12 plasmid
delivery in the Heller et al publications
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. One observation that was noted in the in vitro
42

3D tumor model, discussed in 3D model publications , and also observed in vivo, was
that loosely less adherent tumor cells were transfected more readily and expressed
more protein compared to adherent, keratinized skin cells. Comparing mIL-12 to hIL-15
protein production showed that high expression levels are lost over time after 1Tx and
requires additional boosts to maintained expression. Short lived plasmid expression is
beneficial because it reduces the chance of toxicity due to over expression of the
protein.
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Figure 40: One, Two, Three Treatment Protocol to the Tumor. Delivery of
phIL-15 1.0mg/ml into tumor 2Tx and 3Tx on Days 0, 1 and 2and expression of
IL15 measured in tumor compared to phIL-15 injection alone. Error bars were
calculated as standard deviation.

The amount of protein expressed by the tumor cells following DNA delivery is
dependent upon the plasmid vehicle, concentration of the plasmid, cells type, EP
conditions, EP applicators and number of treatments. hIL-15 expressed lasted longer in
the tumor than in the serum, to enhance protein expression and extend systemic
stimulus, multiple treatment protocols of hIL-15 should be employed. Based on the
expression levels and kinetics, the next sets of experiments were designed to evaluate
expression levels of phIL-15 following multiple tumor treatments. Since hIL-15
expression was short lived and peaked at 12h, the treatment protocols were performed
on Day 0, 1, 2, and samples collected at 12h, 36h, or 60h to identify expression patterns
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with multiple treatment administration. Experiments were performed on 4 mice per group
using a 1Tx protocol, a two-treatment (2Tx) protocol occurring on Day 0 and 1 and three
treatment (3Tx) protocol on Day 0, 1, 2, delivering 1.0mg/ml phIL-15 with EP conditions
1300V/cm or 500V/cm. The expression levels were similar to the levels of the onetreatment (1Tx) protocol after 12h, 36, and 60h, but in the 2Tx protocol collected at 36,
60h protein levels slightly increased, the phIL-15+EP+ 500V/cm did not increase beyond
7.0 Total pg (Figure 40).

Figure 41: One, Two, Three Treatment Protocol Tested in Serum.
Delivery of phIL-15 1.0mg/ml into tumor and expression of IL15 measured in
mouse serum from multiple treatment protocols on Days 0, 1 and 2.
compared to phIL-15 injection alone. Error bars were calculated as standard
deviation.

In the 3Tx protocol, at Day 0, 1, 2, samples were collected at 60h and showed a
slight increase, but IL-15 production did not increase beyond 7.7 Total pg. Multiple
treatments did not increase serum levels of IL-15 (Figure 41), there was no additional
89

up-regulation of expression detected at these early time points 0, 1, 2 with multiple
treatment administrations. In the next experiments the time was spaced further out
between EP deliveries to test if expression levels were enhanced.
The following 2Tx and 3Tx treatment regimens were similar to treatment
28

protocols published in Lucas et al., . The 2.0mg/ml phIL-15 was delivered using EP on
Days 0, and 3, for a 2Tx regimen and Days 0, 3, 6, for a 3Tx regimen with n=12 for each
group. There was no real difference in expression in the tumor compared to Days 0, 1, 2
treatments (Figure 42) and serum levels were very low (Figure 43). The 2Tx and 3Tx
protocols at Day 0, 3, 6, demonstrated a significant increase of IL-15 expression in EP
groups 1300V/cm with a 3.1-fold (p=0.02) and 500V/cm containing a 3.5-fold (p=0.001)
increase of IL15 at Day 3, using the 2Tx protocol and significance increase in the
500V/cm group containing a 5-fold (p= 0.04) increase of IL-15 at Day 6, with a 3Tx
protocol compared to injection alone. Overall, the multiple treatment protocols did not
show enhanced expression levels, but delivery methods were effective in maintaining
protein levels in the tumor with each additional treatment. The initial experiments
showed increase after 1Tx peaking at 12-24h and then decreased by 48h. It was
decided that the 3Tx protocol with treatments at Day 0, 3, 6, would be the best protocol
since significant increase in IL-15 expression was detected and based on the decreased
tumor volume observations recorded during expression experiments. Some tumors were
beginning to regress after 2Tx and 3Tx around Day 4 and Day 7. The injection of IL-15
alone group continued to increase in tumor volume, while the mice treated with hIL15+EP+ began to decrease.
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Figure 42: Two, Three Treatment Protocol Tested in the Tumor. Delivery of phIL15 2.0mg/ml
into tumor and detecting expression of IL-15 after multiple treatment protocols on Days 0, 3 and
6.1300V/cm Day 3 *p=<0.02, 500V/cm Day 3 *p=<0.001, 500V/cm Day 6 *p=<0.04 compared to
phIL-15 injection alone. Error bars were calculated as standard deviation. Statistical analysis
was performed using the Student’s t-test.

Figure 43: Two, Three Treatment Protocol Tested in Serum. Delivery of phIL-15
2.0mg/ml into tumor and detecting expression of IL15 in the serum after multiple treatment
protocols on Days 0, 3 and 6. compared to phIL-15 injection alone. Error bars were
calculated as standard deviation. Statistical analysis was performed using the Student’s ttest.
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Multiple and adjacent administrations of phIL-15 and EP delivery were necessary
to control tumor growth. Previous studies by Heller and Lucas et al.,

28-29

described that

tumors did not regress after 1Tx and 47% of mice experienced tumor regression and
mice survived after 2Tx. The best results were attained after administering 3Tx with
mouse pIL-12 delivery using EP, there was 80% of mice that experienced tumor
regression and survived. Based on these studies, it is important to maintain IL-15
expression to promote continuous tumor regression by administering multiple treatments
of phIL-15 and EP to the tumor and more importantly enhance mouse survival. As noted
in the 2Tx and 3Tx protocols, the groups obtained multiple treatments with 2.0mg/ml
maintained IL-15 expression showing initial signs of tumor volume reduction.
Table 2: Four Separate Regression Studies Measuring Tumor Volume.
overtime
3 Tx Regression
ST Exp 1
ST Exp 2
ST Exp 3
LT Exp 4
Primary
Studies
Response
Day 0, 3, 6
Day 14
Day 30
Day 60
Day 50
Exp 3, 4
n=4
n=4
n=4
n=15
Day 50-60
No Treatment

25%

-

-

-

-

pVax Injection

50%

0

0

0

-

IL-15 Injection

75%

0

0

0

-

pVax 1300 V/cm

100%

75%

75%

6/15
40%

9/19
47%

pVax 500V/cm

100%

75%

75%

11/15
73%

14/19
74%

pIL-15 1300 V/cm

100%

100%

100%

11/15
73%

15/19
79%

pIL-15 500V/cm

100%

75%

100%

8/15
53%*

12/19
63%

Table 2: Regression Studies Short Term (ST) Experiments (Exp) and Long Term (LT) Experiments.

Table 2, shows a set of 4 different regression studies that were performed to
monitored tumor volumes over a period of days such as, Days 14, 30, 50 and 60. Mice
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were inoculated with B16.F10, monitored for 6-10 days and tumors ranging 30-60mm3
were treated with the 3Tx protocol on Days 0, 3, and 6. In the three separate short-term
(ST) tumor regression experiments, mice tumors were monitored every 3 days to
analyze tumor sizes and then tumors were collected for ELISpot and Luminex bead
array analysis on Days 14, 30 and 60, as described in Aim 3. The following treatment
groups were included in experiments: no treatment, pVax inj, IL-15 inj, pVax+1300V/cm,
pVax+500V/cm, phIL-15+1300V/cm and phIL-15+500V/cm. Tumors were monitored in
Experiment 1 Day 14, 8 days after the last treatment, in Experiment 2: Day 30, 24 days
after and in Experiment 3: Day 60, 54 days after the last treatment. Observations were
recorded for comparison regression studies (Table 2). In Experiment 4, a long term (LT)
experiment was performed to observe tumor regression and mouse survival up to 50
days. The surviving mice were challenged with injection of 5X105 B16.F10 cells
subcutaneously on the opposite flank and monitored for an additional 50 Days. The
purpose behind the challenge was to evaluate protection. It was predicted that mice
would mount a primary immune response against tumor antigens and would build a
stronger, faster secondary response against challenge against B16.F10 inoculation as
well as prevent growth of tumors.
In each separate experiment, tumor volume had decreased as early as day 4 and
day 7 in pVax+EP+ and phIL-15+EP+ treatment groups, 1300V/cm and 500V/cm. The
mice in the no treatment, pVax injection, and IL-15 injection groups had mice tumors that
continuously expanded. Some mice became lethargic and grew weak by Day 14 in
Experiment 1. In Experiment 2 by Day 21, the tumors had metastasized to the lymph
nodes and/or spleen and the metastatic properties of B16.F10 caused labored breathing
3

in the mice. The mice that had tumor volumes greater than 1000mm or grew sick
because of metastasis were euthanized between Day 16-21 in Experiment 2 and in
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Experiment 3. The mice treated with pVax+EP+ or phIL-15+EP+ 1300V/cm and
500V/cm had tumors regress completely as early as Day 14-21, in Experiment 2 and
Day 16-23 in Experiment 3. In Experiment 4, many tumors grew deep and some tumors
were abnormally shaped due to initial tumor inoculation. In the IL-15+EP+500V/cm
group, there were 5 mice that grew deep tumors and had succumb to metastasis, while
2 mice were found dead because of EP condition 500V/cm powerful pulses. The needle
placement around the site of injection was important in these EP groups since delivery of
IL-15 was necessary to promote expression in enough cells to signal the innate and
effector response against fast growing melanoma. Since IL-15 contains a short-half life it
is important to deliver to as many cells as possible to overcome the down-regulation of
IL-15 protein signaling, and promotes tumor regression in the non responding mice for
increased survival. The mice in Experiment 3, Day 60 did not have abnormally shaped
tumors or EP complications and all mice in phIL-15+EP 500V/cm survived out to 60
days. Observations indicate that phIL-15 delivered using EP must encompass many
tumor cells to properly administer phIL-15+EP+ treatments and avoid tumor escape
using the short-lived IL-15 plasmid. The mice from Experiment 3, Day 60 and mice from
Experiment 4 Day 50, were combined to determine the total amount of mice that had
tumors regress and therefore enhanced mouse survival that were tumor-free (Table 2).
Tumor regression was observed in the following groups: the pVax+EP+1300V/cm had
9/19

(47%)

of

mice

respond,

pVax+EP+500V/cm

had

14/19

(74%),

phIL-

15+EP+1300V/cm had 15/19 (79%), and ph IL-15+EP+500V/cm had 12/19 (63%) mice
that had regressed tumors remained alive (Table 2). The best primary response against
tumors was obtained from mice in the phIL-15+EP1300V/cm and pVax+EP+500 V/cm
groups.
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The mice from Experiment 4 were monitored for 50 days after the 3Tx protocol
on Day 0, 3, and 6. Tumor volumes were measured every 3-4 days. The volumes were
plotted in Figure 42 a and b. The mice that reacted to treatments demonstrated
decreased tumor volume, these mice were considered responders (Figure 44a). Mice
that did not response to the treatments, known as non-responders contained large
3

tumors that continued to grow until the tumor volumes reached 1000mm and then these
mice were humanely euthanized. The mice that responded to the treatments and
survived primary inoculation were plotted on a Kaplan-Meier survival curve (Figure 44c,
Table 2). The phIL-15+1300V/cm and pVax+500V/cm showed that 73% of the mice
remained alive, while phIL-15 500V/cm showed 53% and pVax+1300V/cm had 40%
mouse survival.

a.

Figure 44a: Non Responders Tumor Volumes Monitored for primary response up to 50
days after 3Tx on Days 0, 3, 6 a. Nonresponders, mice that have not responded to treatment
conditions. n=15. The mice that did not survive were recorded as a percentage.
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b.

Figure 44b: Responders Tumor Volumes Monitored for primary response up to 50 days
after 3Tx on Days 0, 3, 6. a. Responders, mice that have responded to treatment conditions.
n=15. The mice that did survive were recorded as a percentage.

c.

Figure 44c Kaplan-Meier Survival Curve. Demonstrate survival data of mice
receiving 3Txs on Days 0, 3, 6. n=15.
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Table 3: Challenge Study Evaluating Tumor Relapse and Intolerance.
Challenge Exp
3Tx Experiment 4
Day 0, 3, 6

Primary
Inoculation

Secondary
Inoculation

Day 50 n=15

Exp 4Day 50

IL-15 Injection

0

0

pVax Injection

0

0

pVax 1300 V/cm

6/15

3/6

40%

50%

11/15

5/11

73%

45%

11/15

4/11

73%

36%

8/15

6/8

53%+

75%

pIL-15 1300 V/cm

pVax 500V/cm

pIL-15 500V/cm

Table 3:+ Mice in this group did not survive due to damaging EP conditions.

The surviving mice from Experiment 4 were challenged at Day 50 on the
5

opposite flank with 5X10 B16.F10 to determine the extent of secondary response
against tumor cells (Table 3). The IL-15+EP+1300V/cm had 5/11 (45%) mice were
resistant to the second injection of tumor cells compared to the pVax+EP+1300V/cm
which had 3/6 (50%) mice that maintained tumor intolerance. The phIL-15+EP+500V/cm
had

6/8

(75%)

mice

protected

against

secondary

challenge

compared

to

pVax+EP+500V/cm 4/11(36%). The best groups that promoted a secondary and long
term immune response against melanoma were phIL-15+EP+ 500V/cm followed by pIL15+EP+1300V/cm.
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Summary
The experiments in this section demonstrated that phIL-15 delivery using EP
promotes more IL-15 expression at 2.0mg/ml electroporated at 500V/cm. The EP
condition 500V/cm with long pulses delivered more energy to the cells compared to
1300V/cm with short pulses. Both EP parameters maintained expression levels when
delivering the plasmid with multiple treatments and spacing the treatments to promote
cellular recuperation following each EP treatment. There were notable differences in
human IL-15 compared to mouse IL-12 expression when delivery of plasmid using EP
into different cell types, using different EP electrode applicators, and plasmid
concentrations. It was observed that EP is an efficient way to introduce plasmids into
cells. The next section explored the immunological effects obtained when using this
delivery system to introduce phIL-15 plasmid into tumors.

Specific Aim 3
To identify key immune effector cells and cytokines that was directly or indirectly
stimulated following intra-tumoral delivery of pIL-15 using EP
The goal of Aim 3, was to characterize the immune response that was stimulated
by phIL-15 and pVax delivered with EP. The purpose was to identify the key immune
effector cells and cytokines that were directly or indirectly stimulated by IL-15 protein
production introduced by intra-tumoral delivery of phIL-15 using EP.
Immunohistochemistry assays were performed on zinc fixed and snap frozen
tumor samples to identify the up-regulation of local CD8+ and CD4+ T cell responses to
untreated tumors and compared to treated tumors. Tumors were harvested at 24h and
48h and after 1 Tx, as well as Day 7 and Day 11 after 3 Tx. The tumor sample
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containing periphery of skin tissue was stained for T cell markers CD8 and CD4 and NK
cells. No NK cells were detected on Day 1, 2, 7, or 11.

Figure 45: IHC Sections CD4+ and CD8+ T cells Staining Day 1. 1Tx of mouse tumors
collected after 24h and tested for specific CD4 and CD8 staining. 100x n=4 Bar= 50-200µm.
Green staining is the methyl green counterstain, dark brown color is natural pigmentation of
melanoma and the red staining is the specific antibody labeled CD4 or CD8 markers.

Tumor with skin samples were collected from the mouse, cryo-sectioned, fixed in
acetone and then stored at -20C˚until analyzed. Sections were stained separately for
CD8 or CD4 T cell markers and compared to negative controls. The negative controls
consisted of the secondary antibody excluding the addition of specific primary antibody
and unstained cells were counterstained with methyl green.
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Figure 46: IHC Sections CD4+ and CD8+ T Cells Staining Day 2. 1Tx of mouse tumors
collected after 48h and tested for specific CD4 and CD8 staining. 100x n=4 Bar= 50-200µm.
Green staining is the methyl green counterstain, dark brown color is natural pigmentation of
melanoma and the red staining is the specific antibody labeled CD4 or CD8 markers.

B16.F10 cells were naturally pigmented and were observed as a dark brown staining
indicative of tumor location in the section. All pictures were taken with an Olympus
microscope camera at 100x Magnification. Scale bars were added to indicate specific
size of tissue in each picture.
Figure 45, shows the up-regulation of T cells at 24h after one treatment, all
groups showed the presence of CD4+ T cells (CD4) and select groups showed a small
number of CD8+ T cells (CD8). Non-specific staining was not observed in negative
controls exposed only to the secondary antibody. The T cells were observed mostly in
the periphery of the tumor with only a few in the center of the tumor. The no treatment
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tumor samples demonstrated the presence of some CD4 in the center, but most were
located in the periphery of the tumor and no CD8 cells were observed in the no
treatment group at 24h. In the EP alone saline+1300V/cm and saline+ 500V/cm groups
there was an increased of CD4 around the periphery and the center. The
saline+EP+1300V/cm group showed some CD4 present in the periphery, but did not
show presence of CD8, the same CD4 results were detected in the saline+EP+500V/cm
group, but there were few CD8 cells in the periphery. The pVax injection group showed
low presence of CD4 and no CD8. Also, at 24h, the injection of phIL-15 showed few CD4
cells in the periphery similar to what was observed in the saline+EP+ groups. The phIL15 injection group did demonstrate a pronounced presence of CD8 throughout the tumor
and around the periphery. The pVax+1300V/cm and pVax+500V/cm groups showed
very low presence of CD4 and no CD8 at 24h. The phIL-15+EP+1300V/cm showed
detected low staining of CD4 and CD8 while phIL-15+500V/cm group showed much
more CD4, but few CD8. The phIL-15+groups showed more CD4 and CD8 staining than
control groups at 24h, but less CD8 cells than the phIL-15 injection group.
Results from tumor samples that were collected and sectioned at 48h after one
treatment were observed (Figure 46). The no treatment group showed low presence of
CD4 and no stimulation of CD8. The saline+1300V/cm group showed a slight increase of
CD4 stimulation in the periphery and few in the center while there were a small amount
of CD8 cells in the periphery. The saline+500V/cm group showed presence of CD4 in
the periphery and in center, and there was low staining of CD8 detected toward the
center of the tumor and periphery. The pVax injection group did not show CD4 or CD8,
while the phIL-15 injection group showed the presence of CD4 in the periphery but not
as much as saline+EP+ groups 1300V/cm or 500V/cm. No CD8 cells were detected in
the phIL-15 injection group. No CD4 or CD8 cells were detected in the
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pVax+EP+1300V/cm and 500V/cm groups. The phIL-15+EP+1300V/cm group showed
low expression of CD4 similar to the phIL-15 injection group and most of the section was
stained specifically for CD8 throughout the tumor and the periphery compared to other
groups at 48h. The phIL-15+500V/cm did not show expression of CD4 or CD8.
Results of tumor staining for CD4 and CD8 on samples collected at Day 7, 12h
after 3Tx protocol Days 0, 3, and 6 are shown in Figure 47. These sections were
evaluated for possible CD4 and CD8 infiltrate. The no treatment tumor groups showed
presence of more CD4 compared to 24h-48h and some CD8 cells were detected. The
pVax injection group showed a few CD4 cells in the periphery and in the center, there
were some CD8 cells detected in the periphery.

Figure 47: IHC Sections CD4+ and CD8+ T Cells Staining Day 7. 3Tx of mouse tumors
collected on Day 7 and tested for specific CD4 and CD8 staining. 100x n=4 Bar= 50200µm.. Green staining is the methyl green counterstain, dark brown color is natural
pigmentation of melanoma and the red staining is the specific antibody labeled CD4 or
CD8 markers.
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Figure 48: IHC Sections CD4+ and CD8+ T Cells Staining Day 11. 3Tx of
mouse tumors collected on Day 11 and tested for specific CD4 and CD8 staining.
100x n=4 Bar= 50-200µm. Green staining is the methyl green counterstain, dark
brown color is natural pigmentation of melanoma and the red staining is the
specific antibody labeled CD4 or CD8 markers.

The phIL-15 injection group showed no CD4 or CD8 stimulation at Day 7. The
pVax+1300V/cm and 500V/cm showed low presence of CD4 and no CD8 , while the pIL15+1300V/cm showed the most CD4 and CD8 cells in the periphery compared to the
other groups. The highest number of CD4 and CD8 cells was detected in the periphery
of the phIL-15+EP+ 500V/cm group.
Figure 48 shows representative tumor sections that were collected on Day 11, 5
days after the third treatment, the tumors were evaluated for infiltrating CD4+ and CD8+
T cells. The no treatment group showed no CD4 or CD8 stimulation. The pVax injection
group showed low stimulation of CD4 and CD8 in the periphery and some infiltrate in the
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center on Day 11 compared to Day 7 samples. The pVax+EP+1300V/cm showed a low
higher CD4 stimulation at the periphery compared to pVax injection additionally more
CD8 stimulation in the periphery infiltrated into the center of the tumor compared to pVax
injection. Comparing the tumor sizes between pVax injection and pVax+1300V/cm
groups, demonstrated a reduction of tumor size in pVax+1300V/cm with the same optical
magnification 100x. The damaging conditions of pVax+500V/cm group showed an
extremely high infiltrate of both CD4 and CD8 at the periphery and infiltrating into the
tumor. Both pVax+EP+ groups showed tumor sizes that were smaller compared to pVax
injection groups. The phIL-15 injection showed more CD4 and CD8 stimulation around
the periphery compared to pVax injection. The phIL-15+1300V/cm group showed more
CD4 and CD8 stimulation around the periphery and infiltration into the center compared
to IL-15 injection and a more pronounced infiltrate than pVax+1300V/cm group. The
tumors in phIL-15+ groups had decreased in size more quickly by Day11 than
pVax+EP+ groups. The phIL-15+ 500V/cm group had comparable CD4 and CD8 T cells
in the periphery and infiltrate towards the center similar to the pVax+500V/cm group. It
was very difficult to section these tumor samples due to scabbing and scarring of the
tissue. During sample collection tumor cells were completely regressed in the phIL15+500V/cm groups compared to pVax+EP+ 500V/cm group.
Additional experiments were performed on tumors treated with the 3Tx protocol
to test for systemic IFNγ production. The purpose of the experiment was to analyze IFNγ
production in treatment groups to explain IHC CD8 and CD4 infiltrate and regression
data. ELISpot assay was used to analyze IFNγ production in splenocytes or PBMCs
from mice that were treated with pVax injection, phIL-15 injection, pVax+EP+ or phIL15+EP+ 1300V/cm or 500V/cm. The splenocytes and PBMCs were re-stimulated with
tumor cells in culture and evaluated for specific expression of IFNγ (Figure 49). It was
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expected that mice exposed to plasmid plus EP would generate IFNγ production.
General populations of cells were isolated from spleens and peripheral blood, not just
CD8 specific T cells. Previous publications have reported that irradiated B16.F10 can
stimulate splenocyte populations for IFNγ production

164

. The splenocytes and PBMCs

were prepped for ELISpot analysis one day after samples were collected. The assay
consisted of 300,000 splenocytes and 200,000 PBMCs freshly collected on Day 11 and
Day 14.
Initially Day 11 and Day 14, unstimulated cells were tested for IFNγ production
without additional secondary B16.F10 stimulation. PBMCs did not show IFNγ production,
were eliminated from analysis and all splenocytes tested at Day 11 did not show
expression of IFNγ. At Day 14, splenocytes samples pVax and phIL-15+ 1300V/cm and
500V/cm showed some expression of IFNγ compared to pVax and phIL-15 injection
groups. The pVax injection group n=3, served as a control because the IHC staining
demonstrated that pVax injection group showed CD8 infiltrate on Day 7. phIL-15
injection n=3, served as a control because stimulation of CD8 infiltrate was observed on
Days 1, 2, and 11 in IHC. Fresh, unstimulated splenocytes from pVax+1300V/cm mice
showed a 2.1-fold increase on Day 14, n=3 compared to pVax injection group.
The pVax+500V/cm, phIL-15+1300V/cm and phIL-15+500V/cm showed less
IFNγ spot forming cells than pVax+1300V/cm. Testing the same general population of
splenoctyes with B16.F10 plus recombinant IL-2 stimulation for 4 days there was a
difference of INFγ production in treatment groups. Splenocytes from mice treated with
pVax+1300V/cm showed a 2.5-fold increase compared to pVax injection and
pVax+EP+500V/cm showed a 2.1-fold n=4 increase compared to pVax injection.
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Figure 49: ELISpot Analysis IFNγ Spot Forming Cells Detecting IFNγ spot forming cells
from mouse splenocytes and compared stimulation of treatment groups to injection alone
groups. n=3 for Injection groups and pVax+1300V/cm, n=4 for pVax+500V/cm and phIL15+EP groups. Error bars were calculated as standard deviation.

While IL-15+EP+1300V/cm showed a 1.3-fold increase and IL-15+EP+ 500V/cm
showed a 1.4-fold n=4 compared to IL-15 injection alone. There was no real indication of
differences between the pVax+EP+ and IL-15+EP+ groups for the production of
systemic IFNγ. The ELISpot did not show an expression difference between the groups
as was seen with IHC and regression studies. Splenocytes did demonstrate IFNγ
production when stimulated with B16.F10 compared to unstimulated. This does suggests
why there was CD8 and CD4 cellular infiltrate in plasmid+EP groups detected at Day 7
and Day 11 as demonstrated by IHC.
A multi-cytokine Luminex Bead Array (LBA) was performed to further
characterize the immunological signals that are associated with the plasmid+EP delivery
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system. Ten cytokines that are known to be stimulated by IL-15 were analyzed in tumor
lysate and serum samples from many different treatment groups containing n=3 mice per
group. Tumors were treated with 100µg (2.0mg/ml) of plasmid pVax or phIL-15 with or
without EP. Tumor and serum samples were collected at 12h, 24h, and 48h after 1TX,
on Day 3 (12h) after 2 Tx, on Day 6 (12h) after 3Tx, and Day 11, Day 14, Day 30 and
Day 60 after 3Tx. The expression of the cytokines that were measured in this multiplex
assay included IL-1β, IL-2, IL4, IL6, IL-10, GMCSF, MIP1β, TNFα, IL-12, and IFNγ. The
cytokines were analyzed in tumor tissue samples and recorded as average total
picograms (pg), while the serum levels were recorded as average picograms per milliliter
(pg/ml). Each analyte was measure in each of the varied groups and then plotted
together on a graph to characterize the type of cytokines up-regulated by IL-15, T cells,
and NK cells. These cytokines were endogenously expressed in the mouse in response
to pro-inflammatory signaling.
Figures 50-89 shows levels from 10 different cytokines expressed in tumor lysate
and serum samples 12h, 24h, 48h, Day 3 and Day 6, after treatments. The 1Tx, 2Tx and
3Tx protocols were analyzed against controls tumor alone, pVax injection, pVax
+1300V/cm and pVax+500V/cm collected at 24h for each analyte. Cytokine expression
levels within each group was determined by calculating fold change compared to phIL15 injection alone (Table 4-7, Appendix A Table A1-A6 detailed expression levels). A
dotted or solid line superimposed on the graphs demonstrates increased cytokine
stimulation compared to background levels expressed by the no treatment group. The
controls no treatment, pVax injection, pVax+EP+1300V/cm and 500V/cm were collected
at 24h, D11, D14, and naïve samples on D30 and D60 were used to compare stimulated
vs unstimulated cytokine production between treatment groups. Table 4 and 6, describes
fold change (fold) expression from tumor lysate for each analyte tested compared to
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treatment groups and to the IL-15 injection only groups. Table 5 and 7 describe fold
change for serum levels within the treatment groups compared to phIL-15 injection
alone. Treatment groups, phIL-15+1300V/cm and 500V/cm, were also analyzed for
overall cytokines expression compared to control pVax injection, pVax+1300V/cm and
pVax+500V/cm.
Table 4: Cytokines Evaluated in Luminex Bead Array Measured in Tumor Lysate.
Fold change compared to phIL-15 injection group.

Fold Change
IL15 1300 12h
IL15 500 12h
IL15 1300 24h
IL15 500 24h
IL15 1300 48h
IL15 500 48h
IL15 1300 D3
IL15 500 D3
IL15 1300 D6
IL15 500 D6

IL-1β
4.21
3.26
2.69
2.61
1.65
0.88
3.41
3.71
1.65
1.05

IL-2
4.32
2.15
0.22
0.40
0.32
0.08
1.19
4.25
0.13
0.05

IL-4
1.47
1.20
0.41
0.65
0.99
0.91
0.46
1.11
0.38
0.20

IL-6
7.66
14.06
1.19
6.61
0.38
1.33
2.68
2.30
1.14
6.66

IL-10
0.93
0.26
0.09
0.43
0.59
0.01
3.67
5.08
0.01
0.01

IL-1β is stimulated by stromal fibroblast in response to existing melanoma,
mediating an inflammatory response, stimulating lymphocyte cell proliferation,
differentiation and apoptosis
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. The groups tested in tumor lysate and serum included

backbone vector pVax injection, pVax+EP+ at 1300V/cm and 500V/cm, phIL-15+EP+
1300V/cm and 500V/cm. Results shown in Figure 50 demonstrate that the no treatment
tumor group, pVax injection and pVax+EP+500V/cm groups did not stimulate expression
of IL-1β at 24h and expressed lower levels than treatment groups. The control group
pVax+EP+1300V/cm showed a 10-fold increase compared to pVax injection. The tumor
samples treated with phIL-15+EP+ 1300V/cm and 500V/cm were collected at 12h, 24h,
48h, after 1Tx showed an increase an IL-1β compared to controls and to pIL-15
injection. At 12h, hpIL-15+1300V/cm showed a 4.2-fold increase and phIL-15+ 500V/cm
showed a 3.3-fold increase of expression compared to IL-15 injection alone. At 24h phIL108

15+1300V/cm and 500V/cm had a 2.7-fold increase compared to IL-15 injection alone.
At 48h there was a 1.7-fold increase in group phIL-15+1300V/cm compared to IL-15
injection alone, but there was no increase with phIL-15+500V/cm.

Figure 50: Luminex Bead Array Measures IL-1β in Tumor Lysate 12h-Day 6. 12h,
24h, 48h after 1Tx, Day 3 after 2Tx and Day 6 after 3Tx Protocol, expression leves were
compared to no treatment group. n=3. Error bars were calculated as standard deviation.

The stimulation of IL-1β expression was also measured after 2Tx, the first
treatment was initially administered at day 0 and the second treatment was given on Day
3. The tumors were collected 12h after the last treatment. There was a 3.4-fold increase
in IL-1β expression using phIL-15+1300V/cm and 3.7-fold increase using phIL15+500V/cm EP conditions. The 2Tx protocol showed the highest level of IL-1β
expression compared to the other treatment groups and time points at Day 3. The
tumors were also treated three times on Day 0, Day 3 and Day 6. phIL-15 was delivered
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with EP and 12h after the last treatment tumors were collected and assessed for IL-1β
stimulation. There was a 1.7-fold increase in the phIL-15+1300V/cm groups and 1.1-fold

Figure 51: LBA Measures IL-1β in Serum 12h-Day 6. 12h, 24h, 48h after 1Tx, Day 3
after 2Tx and Day 6 after 3Tx Protocol, expression levels were compared to no treatment
group. n=3. Error bars were calculated as standard deviation.

phIL-15+500V/cm increase in expression as compared to injection of IL-15 alone. The
3Tx

protocol

expression

levels

were

similar

to

the

phIL-15+1300V/cm

and

phIL15+500V/cm of the 1Tx protocol at the 12h time point.
The serum samples from tumor treatment groups were collected and analyzed.
Additional serum groups were added for Luminex analysis such as Day 11, Day 14, Day
30 and Day 60 collected after the 3Tx protocol 0, 3, and 6 (Table 5). Tumor samples and
splenocytes for these groups were utilized for the previous IHC and ELISpot on Day 11,
and 14. Samples were collected at Day 11, 5 days after the last treatment and on Day
14, 8 days after, these time points were chosen based on tumor regression data. The
observations indicate that treated tumors regressed as early as 4-7 days and were
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completely regressed by 16-21 days compared to controls groups. The serum samples
were analyzed to identify cytokine expression in the blood and characterize the systemic
response to tumor treatments.

Table 5: Cytokines Evaluated in Luminex Bead Array Measured in Serum.
Fold change compared to phIL-15 injection group.

Comparing cytokine expression levels in the tumor and serum showed mainly
lower levels of cytokine expression in the serum than in the tumor. The expression levels
detected in the serum were compared to control groups such as no treatment at early
time points (similar to tumor sample), pVax injection on D11, Day 14, and naïve pooled
samples for later time points Day 30, and Day 60. Results shown in Figures 51-53,
demonstrate IL-1β expression from serum (Day 11 and Day 14) and late time points
(Day 30 and Day 60). There was a slight up-regulation in the pVax+1300V/cm groups at
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24h, Day 11, and Day 14, the pVax+500V/cm showed a slight increase at Day 11, but a
more robust stimulation at Day14, compared to the no treatment group and pVax
injection. All treatment groups from showed low stimulation of expression at 48h, Day 3,
Day 6, Day 14, Day 30 and Day 60. IL-2 enhances T cell and NK cell proliferation and
IL-15 down regulates IL-2 functions and competes with IL-2 receptor binding

77, 166

. In

tumor lysate the control groups showed low expression in the no tx, pVax injection, and
pVax+500V/cm groups, while in the pVax+1300V/cm group there was a 7-fold increase
of IL-2 expression compared to pVax injection (Figure 54).

Figure 52: LBA Measures IL-1β in Serum Day 11 and 14. 3Tx Protocol,
expression levels were compared to pVax injection alone group. n=3. Error
bars were calculated as standard deviation.

Serum levels were much lower than tumor samples, comparing treatment groups
to phIL-15 injection Table 5 shows increased levels of expression depicted by change
fold. Complete expression values can be obtained from supplementary Tables A1-A6
located in the Appendices.
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Figure 53: LBA Measures IL-1β in Pooled Serum Day 30 and 60. 3Tx Protocol,
expression levels were compared to naive group. n=3.

Expression of IL-2 was present in pVax+1300V/cm, similar to phIL-15 injection
and phIL-15+1300V/cm at Day 3. At 12h, phIL-15+1300V/cm showed a 4.3-fold and
phIL-15+500V/cm showed a 2.2-fold increase compared to IL-15 injection. IL-15
injection was stimulated higher than phIL-15+EP groups at 24h, 48h and Day 6. The 2Tx
protocol 12h after Day 3 showed 1.2-fold increase in the phIL-15+1300V/cm group and
4.3-fold increase in phIL-15+500V/cm. The phIL-15+1300V/cm at 12h and phIL15+500V/cm on Day 3 showed the highest expression of IL-2 in the tumor compared to
all other groups.
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Figure 54: Luminex Bead Array Measures IL-2 in Tumor Lysate 12h-Day 6. 12h,
24h, 48h after 1Tx, Day 3 after 2Tx and Day 6 after 3Tx Protocol, expression levels were
compared to no treatment group. n=3. Error bars were calculated as standard deviation.

Figure 55 LBA Measures IL-2 in Serum 12h-Day 6. 12h, 24h, 48h after 1Tx, Day 3 after
2Tx and Day 6 after 3Tx Protocol, expression levels were compared to no treatment group.
n=3. Error bars were calculated as standard deviation.
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Figure 56: LBA Measures IL-2 in Serum Day 11 and 14. 3Tx Protocol, expression levels
were compared to pVax injection. n=3. Error bars were calculated as standard deviation.

Figure 57: LBA Measures IL-2 in Pooled Serum Day 30 and 60. 3Tx Protocol,
expression levels werecompared to naïve group. n=3.
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IL-2 expression levels were much lower in the serum compared to the tumor
(Figures 55-57). At the early time points 1Tx, 2Tx and 3Tx there was very low
expression in treatments than control groups. The pVax+1300V/cm 24h and IL-15
injection at 12h showed a slight stimulation of IL-2 expression compared to the no
treatment group. The expression detected at later and late time points after 3Tx also
demonstrated low IL-2 expression in mouse serum. On Day 11, there was a slight
simulation in the pVax+500V/cm and phIL-15+500V/cm groups compared to pVax
injection. On Day 14, the pVax+1300V/cm and pVax+500V/cm groups showed a slight
stimulation in expression over pVax injection, and all other treatment groups showed low
stimulation compared to controls. The expression of IL-2 at later time points after 3Tx
showed slight stimulation of IL-2 in pVax+1300V/cm on Day 30 and Day 60 as well as
phIL-15+1300V/cm on Day 30, and Day 60. The phIL-15+500V/cm did not stimulate IL-2
production at the later time points.

Figure 58: Luminex Bead Array Measures IL-4 in Tumor Lysate 12h-Day 6. 12h, 24h,
48h after 1Tx, Day 3 after 2Tx and Day 6 after 3Tx Protocol, expression levels were
compared to no treatment group. n=3. Error bars were calculated as standard deviation.
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IL-4 stimulates monocyte differentiation into immature dendritic cells and is an
anti-inflammatory cytokine

167

. As expected, IL-4 stimulation was low in the tumor lysate

(Figure 58). The highest levels were observed with pVax+1300V/cm inducing a 2.5-fold
increase compared to pVax injection. The groups at 12h had low detectable IL-4
expression, at 24h and Day 6. The phIL-15 injection groups demonstrated low levels
compared to control pVax+1300V/cm at early time points, but higher than phIL-15+EP
groups. At 48h all phIL-15+EP+ groups showed similarly low expression compared to
the control groups pVax injection and pVax+500V/cm. The next highest expression of
IL4 was detected on Day 3 in the phIL-15 injection and phIL-15+500V/cm groups
compared to pVax+1300V/cm, but there was very small difference between the groups.

Figure 59: LBA Measures IL-4 in Serum 12h-Day 6. 12h, 24h, 48h after 1Tx, Day
3 after 2Tx and Day 6 after 3Tx Protocol, expression levels were compared to no
treatment group. n=3. Error bars were calculated as standard deviation.
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Figure 60: LBA Measures IL-4 in Serum Day 11 and 14. 3Tx Protocol, expression levels
were compared to pVax injection group. n=3. Error bars were calculated as standard deviation.

Figure 61: LBA Measures IL-4 in Pooled Serum Day 30 and 60. 3Tx
Protocol, expression levels were compared to naïve group. n=3.
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Serum levels of IL-4 were low in all groups at early time points (Figures 59-61).
There was a defined increase in IL-4 expression by pVax+500V/cm on Day 14, but no
other groups at Day 11, Day14, Day 30 or Day 60 stimulated expression.
IL-6 expression is stimulated by TILs and restores the NK activity and IFNγ
stimulation

168

. Tumor lysate from control groups showed IL-6 expression in

pVax+1300V/cm and the highest expressing group was pVax+500V/cm measuring 66fold increase of IL-6 production compared to pVax injection (Figure 62). Amongst the
treatment groups at the12h time point, phIL-15+1300V/cm showed a 7.7-fold increase
and phIL-15+500V/cm showed a 14.6-fold increase compared to phIL-15 injection. At
24h, phIL-15+1300V/cm showed a 1.2-fold and phIL-15+500V/cm showed a 6.6-fold
increase. At 48h, phIL-15+1300V/cm did not demonstrate an increase in IL-6 production,
but there was a 1.3-fold increase by phIL-15+500V/cm.

Figure 62: Luminex Bead Array Measures IL-6 in Tumor Lysate 12h-Day 6. 12h, 24h, 48h
after 1Tx, Day 3 after 2Tx and Day 6 after 3Tx Protocol, expression levels were compared to no
treatment group. n=3. Error bars were calculated as standard deviation.
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The 2Tx protocol showed a 2.68-fold increase in phIL-15+1300V/cm and 2.3-fold in
phIL-15+500V/cm groups. The 3Tx protocol showed a 1.1-fold increase in phIL15+1300V/cm and 6.7-fold increase in phIL-15+500V/cm groups, all compared to phIL15 injection group.
IL-6 stimulation in the serum was similar to tumor lysate (Figures 63-65).
Expression levels of IL-6 production in the treatment groups were less than control
pVax+500V/cm at 24h showing >1000pg/ml of protein production. The following groups
also showed IL6 stimulus, phIL-15 Injection 12h, 24h, phIL-15+1300V/cm 12h, 24h, Day
3 and Day6. The phIL-15+500V/cm group showed stimulation at 12h, 24h, 10.2-fold
increase compared to phIL-15 at 48h, 43.8-fold at Day 3 and 135.9-fold at Day 6 (Table
5). At Day 11 and Day 14, there were lower levels of stimulation compared to earlier time
points. On Day 11, the phIL-15 injection group was the only group that showed
increased IL-6. The pVax+500V/cm group at Day 14 had IL-6 levels that were slightly
greater than pVax Injection. From the groups measured at Day 30 and 60 the only
groups that stimulated IL-6 were pVax+1300V/cm and phIL-15+1300V/cm at Day 30 and
Day 60. The late time points showed much less IL6 expression than the earlier time
points.
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Figure 63: LBA Measures IL-6 in Serum 12h-Day 6. 12h, 24h, 48h after 1Tx,
Day 3 after 2Tx and Day 6 after 3Tx Protocol, expression levels were compared
to no treatment group. n=3. Error bars were calculated as standard deviation.

Figure 64: LBA Measures IL-6 in Serum Day 11 and 14. 3Tx Protocol, expression
levels were compared to pVax injection group. n=3. Error bars were calculated as
standard deviation.
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Figure 65: LBA Measures IL-6 in Pooled Serum Day 30 and 60. 3Tx Protocol,
expression levels were compared to naïve group. n=3.

IL-10 is a mediator between Th1 and Th2 and functions to regulate IL-15
production by macrophage, and suppresses TNFα and IFNγ by inhibiting IL-12
production
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. The stimulation of IL-10 expression in tumor lysate was enhanced in

groups such as pVax+1300V/cm at 24h (Figure 66). The phIL-15+1300V/cm groups
showed expression at Day 3, a 3.7-fold increase and phIL-15+500V/cm group showed a
5.1-fold increase. Again IL-15 injection showed an increase in IL-10 expression at 12h,
24h, 48h and Day 6 comparable to pVax+1300V/cm at 24h and similar to results found
in IL-4 on a larger scale.
IL-10 expression in the serum was similar to expression in the tumor lysate
(Figure 67-69). The groups that slightly stimulated IL-10 were pVax+500V/cm 24h, phIL15 injection 12h, 24h, and Day 6. The phIL-15 +500V/cm group showed 18-fold higher
expression than pVax+500V/cm Day 3 and 3.7-fold higher than phIL-15 injection on Day
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6 (Table 5). There was no stimulation of IL-10 at 12h, 24h, 48h and Day 11 in the
treatment groups. On Day 14, the only groups that slightly stimulated IL-10 were
pVax+500V/cm and phIL-15+500V/cm. At late time points Day 30 and Day 60
stimulation of IL-10 were low in the serum in groups pVax+1300V/cm, pVax+500V/cm,
and phIL-15+1300V/cm at Day 30 compared to naïve groups, while no groups
stimulated IL-10 at Day 60.

Figure 66: Luminex Bead Array Measures IL-10 in Tumor Lysate 12h-Day 6. 12h, 24h, 48h
after 1Tx, Day 3 after 2Tx and Day 6 after 3Tx Protocol, expression levels were compared to
no treatment group. n=3. Error bars were calculated as standard deviation.
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Figure 67: LBA IL-10 in Serum 12h-Day 6. 12h, 24h, 48h after 1Tx, Day 3 after 2Tx
and Day 6 after 3Tx Protocol, expression levels were compared to no treatment group.
n=3. Error bars were calculated as standard deviation.
Day 6

Figure 68: LBA Measures IL-10 in Serum Day 11 and 14. 3Tx Protocol, expression levels
were compared to pVax injection group. n=3. Error bars were calculated as standard deviation.
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Figure 69: LBA Measures IL-10 in Pooled Serum Day 30 and 60. 3Tx Protocol,
expression levels were compared to naïve group. n=3.

Table 6: Cytokines Evaluated in Luminex Bead Array Measured in tumor lysate.
Fold change compared to phIL-15 injection group.

Fold Change
IL15 1300 12h
IL15 500 12h
IL15 1300 24h
IL15 500 24h
IL15 1300 48h
IL15 500 48h
IL15 1300 D3
IL15 500 D3
IL15 1300 D6
IL15 500 D6

IL-12
1.47
1.20
0.41
0.65
0.99
0.91
0.49
0.99
0.38
0.20

IFNγ
62.84
30.50
1.27
2.72
1.51
1.22
3.84
1.65
1.07
0.42

GM-CSF
2.97
9.21
0.29
0.49
0.55
2.09
0.04
0.51
0.77
0.11

MIP-1β
1.33
1.19
6.04
6.29
3.58
3.99
2.15
0.63
2.39
1.87

TNFα
1.58
1.62
0.50
1.06
1.26
1.31
0.72
1.14
0.79
1.34

Additional cytokines were assayed using the Luminex bead as shown in Table 6.
Pro-inflammatory cyotokine IL-12 functions to up-regulate IFNγ, through NK, and CD8+T
cell response and promotes CTL effector function
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170

. The level of IL-12 was reduced in

the tumor lysate, the group that showed an increase in expression compared to controls
were pVax +1300V/cm with a 2.4-fold compared to pVax injection (Figure 70).

Figure 70: Luminex Bead Array Measures IL-12 in Tumor Lysate 12h-Day 6. 12h, 24h,
48h after 1Tx, Day 3 after 2Tx and Day 6 after 3Tx Protocol, expression levels were
compared to no treatment group. n=3. Error bars were calculated as standard deviation.

The phIL-15 injection group had slightly increased IL-12 expression compared to
treatment groups at 24h, 48h, Day 3 and Day 6, but there were low levels at 24h
compared to control. There were small differences between controls and treatment
groups for this cytokine at the tumor level.
Evaluation of IL-12 expression in the serum demonstrated that the treatment
groups and control groups showed similar levels to expression levels found in the tumor
(Figures 71-73). All samples expressed IL-12 lower than the no treatment group at the
early time points. IL-12 expression in the serum were slightly higher at later time points
than the early time points, the groups that demonstrated IL-12 stimulation were
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pVax+500V/cm on Day 14, phIL-15+1300V/cm and 14.1-fold higher in phIL-15+500V/cm
compared to phIL-15 injection on Day 14 (Table 7). At the late time points, IL-12
expression levels were low again and comparing groups there was a stimulation of
expression in groups pVax+1300V/cm on Day 30 and Day 60, pVax+500V/cm on Day
60 and phIL-15+1300V/cm on Day 30, compared to naive groups.

Figure 71: LBA Measures IL-12 in Serum 12h-Day 6. 12h, 24h, 48h after 1Tx,
Day 3 after 2Tx and Day 6 after 3Tx Protocol, expression levels were compared
to no treatment group. n=3. Error bars were calculated as standard deviation.
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Figure 72: LBA Measures IL-12 in Serum Day 11 and 14. 3Tx Protocol, expression levels
were compared to pVax injection group. n=3. Error bars were calculated as standard deviation.

Pro-inflammatory IFNγ functions to further up-regulate T cells and CTL effector
function

167

. IFNγ was stimulated in the treatment groups compared to controls groups

(Figure 74). The highest expression of IFNγ was demonstrated in tumor lysate in the
following groups phIL-15+1300V/cm showed a 62.8-fold and phIL-15+500V/cm showed
a 30.5-fold increase compared to phIL-15 injection at 12h. At 24h, phIL-15+500V/cm
showed a 2.7-fold increase in expression compared to phIL-15 injection. At 48h, all
groups were lower than controls groups. The 2Tx protocol demonstrated a 3.8-fold
increase in expression at Day 3 group phIL-15+1300V/cm and 1.7-fold increase in phIL15+500V/cm compared to injection. The 3Tx protocol showed a 1.1-fold increase phIL15+1300V/cm at Day 6, but the phIL-15+500V/cm did not show an increase in
expression.
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Table 7: Cytokines Evaluated in Luminex Bead Array Measured in serum.
Fold change compared to phIL-15 injection group.

Figure 73: LBA Measures IL-12 in Pooled Serum Day 30 and 60. 3Tx Protocol,
expression levels were compared to naïve group. n=3.
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Figure 74: Luminex Bead Array Measures IFNγ in Tumor Lysate 12h-Day 6. at 12h,
24h, 48h after 1Tx, Day 3 after 2Tx and Day 6 after 3Tx Protocol, expression levels were
compared to no treatment group. n=3. Error bars were calculated as standard deviation.

Levels of IFNγ in the serum were much lower compared to tumor lysate (Figures
75-77). At early time points the groups that stimulated IFNγ in the serum were
pVax+1300V/cm, pVax+500V/cm at 24h, phIL-15 injection at 12h, 24h and Day 6, phIL15+1300V/cm at 12h, 48h, and 21.2-Fold compared to phIL-15 injection on Day 3, phIL15+500V/cm at 12h, 7.2-Fold on Day 3 and Day 6 compared to controls and other
treatment groups (Table 7). The stimulation of IFNγ was lower at later time points, there
was no difference observed at Day 11 except for phIL-15+500V/cm on Day 14. Late time
points showed very low stimulation in groups pVax+1300V/cm at Day 30, phIL15+1300V/cm Day 30 and Day 60 and phIL-15+500V/cm at Day 30 compared to
controls and treatment groups.
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Figure 75: LBA Measures IFNγ in Serum 12h-Day 6. 12h, 24h, 48h after 1Tx, Day 3
after 2Tx and Day 6 after 3Tx Protocol, expression levels were compared to no
treatment group. n=3. Error bars were calculated as standard deviation.

Figure 76: LBA Measures IFNγ in Serum Day 11 and 14. 3Tx Protocol, expression levels
were compared to pVax injection group. n=3 Error bars were calculated as standard deviation.
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Figure 77: LBA Measures IFNγ in Pooled Serum Day 30 and 60. 3Tx Protocol,
expression levels were compared to naïve group. n=3.

Figure 78, evaluates expression of GM-CSF which promotes differentiation of
monocytes into immature dendritic cells and is produced by stimulated macrophages
and neutrophils

167, 171

. The groups that stimulated GMCSF were pVax+1300V/cm at

24h, phIL-15 injection at Day3, and Day 6, phIL-15 1300V/cm at 12h, and Day 6, phIL15+500V/cm at 12h, 48h, and Day 3 (Figure 78).
The 1Tx protocol at 12h showed an up-regulation of GM-CSF in the phIL15+1300V/cm showing a 3-fold increase and phIL-15+500V/cm showed a 9.2-fold
increase compared to phIL-15 injection, at 48h there was a 2.1-fold increase using the
phIL-15+500V/cm compared to phIL-15 injection, but lower than controls. There was no
increase of GM-CSF in the phIL-15+1300V/cm group and injection of phIL-15 showed
higher expression of GM-CSF at 24h, Day 3 and Day 6 similar to IL-2, IL4, IL-10, and IL12.
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GM-SCF expression in serum was lower than tumor lysate (Figures 79-81). At
the early time points control pVax+1300V/cm showed stimulation at 24h and levels were
higher than the treatment groups. phIL-15 injection showed GM-CSF stimulation at 12h,
24h, 48h, and Day 6 compared to the treatment groups. The only group that reflected
stimulation levels similar to controls was phIL-15+500V/cm at 24h.There was higher GMCSF stimulation in the IL-15+1300V/cm group 32.9-fold compared to phIL-15 injection
(Table 7) at Day 11compared to phIL-15 injection and the other controls and at Day 14,
the pVax+500V/cm seem to stimulate GM-CSF compared to the other controls and
treatment groups. At the later time points the only group that stimulated very low
expression levels was control pVax+1300V/cm at Day 30; there were no other groups
that stimulated GM-CSF at Day 30 or Day 60.

Figure 78: Luminex Bead Array Measures GM-CSF in Tumor Lysate12h-Day 6. 12h,
24h, 48h after 1Tx, Day 3 after 2Tx and Day 6 after 3Tx Protocol, expression levels were
compared to no treatment group. n=3. Error bars were calculated as standard deviation.
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Figure 79: LBA Measures GM-CSF in Serum 12h-Day 6. 12h, 24h, 48h after 1Tx,
Day 3 after 2Tx and Day 6 after 3Tx Protocol, expression levels were compared to no
treatment group. n=3. Error bars were calculated as standard deviation.

Figure 80: LBA Measuring GM-CSF in Serum Day 11 and 14. 3Tx Protocol,
expression levels were compared to pVax injection group. n=3. Error bars were
calculated as standard deviation.
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Figure 81: LBA Measures GM-CSF in Pooled Serum Day 30 and 60. 3Tx Protocol,
expression levels were compared to naïve group. n=3.

The chemokine MIP-1β (macrophage inflammatory protein) functions as a
chemoattractant for tumoricidal monocytes

172

. The controls demonstrated low

expression levels in tumor lysate except pVax+1300V/cm showing a 50-fold increase
compare to pVax injection (Figure 82). The 1Tx protocol demonstrated expression at
12h in the phIL-15+1300V/cm group showing a 1.3-fold increase and phIL-15+500V/cm
showed a 1.2-fold increase and compared to the increased IL-15 injection group. At 24h,
the phIL-15+1300V/cm showed a 6-fold increase and phIL-15+500V/cm showed a 6.3fold increase. At 48h, the phIL-15+1300V/cm group showed a 3.6-fold increase and
phIL-15+500V/cm showed a 4-fold increase compared to injection of phIL-15. The 2Tx
protocol showed a 3.3-fold increase at Day 3, in the phIL-15+1300V/cm, but the phIL15+500V/cm group did not show expression of MIP-1β. The 3Tx protocol on Day 6,
demonstrated a 2.4-fold increase in the phIL-15+1300V/cm group and a 1.9-fold
increase in the phIL-15+500V/cm group.
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Expression of MIP-1β in serum was lower than tumor lysate. At the earlier time
points, the groups that stimulated expression were phIL-15 injection 12h, 24h and slight
stimulation at 48h and Day 6. The phIL-15+1300V/cm group showed stimulation at 12h,
24h, 48h, 2.6-fold compared to phIL-15 injection on Day 3 and Day 6, and phIL15+500V/cm showed stimulation at 12h, 24h, 48h, 4.7-fold on Day 3 and Day 6 (Figures
83-85, Table 7). The treatment groups at 48h were equivalent to injection of phIL-15
injection group. At later time points there was no real difference in treatment groups
compared to controls on Day 11. The groups that slightly stimulated MIP-1β at Day 14
were pVax+500V/cm, pVax+1300V/cm and phIL-15 injection. At late time points there
was an increase in MIP-1β expression at Day 30 and 60. The groups that stimulated
MIP-1β were pVax+1300V/cm on Day 30 and Day 60, phIL-15+1300 Day 30 and Day 60
and pIL-15+500 on Day 60 compared to controls and expression levels on Day 14. The

Figure 82: Luminex Bead Array Measures MIP-1β inTumor Lysate 12h-Day 6. 12h,
24h, 48h after 1Tx, Day 3 after 2Tx and Day 6 after 3Tx Protocol, expression levels were
compared to no treatment group. n=3. Error bars were calculated as standard deviation.
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group that demonstrated the best MIP-1β expression was phIL-15+1300V/cm
demonstrating a 4-fold increase compared to the naïve group on Day 30 and pVax+1300
showing a 12.5-fold increase at Day 60.

Figure 83: LBA Measures MIP-1β in Serum 12h-Day 6. 12h, 24h, 48h after 1Tx, Day
3 after 2Tx and Day 6 after 3Tx Protocol, expression levels were compared to no
treatment group. n=3. Error bars were calculated as standard deviation.

Figure 84: LBA Measures MIP-1β in Serum Day 11 and 14. 3Tx Protocol, expression levels
were compared to pVax injection group. n=3. Error bars were calculated as standard deviation.
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Figure 85: LBA Measures MIP-1β in Pooled Serum Day 30 and 60. 3Tx Protocol,
expression levels were compared to naïve group. n=3.

TNFα functions to cause tumor necrosis, enhances NK activity and facilitates
leukocyte adhesion and migration

170, 172-173

.There was an increase in TNFα expression

in control group pVax+1300V/cm with a 2.6-fold expression at 24h compared to the
other control groups (Figure 86). At 12h phIL+1300V/cm and phIL-15+500V/cm groups
showed a 1.6-fold increase, at 24h the phIL-15+1300V/cm did not express TNFα, but the
phIL-15+500V/cm group showed a 1.1-fold increase compared to injection of phIL-15. At
48h, the phIL-15+1300V/cm and the phIL-15+500V/cm groups showed a 1.3-fold
increase. The 2Tx protocol did not show expression in the phIL-15+1300V/cm group,
while the phIL-15+500V/cm group showed a 1.1-fold increase in expression compared to
phIL-15 injection. The 3Tx protocol did not show expression in the phIL-15+1300V/cm
group, while the phIL-15+500V/cm showed a 1.3-fold increase of TNFα expression. The
IL-15 injection group showed an increase in expression at 24h, Day 3 and Day 6. There
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was small expression differences identified between treatment groups expressing TNFα
in tumor lysate.
TNFα serum levels were slightly lower than tumor lysate. At early time points, the
pVax+1300V/cm and pVax+500V/cm showed increased expression compared to pVax
injection (Figures 87-89). The IL-15 injection group showed stimulation of expression
higher then EP groups at 12h, 24h, and 48h, and was slightly stimulated at Day 3 and
Day 6. The phIL-15+1300V/cm increased expression at 3.1-fold compared to phIL-15
injection on Day 3 and phIL-15+500V/cm showed an increase of expression 15.1-fold at
Day 3 and 5.11-fold Day 6 (Table 7), but much lower levels than tumor lysate. At later
time points, there was not much expression detected between treatment groups on Day
11, there was a prominent stimulation of TNFα in pVax+500V/cm at Day 14 and phIL15+500V/cm at Day with a14.3-fold increase (Table 7). The levels experienced in the
serum at Day 30 and Day 60 were much lower than the earlier time points. The groups
pVax+1300V/cm and phIL-15+500V/cm slightly stimulated expression compared to the
naïve group. The phIL-15+1300V/cm group stimulated slightly more expression on Day
30 and Day 60 compared to controls and other treatment groups.
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Figure 86: Luminex Bead Array Measures TNFα in Tumor Lysate 12h-Day 6. 12h, 24h,
48h after 1Tx, Day 3 after 2Tx and Day 6 after 3Tx Protocol, expression levels were
compared to no treatment group. n=3. Error bars were calculated as standard deviation.

Figure 87 LBA Measures TNFα in Serum 12h-Day 6. 12h, 24h, 48h after 1Tx, Day 3 after
2Tx and Day 6 after 3Tx Protocol, expression levels were compared to no treatment group.
n=3. Error bars were calculated as standard deviation.
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Figure 88: LBA Measures TNFα in Serum Day 11 and 14. 3Tx Protocol, expression levels
were compared to pVax Injection group. n=3. Error bars were calculated as standard deviation.

.

Figure 89: LBA Measures TNFα in Pooled Serum Day 30 and 60. 3Tx Protocol,
expression levels were compared to naïve group. n=3.
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Summary
Utilizing IHC, ELISpot and Luminex bead array assays characterized the
expression of immune modulators present at different time points after tumor treatments.
The three assays showed similar results and detailed the specific cytokines and T cells
stimulated in the primary and secondary responses when delivering of phIL-15 using EP.
The assays also demonstrated the type of immune response cells and cytokines that
were up-regulated to promote tumor regression and enhance mouse survival as
observed in Aim 2. The delivery of plasmid plus electroporation stimulated an innate and
adaptive response against melanoma and facilitated a long-term response to tumor
recurrence.
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DISCUSSION
Specific Aim 1
3DTumor Model
A unique biosynthetic 3D tumor model was generated to test EP delivery
conditions and study cellular interactions. This large-scale, free floating 3D tumor model
was used to elucidate EP parameters to enhance phIL-15 gene delivery into melanoma
cell lines. Furthermore, the in vitro 3D tumor model was utilized to study the effects of
EP on different cell types, and evaluate different EP conditions to improve delivery
techniques in vivo. Utilizing the 3D tumor model, it demonstrated that similar levels of IL15 expression patterns were obtatined compared to the skin and tumor following in vivo
delivery. Therefore, the goal was to use the EP conditions established in the 3D tumor
model to develop a potential adjuvant system that would up-regulate IL-15 expression
and induce an immune response against melanoma.
Generating a Stable 3D Model System
In Aim 1, the 3D model was used to obtain information about cellular behavior
when subjecting cells to chemical and physical stimuli. The environment generated by
the 3D scaffold encouraged melanoma cells to grow and develop into semi-normal,
tumor cells populations. The objective was to understand how the 3D scaffold promoted
an environment suitable for tumorigenesis and how this model could be used to optimize
delivery methods for therapeutic interventions against cancer. Several matrices were
evaluated to provide a framework that would support the growth of melanoma in a 3D
construct (Figure 3-7). However, the initial matrices tested expanded melanoma growth
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over many days, and were unable to provide a large enough structure for evaluating
delivery applications. The aggregation of HaCaT cells forming a spheroid was able to
support the proliferation and development of B16.F10 cells. This process was facilitated
by the HARV’s horizontal rotation, laminar flow of fluid, hydrodynamic forces and passive
oxygenation. It was these mechanical properties that provided a microenvironment
suitable for cellular growth, encouraging cells to behave similar to those in nature
56

44, 53,

. The HARV promoted aggregation of HaCaT into spheroids as quickly as 1 to 2 days,

and measuring about 1 cm in diameter. The time period required for the scaffold to
organize cells and support tumor mass formation exceeded the dimensions and time it
took for cancer cells to develop on the bead, sponge and algi matrix scaffolding

44, 174-175

.

Viability and Stability of Model
The malleable, stable HaCaT construct mimicked the complex environment
needed to integrate many small populations of melanoma cells throughout the scaffold
thereby encouraging viable cellular interactions (Figure13-16, 21), proliferation (Figure
19), cellular communication (Figure 18), expansion (Figure 17), differentiation (Figure
18, 22), and production of its own extracellular matrix (Figure 20). The adherent
scaffolding was able to keep loose, fluid B16.F10 cells in close proximity to promote
tumorigenesis and stimulate B16.F10 differentiation. Maturation was observed by the
production of mature pigmented cells (Figure 13-14) similar to malignant cancer
development

176

.

Due to the strong adhesive properties of the HaCaT scaffold, diffusion of
nutrients into the center of the construct was reduced. However, injection of the B16.F10
cells into the scaffold, caused an influx of the surrounding media and provided nutrients
to the cells during proliferation. This injection technique enhanced cellular viability 4-6
days after inoculation. Viability of both HaCaT and B16.F10 cells remained greater than
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80% because they received an even exchange of nutrients and oxygen while rotating in
the bioreactor (Figure 15-16). Viability and stability was monitored over a 10-15 day
period. The heavily pigmented cells located in the center of the scaffold were mostly
viable (Figure 13).
The mechanism underlying the functionality of this model was determined by IHC
analysis. The cellular makeup of the spheroid was determined to be a 3:1 ratio of HaCaT
spheroids to B16.F10 cells. The HaCaT cells in the spheroid enhanced and regulated
B16.F10 proliferation through keratinocyte’s adhesive proteins (Figure 15). IHC analysis
showed evidence of cellular proliferation. This was indicated by variable nuclei staining
of the B16.F10 and HaCaT cells. The varying shades of brown suggested that each cell
was present at different stages of the cell cycle (Figure 19). Moreover, stable cellular
proliferation, communication, signaling and survival properties were also observed by
IHC staining. Immunofluorescence (IF) analysis demonstrated changes in B16.F10
cellular morphology by Day 6. The cells underwent elongation to form dendrite-like
processes suggesting that the B16.F10 cells were interacting and communicating with
adjacent B16.F10 and HaCaT cells in the spheroid environment (Figure 18). HaCaT
cells in the 3D model have the same properties as naturally occurring keratinocytes and
have the ability to mimic with similar cellular reactions. HaCaT cells regulated B16.F10
growth and survival, displayed organized growth patterns forming tight junctions with
adjacent HaCaT cells and promoted cell-cell interaction of B16.F10 cells through their
dendrite-like processes

71-72, 175, 177

. The IHC showed a collective grouping of B16.F10

cells into smaller populations that readily integrated with HaCaT cells (Figure 17). The IF
assay demonstrated that while HaCaT and B16.F10 cells resided in the spheroid, the
cells would stack upon one another forming the walls of the scaffold (Figure 17).
Interestingly, the tumors proliferated in the absence of the basement membrane and
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matrix rigidity . The HaCaT and B16.F10 cells stimulated the production their own
extracellular matrix while proliferating and developing in the 3D spheroid construct
(Figure 20).
Communication and Functional Properties
The spheroid model was shown to be a functional system that supported the
production of E-cad protein production by keratinocytes. These adherent proteins
function to control the fast growing properties of melanoma during early stages of
development (Figure 22). Western blot analysis was used to confirm the up-regulation of
E-cad expression and thereby the functionality of the 3D system (Figure 22). At early
stages of melanoma development, the keratinocytes expresses E-cad to support and
control melanoma growth

178-179

. As described in the literature, melanoma progresses

into metastatic melanoma by decreasing E-cad production and increasing N-cadherin
expression

178-179

. This process, termed cadherin-switch, facilitates the escape of

melanoma from keratinocyte control allowing melanoma to metastasize, into deeper
layers of the skin

177-180

. The data suggests that, HaCaT+B16.F10 cells residing in the

3D model together up-regulated adherent properties of E-cad to ensure the proliferation
and stability of tumor development. As expected, there was a definitive difference in Ecad expression levels between HaCaT+B16.F10 cells compared to HaCaT alone and
HaCaT+SKMEL-5. The low levels of E-Cad expression observed in the SKMEL-5 cell
lines were expected because previous reports in the literature indicate these cells have
lower levels of E-Cad expression when interacting with keratinocytes in vivo

181-182

.

There was a reduction in terminal differentiation of the HaCaT cells when injected
with B16.F10 cells. The evidence was provided by the western blot analysis
demonstrating a decrease in Cyto 8 production compared to HaCaT cells alone. This
suggests that HaCaT differentiation was reduced to promote B16.F10 survival and
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progression. The 3D tumor model demonstrated its functionality through the production
of human E-Cad and Cyto 8 collected on Day 2 and Day 4 after melanoma inoculation
into the HaCaT scaffold. The expression of Cyto 8 and E-cad proteins were verified by
the presence of positive control MCF-7 cells

183

. Furthermore, it is known that cyto 8 is

up-regulated during late stage cancer differentiation and decreased during early time
points

184-185

. The slight decrease in cyto 8 by HaCaT+melanoma suggests that

melanoma retards HaCaT terminal differentiation and helps to maintain the structural
integrity of the spheroid by up-regulating adhesive protein E-Cad. The AE1/AE3 is a
broad spectrum pan-cytokeratin antibody that measures all states of epithelial cell
development at different states of differentiation

186

. It can be inferred from the staining of

HaCaT with AE1/AE3 in IF analysis cells possibly expanded in an undifferentiated state
or possibly driven to a state of differentiation to allow continuous survival of B16.F10
cells, (Figure 15, 20-21). In IF staining, there was a strong fluorescent signal observed
for HaCaT indicating that keratinocytes were undergoing proliferation and differentiation
while a weak signal meant that cells were present at an undifferentiated stage (Figure
17-18). Further testing to determine the state of differentiation, must be performed to
confirm observations.
Optimizing EP Conditions Using the 3D Tumor Model
This large-scale, free-floating in vitro 3D tumor model is a functional and stable
model that allows us to test delivery of genes using varying EP conditions and
parameters. The goal was to generate an in vitro tumor model would withstand the
electric fields of EP, transfect melanoma cells with phIL-15, to promote IL-15 protein
expression and translate the delivery methods in vivo. Differences in IL-15 and GFP
expression levels were observed between B16.F10 and HaCaT as well as EP conditions
1300V/cm and 500V/cm. The differences in transfection efficiencies were confirmed by
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immunofluorescence, flow cytometry and ELISA. As predicted, numerous melanoma
cells injected into the spheroid were strongly transfected with GFP using tumor EP
conditions 6PE 1300V/cm and 500V/cm compared to HaCaT spheroid electroporated
with 4-needle and 4-PE conditions (Figure 23-24). One theory for this phenomenon is
that loosely suspended B16.F10 cells injected into the spheroid are more likely to be
transfected than the organized HaCaT spheroid. HaCaT cells express the adherent
protein E-cad, which promotes tight aggregate formation in the spheroid and decreases
42

EP transfection into cells . The literature imply that the electric fields (EF) fired in
multiple directions may help overcome cellular barriers in a 3D structure

28, 42, 160

. This

information suggest that using electrodes that fire the electric field in multiple directions
improved expression levels but it also depends on the cell type and its physiology.
Testing In Vitro Delivery Conditions with phIL-15
It was determined that a 6PE firing an electric field (EF) in multiple-directions increased
GFP and phIL-15 transfection compared to the 4-needle or 4-PE. The transfection was
not only dependent on the electrode, but also the cell type because during the
experiment it was observed that B16.F10 cells were transfected more readily than tightly
bound HaCaT cells. Also, GFP and IL-15 expression was dependent on the EP
conditions used, plasmid transfection increased with lower EF, 500V/cm with longer
pulses 20ms compared to higher EF, 1300V/cm with shorter pulses 100µs as
determined by IF distribution (Figures 24-25), quantitative flow cytometry and ELISA
analysis (Figure 26-28). The flow data showed a 7.3-fold significant increase in the
GFP+500V/cm group (Figure 27).The ELISA analysis showed that there was a 10-fold
increase of IL-15 expression at 24h and a 15-fold increase at 48h delivering phIL15+500V/cm into the HaCaT+B16.F10 group (Figure 28). In this model, it was important
to fire the EF over a large radius. The 6PE contains a 0.8cm-1cm diameter gap between
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the electrode plates, lower EF and longer pulses were needed to ensure delivery of GFP
and phIL-15 to many cells at one time and overcome this potential cellular barrier while
avoiding cell death (Figures 27-28). This data shows that different EP conditions and
electrode configurations were required to obtain the desired delivery and expression
amongst different cell types and their physiological properties. We also observed that
closely packed HaCaT cells contributed to lower levels of IL-15 and GFP protein
expression compared to the B16.F10 cells that were injected into the spheroid prior to
EP. Decrease in HaCaT transfection was possibly due to the presence of adhesive
proteins that could cause cells to aggregate and become less permeable thereby
requiring different EP electrodes/conditions to enhance DNA delivery.
Comparing phIL-15 Delivery Using the EP Conditions In Vitro vs In Vivo
The in vivo studies demonstrated that the 3D model was able to predict IL-15 expression
patterns similar to in vitro. The expression levels between skin and tumor differed; tumor
samples were easily transfected compared to skin cells. Plasmid delivery and protein
expression was enhanced at 500V/cm compared to 1300V/cm (Figure 29). There was a
9.6-fold increase in expression using phIL-15+500V/cm and 7.1-fold increase using
phIL-15+1300V/cm, similar to fold changes measured at 24h in the 3D tumor model. The
amount of IL-15 expression differed between the in vitro 3D models and in vivo mouse
models at different time points, but the overall trend in expression was the same
between the groups. In vivo, IL-15 expression is regulated by many factors such as the
plasmid promoter region, at the transcription and translation level, mRNA and protein
short half-life, at the protein expression level, negative feedback inhibition mechanisms
stimulated through paracrine and autocrine pathways, and decreased internal secretion
controlled by the golgi. The advantage of the 3D model system is that investigators can
study each pathway system independently from one another in culture, and compare to
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cell signaling in vivo

187-189

. In nature, the skin undergoes homeostatic changes and

regeneration. It is necessary to stabilize the synthetic 3D model for long periods of time
to study the effects of complex signaling. For example, using a matrix that does not
interfere with 3D cellular expansion or migration, could help stabilize the model and
allow for cells to mimic natural processes more closely for functional studies

187-190

.

Schoop et al., discussed the production of an organotypic co-culture system ranging 12cm in size after a 2-week period that was used to study complex systems. This model
was not a free floating construct, and was evaluated for potential skin transplantation not
tumorigenesis

191

. This 3D tumor model is a unique system with the potential to have

multiple functions. The 3D model is large scale functional model useful for adapting EP
electrodes and testing delivery techniques in vitro.
The 3D tumor model can be used to control experimental conditions for different
experimental analysis. For example, this model would be useful for evaluating different
cellular behaviors, isolating particular cell systems for analysis, increasing sample for
assays and most importantly reduce live animal experiments. In these studies, the 3D
model was used as a tool to predict how cells react to EP electric fields, stimulate gene
expression, differentiate transfection efficiencies, determine protein expression levels,
and optimize plasmid concentration. The goal was to verify that the plasmids worked
optimally prior to moving delivery techniques in vivo. Specifically, the 3D system was
used to analyze protein expression levels between different cell types and determine the
best route for plasmid administration. These features were all important variables
necessary for the development of an efficient delivery system for therapeutic purposes.
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Specific Aim 2
Examining phIL-15 Plasmid
In Aim 2, EP delivery of phIL-15 was shown to stimulate an increase in primary
and secondary immune responses against tumor antigens. Surprisingly, the delivery of
pVax plasmid with EP also enhanced an immune response and promoted tumor
regression as well. A restriction enzyme digestion was performed on the plasmids to
ensure that the appropriate plasmids were utilized during EP experiments. The gel
demonstrated that negative control pVax (back bone) plasmid was of appropriate size
and absent of the IL-15 gene insert (Figure 30). This suggests that phIL-15 and pVax
both had an adjuvant effect on tumor regression, cytokine production and T cell
response stimulation. The literature suggests that DNA delivered by EP can stimulate
pro-inflammatory effects when the DNA is internalized by cells. The inflammatory
response occurs when unmethylated CpG oligonucleotides stimulate Toll like receptor 9dependent pathways in plasmocytoid dendritic cells

192-193

. On the other hand, TLR-9-

independent pathways promote inflammation by B-form DNA stimulating IκB kinase
protein, Tank binding Kinase 1 in both immune and non-immune cells

193-194

. The

stimulation of the immune response by pVax+EP delivery has not been completely
established. The stimulation of IL-15 signaling improved the primary response and
secondary response to challenge against B16.F10 compared to pVax stimulation. Tumor
regression and challenge studies suggest that IL-15 protein production had a more
specific effect on tumor regression and enhanced mouse survival compared to pVax
plasmid delivery groups (Figure 44, Table 2-3). The low level of IL-15 production was
reflected in expression studies and regression data. Low levels of IL-15 expression
produced by transfected monocytes, dendritic cells and B16.F10 cells was possibly due
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to a decreased hIL-15 binding to endogenous mouse IL-15Rα, decrease in transcription
of IL-15 protein, or secretion pathways. Since IL-15 expression was reduced, there was
a possible decrease in the long-term responses against melanoma antigens.
It has been suggested that the administration of exogenous IL-15 through an
intra-peritoneal injection promotes short-lived memory CD8+T cells response and the
exogenous administration of IL-7 enhances long-lived memory response

195

. Short and

long-lived memory response is dependent upon the survival of CD8+Tcells

195

. This is

important because IL-15 and IL-7 share a common γc receptor on NK and T cells

195-196

.

IL-15 mainly functions to maintain memory by activating anti-apoptotic signals to
enhance CD8+ T cell survival

197

. Some antigen specific CD8+ T cells from the initial

expansion of effector cells are retained to establish long-term immunological memory
response. In these studies, it is possible that the negative feedback mechanism of
producing cells such as monocytes and DC, down regulated IL-15 production and
reduced survival of CD8+T cells causing less IL7 stimulation during the contraction
phase. The contraction phase is when most CD8+ T effector cells undergo cell death
and few effector cells survive

195

. It was also found that IL-15 inhibits immunosuppressive

function of T-regs on naïve or memory CD8+T cells

198

, These publications suggest that

IL-15 is not only regulated at the innate immune response, but also at the memory
response. This means that additional boosts of IL-15 delivery may need to be
administered into the tumor and/or the muscle to enhance survival of CD8+T cells and
reduce T-regulatory function.
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Translating EP Conditions In Vivo to Further Test Delivery of phIL-15
In previous publications, it has been suggested that the benefit of using EP to
deliver plasmid DNA for the therapeutic applications is that it enhances transfection
27

efficacy and efficiency of specific cell types . Increased plasmid transfection into cells
found in the target tissue allows for increased production of the gene encoded by the
plasmid and thereby enhancing therapeutic efficacy

27,36

. This was demonstrated in the

in vivo mouse IL-12 and human IL-15 data. While delivering phIL-15 with EP had
minimal effect on increase IL-15 expression, the IL-12 studies clearly demonstrated the
ability of EP plasmid uptake and IL-12 expression. EP enhanced the production of IL-12
compared to IL-15. The ability for EP to enhance IL-12 and not IL-15 production could be
attributed to the highly regulated mechanisms associated with IL-15 expression and
secretion. Also, the sequence homologies between mouse IL-15 and human IL-15 are
79

73% , but there may not be enough similarities in functional properties to promoted IL15 expression and enhanced IL-15 stimuli as expected.
Regulation of phIL-15
There are many publications suggesting that IL-15 is maintained at low levels
through post-transcriptional and translational mechanisms because IL-15 messenger
77

RNA is ubiquitously expressed in many tissues . The overstimulation of IL-15 is known
to cause many deleterious effects in the human body such as systemic lupus
erythematoses, rheumatoid arthritis, Type I diabetes, hypertension, arthrosclerosis, and
77

muscle disease . Delivery of respective plasmids using EP increased IL-12 or IL-15
expression and maintained protein levels over time (Figures 32-43). Additionally, the IL15 western blot analysis and the 3D tumor model demonstrated that IL-15 production

153

was reduced in vivo compared to mouse IL-12 expression data. This data suggests that
the protein levels of IL-15 expression were tightly regulated at the tumor level. It has
been shown that soluble IL-15 expression is difficult to detect in serum due to regulatory
mechanisms at the transcriptional, translation and secretory stages

101, 150,199

. Several

groups have investigated methods to improve IL-15 protein expression and
secretions

149, 200

. These publications report that optimized human IL-15, also known as

ECRO-IL-15, plasmid transfected into human Rabdomyosarcoma cells increased IL-15
expression 87-fold higher than native pIL-15 and 5.7-fold higher than the long signal
peptide (LSP) IL-15, while short signal peptide (SSP) was retained in the nucleus

199

.A

recent publication by Beragamaschi et al 2009, reported that IL-15 SSP was involved in
IL-15 regulation

201

. The experiments performed suggested that IL-15 SSP competed

with IL-15 LSP for the binding of IL-15Ra possibly reducing IL-15 secretory pathway
stimulation. A publication by Eisenman et al demonstrated that human IL-15 can be used
in mouse models and that human IL-15 ligand does bind to mouse IL-15Rα, but activity
may be hampered because optimal activity occurs with a mouse IL-15 ligand

196

. This

idea is possible because there are sequence homologies between mouse/human ligand
and receptor proteins. Mouse IL-15Rα is 54% homologous to human IL-15Rα and their
79

active site sushi domains are 85% homologous . The homology suggests that human
optimized (opt) expressed IL-15 protein could bind the active sushi domain of mouse IL15Rα, out compete the IL-15 SSP protein binding and promote IL-15 secretion. The
other possibility is IL-15 SSP protein binding blocks opt-IL-15 protein and promotes the
negative down-regulation of IL-15 production.
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Regulation of phIL-15 and Receptor phIL-15
Bergamaschi et al., demonstrated that it is possible to up-regulate IL-15 secretion
when delivering a duel expressing plasmid containing both IL-15 and IL-15Rα genes

201

.

The co-expression of both IL-15 and IL-15Rα in one plasmid would promote intracellular
complex formation and stabilization persuading IL-15 ligand to bind the IL-15Rα with
high affinity. The co-expressing plasmid would result in two active forms; 1) a membrane
bound IL-15Rα that would promote autocrine IL-15 binding and trans-presentation to
responding cells and 2) a secreted active form of soluble IL-15/IL-15Rα ready to
stimulate NK and T cells

201

. There is an abundance of literature reporting studies that

have genetically altered the native IL-15 gene to enhance transcription, translation,
expression, and secretion. The opt-IL-15 plasmid used in these studies was the
optimized form, ligated into a vector containing constitutively active CMV promoter
200

149,199-

published in Kutzler et al., to enhance protein expression and ensure secretion of IL-

15 plasmid from the transfected cells

149

.

Intra-tumoral Delivery of phIL-15
The IL-15 expression levels obtained from intra-tumoral transfection were
described in Aim 2. The tight regulation of IL-15 at the cellular level was overcome
slightly by delivering the plasmid in high plasmid concentrations (100µg) with EP.
western blot analysis demonstrated IL-15 protein expression at 24h, but expression was
undetectable by 48h post-delivery (Figure 31). The studies conducted in the in vitro 3D
tumor model, demonstrated that majority of the IL-15 protein produced was secreted into
the supernatant, but there was still a detectable level of IL-15 protein in the spheroid
homogenate (Figure 28). These experiments suggest that IL-15 expression occurs
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earlier than 24h and that some IL-15 expression is retained intra-cellularly. Studies
evaluating expression of IL-15 in vivo demonstrated that IL-15 expression was shortlived. The tumors in the mice were tested at early time periods 12h and 18h in addition
to the 24h and 48h time points. As expected, IL-15 expression was detected as early as
12h in the phIL-15+1300V/cm and phIL-15+500V/cm groups. In the phIL-15+1300V/cm
group expression peaked at 24h while in the phIL-15+500V/cm groups peaked at 12h. In
both groups lower expression of IL-15 was seen by 48h (Figure 32). The same pattern of
early expression was obtained from experiments testing the skin as a possible delivery
tissue for transfection peri-tumorally to target tumor cells, but levels were much lower
than direct tumor transfection (Figure 33).The IL-15 expression pattern detected in these
151

studies is similar to that reported by Jalah et al. publication,

. The authors, compared

expression leves between different engineered optimized IL-15 plasmids, including the
opt-IL-15 plasmid used in this project. They described that a single hydrodynamic
injection with the opt-IL-15 plasmids into mouse tail veins resulted in higher IL-15
expression detected in the serum at early time points. The expression of the IL-15 from
the optimized plasmids steadily increased up to 24h, at which point IL-15 expression
peaked and then steadily decreased overtime after 1TX

151

. This study supports the IL-15

expression levels obtained from the 3D tumor model and in vivo mouse experiments
conducted in this project.
Observations of the 3D tumor model and mIL-12 data; indicated that there was
much lower transfection efficiency of IL-15 delivery to the skin than there was to the
tumor. As discussed earlier, epidermal skin cells are keratinized cells containing mostly
dead cells with tight adherent properties, while B16.F10 cells are mostly live viable cells
with low adherent properties. Based on the skin and tumor experiments, the electric field
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strength and blast radius encompasses more live tumor cells than viable dermal skin
cells found below the epidermis. The difference in protein expression by different cells
42

types depends on the stage of cell cycle, viability, and adherent properties . B16.F10
cells have less adherent properties, there more are viable cells and longer lived
compared to keratinocytes. The keratinized skin cells undergo cell death as they move
towards the epidermal layer

202

. The cells near the basal, germinal level are less

keratinized and have less adherent proteins than cells in the epidermal layer

14

and are

more likely to uptake plasmid DNA delivered by EP. These observations suggest that
intra-dermal EP would demonstrate better transfection of cells near the basal layer
compared to keratinized cells near the epidermis

160

.

Maintenance of phIL-15 Expression with Multiple Treatment Parameters
The information gathered from the in vitro and in vivo experiments suggests that
in order to obtain the highest level of IL-15 expression multiple evenly spaced treatments
protocols should be administered to treat existing tumor cells. This project demonstrated
that a series of EP plasmid deliveries could produce enough signal to stimulate the
immune response and control the fast growth of aggressive B16.F10 cells. A 2Tx and
3Tx protocol administered phIL-15+ EP (1.0mg/ml) at early time points at 0, 1, 2, days
did not stimulate robust IL-15 expression. It was inferred that delivery of phIL-15 by EP
at such close, adjacent time points may not allow sufficient time for cellular immune
response. For example, there should be sufficient lag time to allow innate immune cells
like phagocytes and macrophages to clear away dying cells, APCs. to process antigens
and recruit new monocytes from the blood to the delivery area that could respond to
additional plamid+EP treatments. Other limiting factors that may have interfered with IL15 expression during the early multiple treatment protocols was possibly due to 1)
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enhanced destabilization of the plasma membrane from transfected cells by the applied
electric fields causing some cell death and less time for clearance between the first
treatment and the next treatment, and 2) also adjacent treatments did not allow enough
time for IL-15 production to recruit cells to the area or IL-15 protein transpresention to
responding cells, which was possibly due to IL-15 negative feedback properties as well.
Experiments using the 3D tumor model demonstrated that the plasmid GFP delivered
with EP to melanoma cells was readily taken up the plasmids and expressed within 24h,
but there was a slight decrease in viability 5-10%. The HaCaT were much hardier cells
with viability close to 92-96% but transfection was much lower than B16.F10 cells
(Figure 26-27). The results suggest that using different EP parameters would increase
the level of HaCaT expression.
Increasing the time between the treatments for the 2Tx and 3Tx protocols
delivering phIL-15+EP+ (2.0mg/ml) was explored on Days 0, 3, and 6. There was a
significant 2-3-fold increase at Day 3, and 2-fold increase at Day 6 in both EP groups.
The 3Tx protocol suggests that cellular turnover can occur as early as 72h after the first
treatment. There was a slight, but significant increase in IL-15 expression at Day 3 and
Day 6 compared to the 12h, 36h, 60h protocol, but not to the extent as predicted (Figure
42-43). The 3Tx protocol on Days 0, 3, and 6 was selected for further studies to monitor
tumor regression and mouse survival. The decision was based on the observations from
early tumor regression studies (Table 2). Fast growing tumors began to regress in
plasmid EP treatments groups by Day 4 and 7, while untreated tumors and tumors
injected with pVax or phIL-15 exponentially grew after Day 9 (Figure 44a-c). These
studies suggested that the multiple treatment protocols using phIL-15+EP required some
time to recruit new cells to the area. This was further suggested by the up-regulation of
IL-1β cell proliferation cytokine, MIP-1β recruitment chemokine and TNFα tumor
158

necrosis detected in tumor lysate when cells were treated with IL-15+ 1300V/cm and
phIL-15+500V/cm at 12h, 24h, Day 3,and Day 6. The highly regulated IL-15 protein
expression and delivery to the mouse model demonstrated that human IL-15 can
possibly bind to mouse IL-15Rα, may trans-present to receptive cells such as NK cells

77

to promote IL-15 stimulated immunological activity in the mouse and can cause tumor
regression.
Analyzing Tumor Regression and Mouse Survival with Delivery of phIL-15 and EP
The main goal of Aim 2 was to stimulate an immune response against tumor
antigens and promote long-term responses to enhance mouse survival. Delivery of both
phIL-15 and pVax using EP elicited a detectable immune response, but it was necessary
to up-regulate a specific innate immune response and in turn stimulate down-stream
signaling proteins to promote an adaptive immune response. The adaptive immune
response would encourage T cells to recognize tumor antigens presented by dendritic
cells and in turn mount a systemic response against B16.F10 cells. The mechanism by
which IL-15 and EP stimulated tumor-specific response is not clear. Therefore
experiments were designed to characterize the innate and adaptive immune responses
that were initiated by IL-15/pVax+EP in tumors and prevented relapse of B16.F10
growth. The combination of IL-15 or pVax with EP acts as an adjuvant therapy
demonstrating tumor regression, cytokine stimulation, and T cell stimulation.
The majority of the mice that had undergone tumor regression survived B16.F10
challenge. The best groups that responded with long term effects were the phIL15+500V/cm group which contained 8 of 15 mice that had complete regression of
primary tumor and had 75% (6 out of 8) of the mice that survived tumor-free after
subsequent tumor challenge, the phIL-15+1300V/cm group contained 11 of 15 mice with
159

complete regression of primary tumor and 45% (5 out of 11) of the mice that survived
tumor-free after subsequent challenge and the pVax+500V/cm group contained 11 of 15
mice with complete regression of primary tumor and 36% (4 out of 11) of the mice that
survived tumor-free after subsequent challenge (Table 3). Although the pVax+500V/cm
and phIL-15+1300V/cm both demonstrated similar results, it was the phIL-15+500V/cm
group that stimulated enough of the innate and adaptive immune response 50 days after
challenge to enhance a possible memory response

203

. The lack of response in some

mice may possibly be due to variability in tumor size or the metastatic properties of
tumor cells that were injected deep into subcutaneous tissues. Perhaps, for the delivery
of phIL-15, many more tumor cells must be subjected to electric fields to increase
transfection area during each treatment and ensure delivery of IL-15 plasmid to increase
expression levels that making up for regulatory processes of IL-15. The multiple
treatment protocol allowed tumors to maintain IL-15 protein expression over time
improving tumor regression and the mouse survival outcome (Figure 42). The regression
and challenge data indicates that IL-15 delivery using EP may be an effective treatment
regimen for melanoma. Evaluation of the data suggests that IL-15 can be used as a
possible cytokine therapy against melanoma because of its ability to promote specific
anti-tumor properties. Also, pVax delivery using EP demonstrates that the back bone
delivered to melanoma can act as an adjuvant causing tumor regression and nonspecific anti-tumor properties. In the regression data, there were a few mice in the phIL15+1300V/cm group and all mice in the phIL-15+500V/cm group with pigmentation loss
to the skin and hair due to EP effects (Table 2-3, Figure 44). Vitiligo occurs as a result of
the TH1/INFγ or TH2/IL-4 balance between the pro-inflammatory and autoimmune
stimulation

204

. It is possible that inducing vitiligo with EP may also contribute to

maintenance of immune response.
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Specific Aim 3
Characterizing Immune Response Delivery of pVax and phIL-15 Plus EP Using IHC
Characterization of the immune response that stimulated tumor regression was
further explored by IHC, ELISpot and bead array to explore the immune mechanisms
that promoted regression and mouse survival. IHC demonstrated the presence of CD8+
and CD4+ T cell in response to different control and treatment groups (Figures 45-48).
The saline+EP groups both caused stress to the surveying CD4+ T cells resident to the
area compared to the no treatment group on Day 1 and 2. The saline+500V/cm
stimulated many residential CD4+ T cells and a few CD8+ T cells. This signified that EP
alone evoked an initial stimulatory effect on residential CD4+ and CD8+ T cells or cells
already stimulated by melanoma. The phIL-15 injection group which expressed very low
amounts of protein from tumors (described in Aim 2), promoted a few more CD4+ and
CD8+ T cells compared to saline+500v/cm and pVax injection on Day 1 and less on Day
2. The pressurized injection of phIL-15 into the tumor could have possibly caused
production of IL-15 expression and promoted the activation of residential CD4+ and
CD8+ T cells. The phIL-15+500V/cm group also stimulated more of both CD4+ and
CD8+ T cells activity compared to pVax+EP groups and phIL-15+1300V/cm on Day 1
and decreased stimulation of T cells by Day 2. Also on Day 2, phIL-15+1300V/cm group
stimulated residential CD8+ Tells. This indicates the possibility that IL-15 had an effect
on priming T cells against melanoma. The IL-15+EP groups containing higher electric
field strengths with shorter pulses, such as the phIL-15+1300V/cm groups, stimulated
initial CD8+T cells more quickly than phIL-15+500V/cm. On the other hand, IL-15+EP
groups with lower field strengths and longer pulses stimulated CD4+Tcells more quickly
at early time points. On Day 7, phIL-15+1300V/cm and phIL-15+500V/cm showed more
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CD8+T cells stimulation compared to the other control groups indicating the CD8+T cells
were recruited by IL-15 to remove tumor antigens most likely through CTL effector
activity. The response was more defined at Day 11 showing an up-regulation of
expanded specific CD8+and CD4+T cells in groups pVax+1300V/cm, pVax+500V/cm,
phIL-15+1300V/cm and phIL-15+500V/cm. Also by Day 11, the tumor size had
regressed significantly in these groups suggesting that CTLs were actively removing
tumor cells. The increased stimulation of CD8+ T cells CTL response was possibly
facilitated by increased CD4+ T cells helper cytokine activity and/or promotes CTL
differentiation by APC through the help of antigen-stimulated CD4+ T cell

166

. These

conclusions were made based on the fact that more CD4+T cells were present in phIL15+1300V/cm group compared to pVax+1300V/cm. The lower amount of CD4+T cells in
the pVax+1300V/cm group may explain why there was a relapse of tumors during the
challenge. CD4+T cells provide help for antigen-specific CD8+Tcells stimulation and to
activate the destruction of melanoma by CTL effector cells

166

. In contrast to these

observations, on Day 11, there were increased amounts of CD4+ T cells stimulated in
the pVax+500V/cm groups than there were in phIL-15+500V/cm group. These results
indicate that phIL-15+500V/cm stimulated an early response of CD4+ T cells at Day 1,
the levels were beginning to diminish since tumors in the phIL-15+500V/cm groups were
necrotic and only residual tumor cells were left behind for CTL and macrophage
removal. Both phIL-15+500V/cm and pVax500V/cm+EP+ groups had sufficient numbers
of CD8+ T cells present but the pVax+EP+ group had small tumors that were still intact
compared to phIL-15+500V/cm by Day 11, based on tumor volume measurements. The
ELISpot and bead array assays show up-regulation of IFNγ in plasmid+EP+ which
agrees with increased CD4+T cell infiltration and CD8+T cells increase observed in IHC.
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ELISpot Assay Performed to Identify Presence of IFNγ Producing Cells
To provide further evidence of possible stimulation of immune response upregulation through IFNγ expression, an ELISpot assay was performed on splenocytes
collected from plasmid+EP+ mouse groups. On Day 14, the ELISpot assay showed an
increase in IFNγ production in all four pVax+EP+ and phIL-15+EP groups stimulated
with B16.F10 and rIL-2. The ELISpot results complimented the IHC images showing the
recruitment of primed CD8+T cells that had homed into the tumor area at Day 11 and
reduced tumor volume possibly through CTL and NK activity. Based on the literature, IL15 binds to IL-15Rα expressed on APC and monocytes and trans-present IL-15 to
118

responding CD8+T cells and NK cells that express the popular βγc receptor complex

.

Trans-presentation and direct stimulation of responding cells depends on expression of
IL-15Rα. It is known that CD8+T cells express IL-15Rα while NK cells do not express IL15Rα making trans-presentation essential for NK stimulation and further enhancement of
CD8+T cell activation

118,197,205

. The bead array also demonstrated an up-regulation of

IFNγ stimulation at 12h, 24h, Day 3 and Day 6 in the tumor from groups phIL15+1300V/cm and phIL-15+500V/cm. Although serum levels of IFNγ levels decreased,
expression was still detected at 24h in pVax+1300V/cm at 12h and 48h in phIL15+1300V/cm, Day 3 and Day 6 in phIL-15+500V/cm and phIL-15+1300V/cm. The
detection method used in this study to measure NK response, did not show NK
stimulation, there was stimulation of both CD8+ T cells and IFNγ indicative of possible
NK activity involvement since tumor regression began as quickly as Day 4 after 2Tx. The
IHC, Luminex bead array and ELISpot data also suggests that IL-15 may stimulate NK
secretion of IFNγ at early time points (12h-Day 6), and indirectly through up-regulation of
IL-12 production by dendritic cells, monocytes or NK cells to promote additional CD8+T
cell CTL response and infiltrate

163

at later time points (Day 11-14) Also, since the bead
163

array identified low levels of IL-12 production by tumor cells and serum levels at early
time points. The only groups that demonstrated an increase of IL-12 in the serum at Day
14 were pVax+500V/cm and hIL-15+500V/cm possibly indicating stimulation T cells
expansion and T cell effector response. Heller et al., demonstrated that early IFNγ
expression was detected in the serum on Day 4 after delivering 1Tx intra-dermal to mice
in groups vector+EP+ control, pmIL-12 injection, pmIL-12+1500V/cm groups

160

.

Additionally, a publication from Lucas et al., demonstrated that intra-tumoral delivery of
28

pmIL-12+1500V/cm treatment stimulated IFNγ in the tumor lysate at Day 5 . These
results indicated that plasmid delivered via EP were able to stimulate an innate immune
response and an adaptive immune response that caused tumor regression and possibly
explains long-term effects against melanoma. In this study, the delivery of phIL-15+EP+
possibly restored immune surveillance

118

and controlled melanoma growth, since there

were no visible metastatic melanoma lesions located in the lung, liver, lymph nodes or
spleens from mice survived and were analyzed on Days 7, 11, 14, 30 and 60 (Samples
from Figures 45-48 and Table 2).
Comparing Differences in Plasmid Constructs pmIL-12 and phIL-15
The primary tumor regression levels stimulated by plasmid+EP groups were
similar to results detailed in Lucas et al,.

28

for the delivery of pmIL-12. Comparing the

results, there were similar primary tumor regression levels in the pmIL-12+1500V/cm
group compared to phIL-15+1300V/cm group, but phIL-15+1300V/cm group was
approximately 55% less effective against challenge compared to pmIL-12+1500V/cm
group. Although, there was no correlation between pmIL-12 and phIL-15+500V/cm gene
expression experiments, this group demonstrated the best long-term responses against
challenge for the IL-15 experiments. The phIL-15+500V/cm group demonstrated the
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highest IL-15 protein expression levels secreted from tumor cells in vitro and in vivo
compared to phIL-15+1300V/cm. Challenged mice in 5000V/cm demonstrated 25% less
effective than mIL-12. In IHC the phIL-15+500V/cm group showed an increased CD8+T
cells, quickly removing tumor cells compared to the rate at which phIL-15+1300V/cm
removed tumor cells by Day 11. Furthermore, 1300V/cm showed the best primary
response causing tumor regression in more mice, possibly due to mild EP conditions
causing less tissue damage compared to phIL-15+500V/cm. However, it was the phIL15+500V/cm group that up-regulated long-term responses and possibly promoted
CD8+T cell memory response against melanoma compared to phIL-15+1300V/cm and
pVax 500V/cm.
Utilizing the Luminex Bead Array to Characterize Cytokines Stimulated by pVax and
phIL-15+EP
In Aim 3, a 10-cytokine bead array assay was used to characterize the innate
and adaptive immune responses stimulated by the plasmid+EP+ delivery system
(Figures 50-89). Treatment groups and controls groups (no treatment and pVax
injection) were analyzed using the bead array to characterize the immune response
stimulated by phIL-15+EP and pVax+EP+. It was expected that non-specific innate
immune cells (i.e. macrophage, NK cells, dendritic cells and monocytes) were present in
the tumor and serum during normal surveillance. It was predicted after the delivery of
phIL-15 using EP, the IL-15 protein would activate mature NK cells and the cytotoxicity
of NK and T cells to target tumors. Macrophages would recognize and process antigens
for presentation to receptive cells

77,197,206

. The receptive NK and T cells would then

mount a specific response by secreting signaling cytokines and chemokines. These
signals would induce proliferation and help prime CD4+T and CD8+T cells for expansion
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to target melanoma. The specific stimulation of CD8+T cells would then promote a long
term response against recurrent tumor antigens

77,197,206

. The purpose for utilizing the

phIL-15+EP+ delivery system was to transfect the tumor cells and promote IL-15
expression to re-stimulate a tolerant system. The stimulated immune cells would
enhance the concentration of cytokine signaling and effector cells signaling

207

in the

tumor location and promote melanoma elimination.
Examining the Stimulation of Different Cytokines Up-regulated by the Innate and
Adaptive Cellular Responses
The expression of cytokines up-regulated by phIL-15+EP+ or pVax+EP+ delivery
and involved in tumor regression, preventing tumor relapse, were analyzed by Luminex
bead array. Macrophages are the first to respond to tumor cells. The macrophages
engulf tumor cells, disrupt the cells and present the antigens to T lymphocytes

206

.

Macrophages produces a multitude of cytokines IL-1β, IL-6, IL-10, IL-12, IL-15, and
TNFα that function to increase CD4+ helper T cells, additional macrophages, neutophils,
and dendritic cells populations. CD4+ helper T cells produce IL-2, IL-15, and IL-12 to
stimulate NK and LAK cells. IL-12, IL-2, and IFNγ can then stimulate CD8+T cells and
CTLs. Also, helper T cells produce IL-2 to continuously stimulate proliferation and
differentiation of CD4+ helper T cells, CD8+ T cells and CTLs. It is known that IL-15
does not stimulate IL-4, which promotes a Th2 response, but IL-10 production can be
stimulated in Th1 and Th2 mediated responses

166,206

. MIP-1β and IL-15 are chemokines

that help recruit monocytes from blood to the tissue and into the stimulated area, while
GM-CSF induces the production of granular cells, and maturation of macrophage and
dendritic cells (DC) from bone marrow cells. Neutophils stimulate macrophage and T

166

cells through TNFα, and macrophage stimulate neutrophils through IL-1 and TNFα. T
cells stimulate macrophage through IL-1, IL-10, TNFα, IL-4 and IFNγ

166, 208

.

Expression of IL-2 stimulates T cell proliferation, but can also compete for IL2Rβγ binding with IL-15 ligand

169,173

. IL-2 can stimulate its own expression through

autocrine factors to help promote T cell proliferation. It has also been suggested that IL-2
can promote T cell survival thereby enhancing memory response

169, 173

. The goal of

these studies was to enhance IL-15 production at early time points to activate NK cells,
IFNγ and then stimulate IL-12 to increase systemic response against recurrent
melanoma tumors. Macrophage inflammatory proteins are chemokines that have
tumoricidal properties that drives Th1 responses
leukocyte adhesion and migration

172

172,209

, IL-1 and TNFα facilitate

. IL-15 promotes the production of GM-CSF, IFNγ,

and TNFα from activated NK cells and synergizes with macrophage stimulation of IL-12
to enhance NK activity

173

. This analysis helped characterize the signals activated in the

tumor by delivery of IL-15 with EP, which amplified a local response and in turn
promoted a systemic, long-term response against melanoma.
Analysis of phIL-15 Injection Alone Group
Tumor lysate was tested to identify local cytokine production in the tumor, while
serum samples were tested to identify systemic cytokine production. The bead array
results were analyzed for levels of cytokine production at different time points compared
to the background levels of control groups no treatment, pVax injection or naïve
samples. Each treatment group tumor lysate and serum samples will be analyzed for
each cytokine in the sections below. The tumors injected with phIL-15 alone induced the
production of different cytokines than the control groups such as IL-1β, IL-2, IL-10, and
MIP-1β. These cytokines were mostly activated at early time points in the tumor. The
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stimulation of these cytokines suggests that IL-15 protein activated macrophage
proliferation, DC differentiation, T cells and NK cell proliferation and recruitment of
neutrophils and monocytes to the area. Also IL-4, IL-12, IL-6, IFNγ, GM-CSF, and TNFα
were mildly increased at early time points. Low stimulation of these cytokine suggests
that IL-15 protein expression was short-lived, but was sufficient to activate CD4+ T cells
surveillance. The reduced concentration of the cytokines suggested that CD8+ T cells or
CTLs were not present. Based on IHC, phIL-15 injection did stimulate some CD4+and
CD8+T cells in the tumor area, but the tumors were able to escape innate and cellular
immune responses. The IHC data showed phIL-15 injection stimulated more surveillance
cells than the no treatment group and pVax injection groups. Similar cytokine
concentrations were detected in the serum of the phIL-15 group; all cytokines
expressions were very low except for IL-1β, IL-2, IL-6, and MIP-1β at early time points.
This suggests that IL-15 stimulated recruitment of lymphocytes from the blood to
infiltrate the tumor and also stimulated monocyte, macrophage, T cell and NK cell
proliferation, monocyte and macrophage differentiation and restored NK/ IFNγ stress
signals.
Analysis pVax+1300V/cm Group
Analyzing tumor lysate samples from the pVax+1300 V/cm group, demonstrated
an up-regulation of cytokines IL-1β, IL-2, IL-4, IL-6, IL-10, GM-CSF, MIP-1β, TNFα, and
IL-12. These cytokines were the same as those stimulated in phIL-15 injection group. In
addition to stimulation of monocyte, macrophage, and T cell proliferation, DC
differentiation, recruitment of tumor infiltrating lymphocytes (TILs), this group also
stimulated tumor necrosis, enhanced restoration of NK and IFNγ signaling, some antiinflammatory signals, and regulation of tumor infiltrating monocytes. In the serum the
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cytokines that were stimulated included IL-1β, IL-10, and MIP-1β at early time points
(12h, 24h, 48h, Day 3 and Day6) and IL-2, IL-6, GM-CSF, and MIP-1β at later time
points (Day 11 and Day 14). The pVax+1300V/cm group also showed an increase in
INFγ at Day 14, as detected by ELISpot. IHC demonstrated low levels of T cell infiltrate
at early time points and these levels increased at later time points signifying that the
response was delayed, but strong primary response, and a weak secondary response
causing tumor recurrence. MIP-1β, TNFα and IL-12 seem to be the key cytokines
stimulating tumor regression.
Analysis of pVax+500V/cm Group
The pVax+500V/cm group demonstrated up-regulation of the following cytokines
in tumor lysate IL-6 and MIP-1β. This suggests that TILs, NK and IFNγ caused the CD4+
and CD8+T cells recruitment. In the serum the cytokines stimulated were IL-6, IL-10
IFNγ GM-SCF, and TNFα at early time points. IL-1β, IL2, IL4, IL6, GM-CSF, IL-10, IL-12,
MIP-1β, and TNFα at later time points and IL-12 and MIP1β at late time points (Day 30
and Day 60). This indicates that pVax+500V/cm stimulated a robust primary response
and secondary response as well as long-term effects due to the burning caused by the
electric field. The extensive tissue damage stimulated macrophage and DCs to enhance
a strong immune response to the wounds and promoted secondary response to antigens
because of tumor ablation. Up-regulation of IL-4, GM-CSF, IL-6, MIP-1β, and TNFα
indicated monocyte and DC differentiation, maturation, tumor necrosis and stimulation of
TILs. There was an increase in IL-12 at late time points suggesting a secondary
response and newly recruited T cells. This could explain the robust immune response at
the tumor site and subsequently regression. Also, there was an increase of IFNγ
observed by the ELISpot at Day 14, and IHC showed CD4+T and CD8+ T cells infiltrate
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at Day 11, signifying that the pVax+500V/cm group did prime T cells for a strong
secondary response and enhanced survival by 36%, and stimulated long-term
responses to challenge. The tissue damage caused by EP simulated an increase in
cytokine production causing a robust secondary response and T cell stimulation as seen
in IHC at Day 11. IHC showed increased CD8+and CD4+ T cell and tumor regression by
Day 11. Tumor cells slowly regressed compared to phIL-15+500V/cm group that showed
lots of tumor degradation.
Analysis of phIL-15+1300V/cm Group
The phIL-15+1300V/cm group demonstrated stimulation of the following
cytokines in the tumor (some cytokines expressed increased levels and are designated
by the word “high”), high IL-1β, IL-2, high IL-6, IL-10, GM-CSF, high MIP-1β, high TNFα,
IL-12, and high IFNγ. In the serum the cytokines expressed were high IL-6, GM-CSF,
MIP-1β, and TNFα at early time points. At later time points IL-12, IFNγ, GM-CSF, and
MIP-1β were expressed and at late time points IL-12, MIP-1β, TNFα, and IFNγ were
expressed. The ELISpot also demonstrated IFNγ production in splenocytes at Day 14.
Since INFγ is found highly expressed at the level of the tumor this suggests that NK cells
were present and promoting cytotoxic activity. The high concentrations of cytokines
found in the tumor and in the serum suggest that these were the signals that promoted
increased tumor regression and up-regulation of a secondary response. The enhanced
CD8+ T cell response could have increased mouse survival to 45% and promoted long
term tumor rejection when challenged. IHC showed tumor regression and up-regulation
of many CD4+ and CD8+ T cells. These results suggest the up-regulation of the innate
immune response promoted increased cytokine production, and recruitment of primed T
cells, CTL and NK cells through IFNγ expression. The IL-12, MIP-1β and TNFα

170

produced at the late time points could be the underlying cause of long-term responses
against tumor challenge.
Analysis of phIL-15+500V/cm Group
The phIL-15+500V/cm group stimulated the following cytokines high IL-1β, high
IL-2, IL-4, high IL-6, IL-10, high GM-CSF, high MIP-1β, high TNFα, IL-12, and IFNγ. In
the serum the cytokines that were stimulated included IL-1β, high IL-6, high IL-10 at
early time points IL-1β, IL-10 IL-12, IFNγ, GM-CSF, high MIP-1β, and TNFα at later time
points IL-1β, high IL-12, IFNγ, high MIP-1β, and TNFα at late time points. The ELISpot
also demonstrated stimulation of INFγ from treated splenocytes. Higher levels of
cytokine stimulation in the tumor and in the serum contributed to tumor regression,
mouse survival and the best long term response resulting in 75% of the mice remaining
tumor free after challenge. IHC showed a more dismantled residual tumor with
unrecognizable tumor cell shapes and some scar tissue due to EP damage. There was
an abundance CD4+ and CD8+ T cells infiltrating the area. The only differences
observed between the phIL-15+1300V/cm and phIL-15+500V/cm groups were increased
levels of IL-2 and IL-4 in the tumor and increased levels of IL-10 and IL6 in the serum
that possibly contributed to CD8+ T cells survival and a potential memory response.
Analyzing the Immune Response to Tumor Antigens
NKs function as immunosurveillance cells. Mature NK cells are stimulated by IL15 to promote anti-tumor effects. NK cells remove malignant cells through cytolytic
6

properties and stimulate TNFα and IFNγ to promote an adaptive immune response .
Although it is known that IL-15 causes an anti-tumor effect by NK and CD8+Tcells,
studies show that when depleting NK and CD8+T cells in an IL-15 transgenic mouse that
anti-tumor mechanisms still occur. It is still unknown if it is a direct effect by IL-15
171

stimulation of cells involved in innate anti-tumor activity through the γc-chain signaling
independently of NK and CD8. One theory is that IL-15 can stimulate macrophages
6

directly . NK cells secrete the cytokines IFNγ, GM-CSF, and TNFα upon activation and
require increased stimulation for cytolytic activity. IL-15 mediates NK cell proliferation
through DC encounter

170

. The activity of NK cells were not directly measured, but the

cytokines associated with NK cells were measured and detected by the bead array,
ELISpot and IHC. The phIL-15+1300V/cm and phIL-15+500V/cm showed an increase in
TNFα, IFNγ, IL-12 and CD8+T cells.
IL-10 up-regulates IL-15 production by macrophages and over expression of IL10 suppresses TNFα and IFNγ, which in turn inhibit IL-12 synthesis by mononuclear
cells at early time points. The up-regulation of IL-15 would re-stimulate IFNγ and
TNFα

169

. IL-10 acts to regulate pro-inflammatory IL-15 production and anti-inflammatory

effects on IFNγ and TNFα. The bead array demonstrated that phIL-15+1300V/cm and
phIL-15+500V/cm increased TNFα, IFNγ, and IL-10.
In vivo delivery using EP can stimulate many of the same cytokine and promote
differentiation of DC. In vitro, studies have demonstrated that monocytes differentiate
into immature DC stimulated by GM-CSF and IL-4, and that differentiation can also
occur through GM-CSF and IL-15. DCs mature in the presence of TNFα, IL-1β and IL-6
expressed together, and additional expression through intracellular toll like receptor 7/8
stimulated IFNγ and TNFα
IL-1β by neutrophils

171

167,210

. GM-CSF stimulates neutrophils and IL-15 stimulates

.

ELISA demonstrated an increase in IL-15and the multi-plex bead array showed
comparable stimulation of different cytokines responding in the tumor lysate. The
cytokines expressed in the tumor stimulated by phIL-15+EP+ suggested that monocytes
matured to DCs and migrated to peripheral lymph nodes. In the peripheral lymph nodes
172

they differentiated, matured into APCs and up-regulated Th1 IL-12, which in turn
promoted T cell synapse leading to T cell expansion

167

. IL-12 stimulates IFNγ by T cells

and NK cells. phIL-15+EP+ groups showed an increase in IL-12, IFNγ, IL-1β, IL-2, MIP1β, GM-CSF, IL-6 and TNFα indicating the therapy may have induced APC proliferation,
differentiation and T cells expansion.
Comparing Recombinant Protein Experiments and Gene Delivery Treatments
Lewko et al., demonstrates that recombinant IL-15 protein influences TILs or
TDAC outgrowth to eliminate primary culture melanoma cells by Day 7. This shows that
recombinant IL-15 was able to cause tumor elimination by Day 7 in culture

211

. Similarly,

in the IHC experiments there was an increase in tumor regression by Day 7 and there
was possibly newly infiltrating T cells migrating to tumor site by Day 11 in the phIL15+EP+groups. It is possible that the low levels of IL-2 were detected because IL-15
competed for binding of the IL-2 receptor due to high affinity binding capabilities

211

. In

the bead array assay, both serum and tumor cells showed low IL-2 expression in phIL15+EP+ groups. Some IL-2 was possibly stimulated through its own autocrine
pathway211-212. Additionally, it is suggested in the literature that human IL-15 binds
mouse IL-15Rα up-regulates mature NK cells and acts as a growth factor for new T cells
development by Days 7-11

76,196-197

. The experiments similarly stimulate immune

responses as the recombinant protein experiments suggesting that the gene delivery
system is enhancing immune responses against melanoma.
Tumor Evasion and Importance of Gene Therapy
One of the major reasons tumors escape anti-tumor control is because they lose
MHC class I expression rendering tumors unrecognizable by CTLs due to self tolerance.
NK cells can recognize MHCI deficient cells, but the overgrowth of tumors escape
lysis

213

. IL-15 is known to enhance NK cell recruitment and development, it has been
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suggested that this cytokine would be beneficial to use as a therapy against MHCI
deficient melanoma cells

213-214

. The purpose would be to effectively stimulate an

immune response against poorly immunogenic B16.F10 using a cytokine treatment to
enhance tumor regression and survival

215-216

. Previous studies indicated that neither

inactivated B16.F1 or short term pre-incubation with IFNα (B16Fα) introduced into
existing disease like melanoma were able to enhance mouse survival

215

. Although,

inactivated and co-inoculation of active B16.F1 cells with IFNα or a long-term exposure
to IFNα enhanced mouse survival

215

. Intraperitoneal (IP) vaccination of B16F1 pre-

incubated with IFNα recombinant proteins stimulated an immune response with long
term effects, but did not up-regulate long term protective response against B16.F1. The
mice had an established tumor at a distant site from inoculation. When treated IP or
subcutaneously 3 days after inoculation with B16Fα 53% of mice showed a complete
response, surviving 90 days after treatment but no challenge experiments were
performed

215

. An IL-15 transgenic mouse study demonstrated importance of IL-15’s

ability to stimulate CD8+T cell (CTL) response against inoculation of B16.F10 cells
compared to non transgenic mice. The authors suggested that early production of IFNγ
by NK cells developed a CTL response against B16.F10 in transgenic mice by overexpressing IL-15. The transgenic mouse enhanced CTL and inhibited tumor
establishment, but was not protective against tumor growth

217

. Some researchers have

switched to direct delivery of cytokine therapy using EP to transfect plasmids encoding
therapeutic genes directly into existing tumors to enhance tumor regression, mouse
survival and long-term protective response.
IL-15 Used as an Adjuvant
Previous publications suggest that IL-15 is a useful adjuvant against existing
tumors as long as there are pre-existing populations of tumor specific CD8+T cells. They
174

also suggest that IL-15 has the ability to stimulate preexisting CD8+T cells through tumor
specific CD8+T recall responses218. This was demonstrated in the IHC results showing
small presence of T cells at early time points Day 1 and Day 2 in phIL-15+EP+ groups,
and a definite increase in T cells by Day 11. There was a robust CD4+ and CD8+T cell
population specifically targeting tumor cells and causing regression. The serum levels
show an increase in IL-6, MIP-1β, and TNFα causing tumor infiltrate at early time points
12h, 24h, 48h, Day 3, Day 6 and at the tumor level and there was definitely an upregulation of cellular infiltrate from the blood because IL-1β, IL-6, MIP-1β, IL-12 and
IFNγ were recruited to the area by 12h, 24h, 48h, Day 3 and Day6 and at later time
points.
It is difficult to measure levels of IL-15 in the serum because expression is highly
regulated. Studies have shown that the IL-15 leader sequences must be replaced to
enhance protein production in transfected tumor cells to promote tumorigenicity

214

. This

study discusses the importance of CD8+ T cell anti-tumor activity when CD8+T cells are
knocked down. IL-15 transfected tumors were injected into CD8+ T cell knockout mice.
Initially the mice rejected tumor growth, but over time tumor cells eventually escaped
immune effector activity and enlarged rapidly

214

. Targeting tumors with EP is a beneficial

approach because the delivery system allows targeting of specific tissue, efficient
transfection tumor cells efficiently allows transient transfection and recruits innate and
26

adaptive immune response to the electroporated area .
EP is an Adjuvant Delivery System that Stimulates an Inflammatory Response
The effect of plasmid delivery using EP stimulated an inflammatory immune
response, caused cellular infiltrate, cytokine stimulation and recruitment of T cells for
primary response

219

. EP enhancement of the inflammatory response proved to be

beneficial for increased gene delivery to recruited cells during multiple EP treatment
175

protocols. The more cells that are recruited to the tumor area the more cells that are
transfected, results in a more potent induction of protein stimulus and tumor regression
as seen in pVax compared to phIL-15 delivery with EP. The difference is that IL-15 was
able to stimulate long-term and protective immune response at higher levels than pVax
thereby demonstrating specific immune responses induced by IL-15 protein. As
mentioned in publications, plasmid+EP+ induces more antigen uptake and cross
presentation. T cells are primed by antigens in the T cell zone of draining lymph
nodes

219

. This was indicated during experiments on Day 7, Day 11 and Day 14 in IHC,

increased cellular infiltrate on those days indicated that new T cells were being primed
and recruited to remove tumor antigens and causing tumor regression. The combination
of EP and plasmid acts as an adjuvant to promote immune stimulus. This gene delivery
system works synergistically to enhance immune effector cells, stimulating anti-tumor
signaling and promoting prophylactic responses

219

.

Intra-tumoral Delivery Stimulates Local Response
Intratumoral EP delivery of IL-15 and IL-6 plasmids into canine melanoma
caused tumor regression by up-regulating tumor infiltrating lymphocytes (TILs) in
progressing cancer cells. The TILs stimulated high concentrations of IL-6 expression
suppressed TGFβ activity, and restored NK and IFNγ activity. Transfection of IL-15
restored NK activity and T cells as well as other growth factors to enhance anti-tumor
effects

168, 220

. IL-15 may require the combination of other cytokines as an additive

response against tumor antigens to produce stronger primary and protective immune
responses. In addition to protein stimulus, EP itself serves as an adjuvant to enhance
immunostimulatory signals by the electrical impulses causing stress and damage to
stimulated cells in the area

221

. As observed in the IHC experiments on Day 11, the

500V/cm group stimulated a robust adaptive immune response recruiting more T cells
176

and enhancing IL-15 expression to stimulated protective response. pVax and EP
showed similar results of immune infiltrate, but showed less protective response against
antigen challenge. The key is to recruit DC, CD4+T cells locally and to stimulate CD8+
CTL response.
Comparing Electroporation Parameters
Dayball et al. illustrated the importance of EP effects in mice using low voltage
electric fields with long pulse durations and also demonstrated the importance of
stimulating CD4+T cells with EP plasmid delivery

221

. The experiments in this study

compared delivery of pCMVβ luciferase plasmid into the muscle of MHC class II deficient
mice using a 2 needle EP applicator at different pulse lengths with same electric field
strengths. They tested 200V/cm at 20ms and 200V/cm at 50ms and found that both EP
conditions increased luciferase expression. The 200V/cm with 50ms pulse duration EP
condition was able to elicit a cellular response in MHC Class II deficient mice while 20ms
did not. The 20ms did elicit a cellular response in wild type mice. The 50ms pulses were
able to overcome the MHC class II requirement eliciting a CD8+T cell response and
bypassing CD4+T cell activation. These observations suggest that MHC Class II
presentation to CD4+T cells was required for CD8 +T cell expansion

221

. This paper also

suggests that EP activity enhances its own adjuvant properties for eliciting a cellular
immune response. The experiments also detected a cellular immune response with
delivery of pVax+1300V/cm and pVax500V/cm. There was an up-regulation in CD4+T
cell stimulation in the EP groups compared to Injection alone and no treatment groups
as seen in IHC. Poorly immunogenic such as B16.F10 do have CD4+T cells present and
can help stimulate and recruit CD8+ T cells to the tumor area and enhance CTL
activity

218

. The rapid tumor regression observed by Day 14 was due to the phIL-

15+1300V/cm and phIL-15+500V/cm groups, which enhanced both CD4+ and CD8+T
177

cells response to promote rapid tumor regression, improve mouse survival and possibly
support a long-term immune response against B16.F10 challenge. This indicates in this
mouse model the presence of CD4+T cell stimulation is important for up-regulating
CD8+T cells. Additionally, the stimulation of CD8+ T cells was maintained by the
presence of TNFα, IFNγ, and IL-12 in the tumor, serum and circulating lymphocytes.
EP Stimulates an Adaptive Immune Response
EP itself helps break tolerance for immune cells that do not recognize evading
tumor antigens

222

. The stress and damage caused by EP at 500V/cm does stimulate

cells to undergo apoptosis and promotes macrophage phagocytosis to removing tumor
cells. Macrophages release of cytokines to recruits APCs and stimulates residential
CD4+T cells to present and stimulate CD8+T cells causing an up-regulation of CTL
cytotoxicty activity and apoptosis by TNFα

222

. The data shows that TNFα is stimulated at

the tumor and serum levels causing tumor necrosis in EP groups as early as Day 3 and
Day 6. It is important to cause tumor necrosis, apoptosis and CTL response not only at
the tumor levels but systemically

222

. Delivery of IL-15 at early time points may have

stimulated NK activity which amplified the signal stimulating IFNγ production and
activation of primed T cells. The process of eliminating subcutaneous melanoma has
been previously demonstrated by Lucas et al., This publication showed that pmIL-12
delivered using EP into the tumor increased IFNγ, CD4+ and CD8+Tcells promoting a
80% response against primary tumors and 100% protective response against
28

challenge . These results were comparable to the results from the IL-15 experiments
presented here which showed a 73.3%-79% response (Table 2) to primary tumors and
75%response to challenge (Table 3).
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Restimulation of Immune Surveillance with phIL-15 Delivery and EP
Tumors resemble normal tissue, derived from self cells and they maintain normal
non-self tolerance to the immune response. Tumor antigens are identified by the
following characteristics: antigen mutations, germ-line silenced genes, over expressed
tumor antigens, oncogenic viral antigens and tissue-specific differentiated antigen

222

.

The goal of a therapeutic approach, like the one presented in Aim 2, is to establish an
immune response using a system that will remove cells expressing tumor antigens. The
goal is to protect the body from tumor recurrence and re-stimulate effector function to
tolerant cells, inducing sufficient concentration of immune cells in the tumor area that will
recognize tumor antigens and cause extensive lymphocytic infiltration of cells to tumor
stroma

222

. EP is an ideal way to introduce genes of interest like IL-15 into tumors without

invasive surgeries or dangerous side effects. EP delivers genes to cells and does cause
stress and damage to cells, depending on the cell type and EP parameters. The phIL15+EP+ multiple treatment protocols helped to enhance short-term IL-15 protein
expression and, maintain IL-15 expression over time in a controlled manner and
prevents toxic effects due to over expression of protein. Most importantly the multiple
treatment protocol recruits immune cells to the area causing tumor regression. IL-15 is
highly regulated; this regulation may help or hinder cytokine therapies. IL-15 stimulates a
controlled amount of cytokine production that may reduce the survival of CD8+T cell
memory and limit short term/long term memory expansion in the mice. Based on the
experimental results IL-15 combined with EP can potentially serve as an adjuvant
therapy to potentially treat existing disease such as melanoma.
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FUTURE DIRECTIONS
3D Tumor Model
The 3D tumor model is an adaptable construct that can be modified to fit different
experimental interests such as wound healing, tissue regeneration, transplantation,
cloning, drug delivery techniques and genetic manipulations

42,187,190,223

. The 3D model

can also be used to study different cellular behaviors when subjected to salt, pH, protein
concentrations, ligand/receptor concentration, temperature, adhesive properties, and
43

oxygen solubility . This 3D model can help in elucidating the differences in cellular
properties when grown in a 3D environment or as a monolayer of cells in culture, in the
hopes of discovering new information about cells grown in vitro. Also, this model can be
utilized to determine how tumor cells react in the presence of other stimuli that can
promote or inhibit tumor development. For example, this model can aid investigators
study proteins that are present during tumorigenesis such as FGF, interleukin 8, and
43-44,51-53,56,224

VEGF

. Moreover, the 3D model would be a useful tool to understand how

tumor cells react in the presence or absence of immune cells and compare to reactions
53

with wild type, knockout, transgenic, NUDE or SCID mice models . Future studies could
be adaptable to clinical therapies such as plastic surgery, organ transplantation, species
specific diseases, and toxicity of drugs

43,52

.

To further improve the model, the HaCaT spheroids could be reinforced by using
different concentrations of growth factors, using a network of collagen type I and IV or
introducing a heterogeneous population of cells such as fibroblasts to stimulate cell
43

communication . Fibroblasts have many signaling properties useful for skin and tumor
180

development. The heterogeneous population of cells could help in the study of the
expansion, growth cycles and development of B16.F10 in the absence of a basement
membrane and stroma. Introduction of an engineered-linker could help facilitate drug
delivery or enhance nutrient exchange to cells residing in the center of the model

190

. To

further test functionality of the 3D tumor model and explore the activity of E to N
cadherin-switch, angiogeneic STAT3/5 pathways and VEGF production to study
metastatic transformation is also possible in vitro

177-179,226

. Additionally, the 3D model

could be used to study specific gene expression, mutations, and cell signaling such as
autocrine loops that regulate tumorigenesis

43-44,51-53,56,224

. The 3D model is a highly

reproducible system that could be used in many studies such as to optimizing EP
delivery conditions before moving to in vivo animal studies and thereby reducing the use
of animals for experimentation. The information gathered thus far from the 3D model
indicated it can provide a wide range of information and has the potential as an
adaptable model to mimic cellular in vivo processes

177,223

.

phIL-15 Delivery +EP Enhance Immune Stimuli
The delivery of IL-15 using EP is a promising approach that could be an effective
gene therapy option for the treatment of melanoma. Additional pre-clinical experiments
should be performed to ensure its functionality. Based on experiments detailed in Aim 2,
non-responsive, abnormally shaped tumors or deep tumors could escape immune
control between Day 9 and Day 12. One option to avoid the pitfall is to increase the
number of treatment regimens of IL-15, 2 or 3 separate treatments additional to the 3Tx
protocol using low voltage and long pulse durations.
The delivery of phIL-15 using EP conditions at 500V/cm 20ms provided the
strongest immune response against existing B16.F10, but was the most damaging. The
181

damage actually assisted in recruiting more cells to the area for plasmid up-take as seen
in pVax+500V/cm group. To reduce damage and maintain delivery efficacy, additional
EP conditions should be explored with the goal of stimulating IL-15-mediated tumor
regression, but reducing tissue damage. Varying the delivery conditions could possibly
promote different cellular responses to EP stimulus. One suggestion for future studies is
to deliver the IL-15 with 500V/cm 20ms on the first treatment and then on the second
and third treatment use milder conditions such as 804V/cm 400µs or 300V/cm-400V/cm
with 20-50ms. The end goal of this therapeutic approach is to stimulate a strong initial
immune response with IL-15 and then maintain expressions levels of the protein to
promote stable immune cell recruitment. The expression data demonstrated that the
highest levels of IL-15 protein were recorded at the earliest time points 12h or 24h and
then decreased at 24h or 48h depending on the EP conditions. Each plasmid reacts
differently to EP stimuli. The 3D model could be used to provide information about
expression levels for optimization of IL-15 expression prior to moving farther with in vivo
studies. For IL-15 experiments, it seemed as though IL-15 expression reached a
threshold with the strongest EP condition 500V/cm and did not express higher levels
with additional boosts. This suggests that inherent tight regulatory mechanisms that
control IL-15 protein levels inhibited further expression.

Different Cytokine Combination Delivery Systems
It would also be important to evaluate different cytokine combinations that could
complement IL-15 signaling and produce a synergistic response. Some suggested
combinations are IL-15 plus IL-15Rα to enhance the availability of the high affinity IL15Rα for IL-15 when co-expressed in the same cells when either bound to the
membrane or secreted as an active, soluble form for trans-presentation to receptive
182

cells

201,225

. Another option is to use plasmid IL-12 encoding the mouse IL-12 delivered

by EP increased expression, and based on previous studies, enhanced immune
28

response . The combination of IL-15 and IL-12 could possibly promote tumor
regression,

CD8+T

cell

survival

and

memory

responses.

Researchers

have

demonstrated that some CD8+ memory T cells are long lived while others are short
lived

195

. To enhance memory, researchers combined IL-15 and IL-7 because IL-15

stimulates the survival of CD8+T cells and the short-lived memory, while IL-7 stimulates
the long lived memory precursor CD8+T cells. The combination of IL-15, IL-7 and
possibly IL-12 may enhance the innate, adaptive and memory responses resulting in a
robust response against melanoma. The timing of delivery, plasmid concentrations and
routes of delivery will be important to optimize for future immunological studies. The
future of the immunogene therapy field may be in these combination delivery systems, to
enhance multiple signaling pathways to mount a protective response against recurring
tumors.
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